diff --git "a/PMC_clustering_833.jsonl" "b/PMC_clustering_833.jsonl"
new file mode 100644--- /dev/null
+++ "b/PMC_clustering_833.jsonl"
@@ -0,0 +1,379 @@
+{"text": "Bone Research 10.1038/s41413-020-0084-5, published online 14 February 2020Correction to: 1 previously published in Bone Research, we regrettably found a omitting in the acknowledgement section relating to the supporting foundation.During a re-read of our articleThat work was also supported by the Key Laboratory of Trauma & Neural Regeneration (Peking University), Chinese Ministry of Education (Number: BMU2019XY007-01); and Major R&D Program of Chinese National Ministry of Science and Technology (2018YFB1105504)."}
+{"text": "APOE-\u03b54 allele, most variants bear only little individual effect and have, therefore, limited diagnostic and prognostic value. Polygenic risk scores aim to collate the disease risk distributed across the genome in a single score. Recent works have demonstrated that polygenic risk scores designed for Alzheimer\u2019s disease are predictive of clinical diagnosis, pathology confirmed diagnosis and changes in imaging biomarkers. Methodological innovations in polygenic risk modelling include the polygenic hazard score, which derives effect estimates for individual single nucleotide polymorphisms from survival analysis, and methods that account for linkage disequilibrium between genomic loci. In this work, using data from the Alzheimer\u2019s disease neuroimaging initiative, we compared different approaches to quantify polygenic disease burden for Alzheimer\u2019s disease and their association (beyond the APOE locus) with a broad range of Alzheimer\u2019s disease-related traits: cross-sectional CSF biomarker levels, cross-sectional cortical amyloid burden, clinical diagnosis, clinical progression, longitudinal loss of grey matter and longitudinal decline in cognitive function. We found that polygenic scores were associated beyond APOE with clinical diagnosis, CSF-tau levels and, to a minor degree, with progressive atrophy. However, for many other tested traits such as clinical disease progression, CSF amyloid, cognitive decline and cortical amyloid load, the additional effects of polygenic burden beyond APOE were of minor nature. Overall, polygenic risk scores and the polygenic hazard score performed equally and given the ease with which polygenic risk scores can be derived; they constitute the more practical choice in comparison with polygenic hazard scores. Furthermore, our results demonstrate that incomplete adjustment for the APOE locus, i.e. only adjusting for APOE-\u03b54 carrier status, can lead to overestimated effects of polygenic scores due to APOE-\u03b54 homozygous participants. Lastly, on many of the tested traits, the major driving factor remained the APOE locus, with the exception of quantitative CSF-tau and p-tau measures.Genome-wide association studies have identified dozens of loci that alter the risk to develop Alzheimer\u2019s disease. However, with the exception of the  APOE locus, polygenic scores were associated with clinical diagnosis, CSF-tau and p-tau and progressive atrophy, but not with amyloid beta pathology.Altmann et al. compared different approaches to quantify polygenic disease burden for Alzheimer\u2019s disease and their association with a broad range of Alzheimer\u2019s disease-related traits. Beyond the   APP, PSEN1 and PSEN2 mutations in familial Alzheimer\u2019s disease . Consequently, the effect of APOE-\u03b54 on various Alzheimer\u2019s disease biomarkers has been studied extensively over the last decades . M.A.S. acknowledges financial support the Engineering and Physical Sciences Research Council (EPSRC)-funded UCL Centre for Doctoral Training in Medical Imaging (EP/L016478/1). L.M.A. has received funding European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No. 666992. E.d.S. acknowledges supported from the National Institute for Health University College London Hospitals Biomedical Centre. D.M.C. is supported by grants from the Alzheimer Society (AS-PG-15-025), Alzheimer\u2019s Research UK (ARUK-PG2014-1946) and Medical Research Council UK (MR/M023664/1). J.H. was supported in part by the Dolby Family Fund, the UK Dementia Research Institute and the Health University College London Hospitals Biomedical Centre as well as by an anonymous foundation. J.M.S. acknowledges the support of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, Wolfson Foundation, Engineering and Physical Sciences Research Council (EPSRC) (EP/J020990/1), Medical Research Council (MRC) Dementias Platform UK (MR/L023784/1), Alzheimer\u2019s Research UK (ARUK-PG2017-1946), Brain Research UK (UCC14191), Weston Brain Institute (UB170045) and European Union\u2019s Horizon 2020 research and innovation programme (Grant 666992).www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer\u2019s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.Data collection and sharing for this project were funded by the Alzheimer\u2019s Disease Neuroimaging Initiative  and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer\u2019s Association; Alzheimer\u2019s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ; has consulted for Roche, Eli Lilly, Biogen and Merck, GE; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE.fcz047_Supplementary_DataClick here for additional data file."}
+{"text": "A novel coronavirus SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) has entered the human population and has spread rapidly around the world in the first half of 2020 causing a global pandemic. The virus uses its spike glycoprotein receptor-binding domain to interact with host cell angiotensin-converting enzyme 2 (ACE2) sites to initiate a cascade of events that culminate in severe acute respiratory syndrome in some individuals. In efforts to curtail viral spread, authorities initiated far-reaching lockdowns that have disrupted global economies. The scientific and medical communities are mounting serious efforts to limit this pandemic and subsequent waves of viral spread by developing preventative vaccines and repurposing existing drugs as potential therapies. In this review, we focus on the latest developments in COVID-19 vaccine development, including results of the first Phase I clinical trials and describe a number of the early candidates that are emerging in the field. We seek to provide a balanced coverage of the seven main platforms used in vaccine development that will lead to a desired target product profile for the \u201cideal\u201d vaccine. Using tales of past vaccine discovery efforts that have taken many years or that have failed, we temper over exuberant enthusiasm with cautious optimism that the global medical community will reach the elusive target to treat COVID-19 and end the pandemic. Coronavirus disease 2019 (COVID-19) is caused by the novel beta-coronavirus family member coined SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) . In Decevia the receptor-binding domain (RBD) of this glycoprotein in the \u201cprefusion\u201d state  . Severe Knowing the genetic makeup of SARS-CoV-2 is essential for COVID-19 diagnostics. The 30 kb SARS-CoV-2 genome sequence analysis of a patient isolate from Wuhan at the epi-center in China, published in early January 2020, took place swiftly after viral isolation . From JaReverse transcriptase-polymerase chain reaction (RT-PCR) is the hallmark laboratory diagnostic technology to detect viral nucleic acid obtained from nasal swabs. Each jurisdiction around the world has designated screening assays using primer sets from either N, E, RNA-dependent RNA polymerase, ORF1a or ORF1b sequences . ReliablVaccines are one of the monumental achievements in human medical intervention to mitigate the dispersion and impact of infectious disease. Polio was a serious crippling disorder for decades until the development of two separate vaccine candidates by Jonas Salk and Albert Sabin . From thWorld Health OrganizationCoalition for Epidemic Preparedness InnovationsMilken Institute+ years for an approved vaccine down to 12\u201318 months. CEPI, the Biomedical Advanced Research and Development AuthorityGAVI, The Vaccine AllianceOperation Warp SpeedGiven the worldwide magnitude of the COVID-19 pandemic and comparisons to the great Spanish flu of 1918, the race for a vaccine candidate has taken on unprecedented urgency and commitment across the globe. Established organizations are maintaining databases of vaccines under development including the neutralizing antibodies to SARS-CoV-2 antigens (e.g. S and/or N) is imperative  The candidate vaccine should limit any serious adverse events (SAEs) at the injection site or systemically, for example, fever in infants and young children. In the case of respiratory disorders caused by infectious agents, it is essential that vaccine-associated enhanced respiratory disease (VAERD), antibody-dependent enhancement (ADE), antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, including cytokine storm-inducing effects are completely avoided  a robust immune response generating long-lasting  avoided . Some of avoided . Since t avoided , blockin avoided  and hypeeasy to administer and preferably in a single dose at the lowest possible amount. An oral or intranasal vaccine would be ideal. (ii) The vaccine should be facile to produce and scale-up. Manufacturing millions to billions of doses required to immunize the human population must be feasible and rapid. (iii) Long-term storage of the vaccine at room temperature should be a sought after goal to facilitate transport and stockpiling in underdeveloped nations with inadequate supply chains and cold chain capacities  the vaccine should be The normal strides taken to achieve successful vaccine development are similar to those for any drug. The process should be very stringent seeing that it will culminate in administration of the vaccine candidate to billions of humans. The typical paradigm is depicted in DNA (12 candidates) and RNA (20+ candidates), which could be sub-divided further according to particular traits related to delivery and carriers  but for simplicity are considered only as two categories. These nucleic acid platforms belong to the new generation of vaccines. Neither has reached licensing for human use but a number are being tested in humans  includes a broad range of technologies to prepare immune-stimulating viral protein antigens and represents the largest category of all current COVID-19 vaccine candidates (currently 44+) in development. Like nucleic acids, protein-based vaccines represent a newer technology but some are already in use in the clinical realm (e.g. Gardasil for human papillomavirus). The fourth and fifth categories are viral-based vectors, similar to those used in gene therapy and include nonreplicating (16+ candidates) and replicating (14+ candidates) vectors. The next two are the SARS-CoV-2 viruses themselves, either inactivated , the use of non\u2013SARS-CoV-2 virus carriers such as killed rabies (CORAVAX) and live modified horsepox (TX-1800). There are 10+ in this category. Repurposed existing vaccines for polio or tuberculosis to evoke general immunity, various cellular immunotherapies to stimulate the host immune system, encapsulated convalescent serum, and \u201cunknown\u201d platform designation (listed in The Milken Institute database) are excluded from our analyses  or in a  culture . The \u201cOtFor the ideal COVID-19 vaccine to reach routine use in humans, it is imperative that the vaccine protects against both clinical disease and viral transmission, in order to break the chain of person-to-person pandemic spread. Some of the advantages/disadvantages of each platform are considered in In this section, we provide some specific details on 16 (of >125) vaccines in the pipeline that are registered for clinical trials or already being tested , in addition to those that are currently CEPI- and/or BARDA-sponsored from each platform that are, or not yet, in clinical trials. This is to provide a snapshot of the field in early endeavors to procure a functional SARS-CoV-2 vaccine in man and their proposed developmental pipeline (DNA Vaccines(i) Name: INO-4800 (Company (Country):Inovio (USA)INO-4800  Company Antigen: SARS-CoV-2 Spike glycoprotein (S)Details of platform: DNA plasmid encoding S delivered by CELLECTRA\u00ae 2000 electroporatorRoute/mode of administration: intradermal injection followed by electroporationSafety of Platform: Inovio's method has been tested in >2,000 people with >6,000 administrations with a favorable safety and tolerability profile. However, DNA vaccines are not currently in use in humansAdvantages: fast design/manufacturing; no cold chain for storage/distribution; robust immune responseClinical Trial Registration: NCT04336410Start date: April 6, 2020Official Name of Trial: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy VolunteersStudy design: Phase I, non-randomized open label with Groups 1 and 2 for 18-50 y.o, n=40 at two clinics (in US); Dosing Regimen: Single 1 mg dose of INO-4800 followed by electroporation using the CELLECTRA\u00ae 2000 device (Group 1) and dual injections of 1 mg  of INO-4800 followed by EP using the CELLECTRA\u00ae 2000 device per dosing visit at Days 0 and 28; Endpoints: Primary \u2013 General safety including percentage with adverse events (AEs) and local injection site reactions up to 52 weeks; Ag-specific binding titer and IFN-\u03b3 increase from baselinePartners: Beijing Advaccine Biotechnology (China) and International Vaccine Institute (Korea)Funding Partners: Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation, and the US Department of DefenseManufacturing partners: VGXI, Inc., Richter-Helm, and Ology BioservicesNext stage: Preliminary data end June 2020; starting Phase II/III late summer/Fall 2020Timeline: 1 million doses of INO-4800 by the end of 2020 (ii) Name: BacTRL-Spike  Company (Country):Symvivo (Canada)Antigen: SARS-CoV-2 Spike glycoprotein (S)Details of platform: DNA plasmid expressing trimeric S and a hybrid transporter protein within Bifidobacterium longum delivered to colonic epithelial cells to prime an immune response via colonic lymphoid tissuesRoute/mode of administration: oral ingestion of probiotic capsuleSafety of Platform: Extensive worldwide use of probiotics. However, DNA vaccines are not currently on the market for use in humans and this particular strategy is untested.Advantages: fast design and manufacturing; no cold chain for storage and distribution; robust immune response and mucosal immunity predictedClinical Trial Registration: NCT04334980Start date: June 2020 (projected)Official Name of Trial: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy AdultsStudy design: Phase I, dose-escalating with three cohorts, n=84; Dosing Regimen: Single oral dose of BacTRL-Spike at three doses  or placebo in each cohort (with n=63 for vaccine and n=21 for placebo); Endpoints: Primary \u2013 Incidence and severity of adverse events (AEs) Secondary: Seroconversion, virus stool shedding, protection from COVID-19Partners: none announcedFunding Partners: none announcedManufacturing partners: none announcedNext stage: Obtain results of Phase I study by end of the year and get 10,000+ enrolled in further Phase II/III studiesTimeline: 5000 doses by July 2020 and goal of 10 million doses/week through manufacturing scale upRNA Vaccines(i) Name: mRNA-1273 (13 candidates in development) Company (Country):Moderna (USA)Antigen: Full-length prefusion stabilized SARS-CoV-2 Spike glycoprotein (S)Details of platform: Non-replicating RNA genetic material mixed with LNP formulation Route/mode of administration: i.m. deltoidSafety of Platform: >1500 injections with Moderna's RNA formulations for Zika, RSV, CMV, Chikungunya viruses have taken place in other Phase I and II clinical trials and are generally well-tolerated. No RNA vaccines are currently licensed and approved for use in humansAdvantages: fast design and manufacturing; robust immune responseClinical Trial Registration: NCT04283461 (NCT04405076) Start date: March 16, 2020 (IND for Phase II approved May 7 and started early June 2020)Official Name of Trial: Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)Study design: Phase I, non-randomized open label with Arms 1\u20133 for 18\u201354 y.o., n=15/arm, Arms 4\u20136 for 55\u201370 y.o., n=10/arm and Arms 7\u20139 for 71+ y.o., n=10/arm; Dosing Regimen: Dual 25, 100, or 250 \u03bcg in 0.5 ml on Days 1 and 29 followed up to 12 months after 2nd injection; Endpoints: Primary \u2013 General safety including local reactogenicity and serious adverse events (SAEs) throughout the study duration; Secondary - mean increase general Ab and IgG titers from baseline, percentage subjects with seroconversion at Day 57Partners: NIAID/NIH; Operation Warp SpeedFunding Partners: CEPI, BARDAManufacturing partners: LonzaNext stage: Obtain complete results of Phase I (see interim results below) and get 10,000+ enrolled in Phase II/III studiesTimeline: scaling up manufacturing capacity toward the production of millions of doses per month, in the potential form of individual or multidose vials, with goal of 1 billion doses/year(ii) Name: BNT162 Company (Country):BioNtech SE (Germany)/Pfizer (USA)Antigens: SARS-CoV-2 3C-like protease (3CLpro), NSP5, SARS-CoV-2 main protease (Mpro)Details of platform: Uridine containing mRNA (uRNA) or nucleoside modified mRNA (modRNA) mixed with proprietary lipoplex formulation for the three antigens, as well as a fourth vaccine candidate self-amplifying mRNA (saRNA)Route/mode of administration: i.m. injection (0.5 ml) prime and boostSafety of Platform: No RNA vaccines are currently licensed and approved for use in humansAdvantages: fast design and manufacturing; robust immune responseClinical Trial Registration: NCT04368728  Start date: April 29, 2020Official Name of Trial: Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates against COVID-19 in Healthy AdultsStudy design: Phase I/II, randomized, placebo-controlled, observer-blind, dose-finding, and vaccine candidate-selection study in healthy adults. 18 experimental arms each with four vaccine targets  x 3 age groups  \u00d7 2 dosing time points (timing not specified) \u00d7 3 doses  + 3 placebo comparator arms carried out in three stages; Stage 1: to identify preferred vaccine candidate(s), dose level(s), number of doses, and schedule of administration (with the first 15 participants at each dose level of each vaccine candidate comprising a sentinel cohort); Stage 2: an expanded-cohort stage; and Stage 3; a final candidate/dose large-scale stage; n=7400; Dosing Regimen: Single and dual doses to be tested; Endpoints: Primary \u2013 General safety, incidence and severity of adverse events (AEs) up to a week after each dose and blood chemistry in sentinel cohort; Secondary: Various immune parameters and incidence of COVID-19Partners: Fosun Pharma ; Operation Warp SpeedFunding Partners: PfizerManufacturing partners: Pfizer (3 sites in USA and 1 in Belgium)Next stage: Move quickly through Phase I and recruit up to 8000 volunteers for Phase IITimeline: Millions of doses by year end  and hundreds of millions by end of 2021(iii) Name: \u201cLead candidate\u201d Company (Country):CureVac AG (Germany)Antigen: undisclosedDetails of platform: Engineered RNA genetic material mixed with LNPs (from either Acuitas or Arcturus) or proprietary CureVac Carrier MoleculeRoute/mode of administration: presumably i.m. injectionSafety of Platform: No RNA vaccines are currently licensed and approved for use in humans but their platform has been tested for vaccine development directed toward other virusesAdvantages: fast design and manufacturing; robust immune responseClinical Trial Registration: not yet registered Start date: June 2020 (projected)Study design: Phase I in two European sites; Dosing Regimen: Single and dual doses to be tested; Endpoints: Initial immunogenicity and safety resultsPartners: Paul Ehrlich InstituteFunding Partners: CEPI $8.3M and the EU has promised 80M Euro for scale-up and production; Bill and Melinda Gates Foundation; Defense Advanced Research Projects AgencyManufacturing partners: not announcedNext stage: Start Phase I studies in summer 2020 and Phase II projected for Fall 2020Timeline: up to several hundred million doses of bulk RNA/year with their current GMP III facility; a new GMP IV suite will be put into operation within two years where capacity for production of one billion or more doses per year is possibleRecombinant Protein-Based Vaccines(i) Name: NVX-CoV2373 Company (Country): Novavax (USA)Antigen: Recombinant SARS-CoV-2 Spike protein (S) in prefusion stateDetails of platform: Recombinant protein is expressed in genetically engineered Sf9 insect cells and the properly folded and post-translationally modified protein is incorporated into a nanoparticle formulation along with Novavax's saponin-based Matrix-M adjuvantRoute/mode of administration: i.m. injection to deltoid muscleSafety of Platform: Novavax's platform has been tested in several Phase I, II, III trials for seasonal influenza, Ebola and RSV and appears to be safeAdvantages: fast design and relatively rapid production possibleClinical Trial Registration: NCT04368988 Start date: May 15, 2020Official Name of Trial: A 2-Part, Phase I/II, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with or without MATRIX-M\u2122 Adjuvant in Healthy SubjectsStudy design: Phase I clinical trial  is a placebo-controlled observer blinded study of about 130 healthy adults followed by Phase II in multiple countries; Dosing Regimen: Single and dual doses to be tested at Day 0 and 21, either 5 or 25 \u03bcg with 50 \u03bcg Matrix M; Endpoints: include assessment of dosage amount and number of vaccinations, along with preliminary immunogenicity and safety resultsPartners: Emergent BioSolutionsFunding Partners: CEPI $388 millionManufacturing partner: Emergent BioSolutions; Praha Vaccines and Serum Institute of IndiaNext stage: Preliminary data from Phase I in July, then proceeding to Phase II (2200 volunteers in multiple countries) later in summer with results expected by the end of 2020Timeline: 100 million doses by year-end and a billion by end of 2021(ii) Name: SCB-2019 Company (Country):Clover Biopharmaceuticals Inc. (China)Antigen: Recombinant trimeric SARS-CoV-2 Spike protein (S)Details of platform: patented Trimer-Tag\u00ae technology to produce a S-Trimer protein subunit vaccine that resembles the native trimeric viral spike via a rapid mammalian cell-culture based expression systemRoute/mode of administration: i.m. injection to deltoid muscleSafety of Platform: Clover has previously developed recombinant subunit-Trimer vaccines for RSV and Influenza viruses utilizing its Trimer-Tag\u00ae technology and has demonstrated that they are able to evoke protective neutralizing antibody responses in multiple animal models and appears to be safe.Advantages: fast design and relatively rapid production possibleClinical Trial Registration: NCT04405908Start date: June 20, 2020 (projected)Official Name of Trial: SCB-2019 as COVID-19 vaccineStudy design: Phase I, Randomized, double blind, placebo controlled, n=150, SCB-2019 alone or with two different adjuvants; Dosing Regimen: twice (Day 1 and Day 22) at three doses ; Endpoints: includes assessment of dosage amount, number of vaccinations, along with preliminary immunogenicity and safety resultsPartners: Chengdu Hi-Tech Park (R&D) and Chengdu Clinical Center for Public Health/Clover Australia ; both GSK and Dynavax (Adjuvants)Funding Partners: CEPI ($3.8 M)Manufacturing partner: Clover has one of the largest in-house, commercial-scale cGMP biomanufacturing capabilities in China and is partnering with GSK to use their Pandemic adjuvant System and Dynavax for their (TLR9 agonist) CpG 2018 adjuvant (the adjuvant used in HEPLISAV-B\u00ae , an adult hepatitis B vaccine approved by FDA)Next stage: Get clinical trials underway and evaluate dataTimeline: not disclosed yet(iii) Name: \u201cLead candidate\u201d Organization (Country):University of Queensland Antigen: Recombinant trimeric SARS-CoV-2 Spike protein (S)Details of platform: molecular clamp platform by synthesizing viral surface proteins, which attach to host cells during infection, and \u201cclamping\u201d them into shape, making it easier for the immune system to recognize them as the correct antigenRoute/mode of administration: presumably i.m. injectionSafety of Platform: unknown details for this specific platformAdvantages: fast design and relatively rapid production possibleClinical Trial Registration: not yet registered Start date: July 2020 projectedOfficial Name of Trial: not yet started but will take place in AustraliaStudy design: Phase I not started yet; Dosing Regimen: not known; Endpoints: not knownPartners: Peter Doherty Institute for Infection and Immunity, Melbourne (Vaccine development), Viroclinics Xplore , GSK (Adjuvant)Funding Partners: CEPI $10.6 MManufacturing partner: Cytiva , as well as Lonza and Thermo Fisher Scientific; CSL/Seqirus, Dynavax and GSK will supply adjuvantsNext stage: Get clinical trials underwayTimeline: not disclosed yet(iv) Name: \u201cLead candidate\u201d Company (Country):Sanofi/GSK collaboration (France/UK)Antigen: Recombinant trimeric SARS-CoV-2 Spike protein (S)Details of platform: Sanofi's recombinant DNA technology and their Sf9 insect cell expression systemRoute/mode of administration: presumably i.m. injectionSafety of Platform: the combination of a protein-based antigen together with an adjuvant, is well-established and used in a number of vaccines available todayAdvantages: fast design and relatively rapid production possibleClinical Trial Registration: not yet registered Start date: July-September 2020 projectedOfficial Name of Trial: not yet namedStudy design: Phase I not started yet; Dosing Regimen: not known; Endpoints: not disclosed yetFunding Partners: BARDAManufacturing partners: both Sanofi and GSK are global leaders in vaccine development and they have the capacity to generate millions of dosesNext stage: Get clinical trials underway and complete the development required for availability of a vaccine by the second half of 2021Timeline: not disclosed yetViral Vector-Based (Nonreplicating)Name: AZD1222 (formerly ChAdOx1 nCoV-19) Company (Country):University of Oxford/Astra Zeneca collaboration (UK)(i) Antigen: SARS-CoV-2 Spike glycoprotein (S)Details of platform: AZD1222 derives from a chimpanzee viral vector (ChAdOx1), which is a weakened version of a common cold adenovirus with the Spike-encoding region cloned into the E1 locus. Although it infects this primate, it is genetically altered so that it is incapable of viral spread in humans. The same vector modality is in vaccine candidates for influenza, tuberculosis, Chikungunya and Zika viruses.Route/mode of administration: i.m. injectionSafety of Platform: Vaccines made from the ChAdOx1 viral vector platform for over 10 different pathogens have been tested in thousands of volunteers (1 week to 90 y.o.) to date and are safe and well tolerated, although they can cause temporary side effects, such as a temperature elevation, headache or sore armAdvantages: favorable safety and tolerability profile of the platformClinical Trial Registration: NCT04324606  Start date: April 23, 2020Official Name of Trial: A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult VolunteersStudy design: Phase I/II single-blinded, randomized multicenter participants recruited in UK; n=1102 volunteers 18\u201355 y.o. good health, n=551 in active arm ChAdOx1 nCoV-19 and n=551 in control arm using MenACWY vaccine (same vector but against meningitis); Dosing Regimen: Single 5 \u00d7 1010 vp  Endpoints: Primary - Number of virologically confirmed (PCR positive) symptomatic cases of COVID-19; Occurrence of serious adverse events (SAEs) throughout the study duration; Secondary - safety/tolerability/reactogenicity/immunogenicityPartners: Vaccitech (role taken over by Astra Zeneca); Operation Warp SpeedFunding Partners: CEPI, GAVI, BARDAManufacturing partners: Serum Institute of India and WuXi Biologics Inc., Vaccines Manufacturing and Innovation Centre Next stage: Preliminary human data June 2020; Phase III efficacy of 5000 volunteers by Fall 2020Timeline: 20-40 million doses of AZD1222 by September 2020 and 400 million by end 2020Name: Ad5-nCoV Company (Country):CanSino Biologics Inc. (China)(ii) Antigen: Full-length SARS-CoV-2 Spike glycoprotein (S)Details of platform: Ad5 vectors are well studied and can be grown into high titer stable stocks, they infect non-dividing and dividing cells, they are maintained in cells as an episome; the essential E1A and E1B genes are deleted and replaced by an expression cassette with a high activity cytomegalovirus immediate early (CMV) promoter, which drives expression of the target S proteinRoute/mode of administration: i.m. injection into deltoidSafety of Platform: In general, safe and well tolerated; however, can be dangerous in immunocompromised individuals. One drawback is that there could be pre-existing neutralizing Abs to the Ad5 vector in some adultsAdvantages: well-tested vector in gene therapy and vaccination trials (MERS and Ebola) but could be difficult for large-scale manufacturingClinical Trial Registration: (i) NCT04313127; (ii) ChiCTR2000031781/(NCT04341389) Start date: (i) March 16, 2020; (ii) April 12, 2020Official Name of Trial: (i) A Single-center, Open-label Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (ii) A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 yearsStudy design: (i) Phase I, non-randomized open label dose-escalating with three cohorts  Phase II randomized, double-blinded, placebo-controlled with 3 groups  n=500; Dosing Regimen: (i) Single dose  single dose ; Endpoints: Primary \u2013 General safety including any adverse events (AEs) up to 7 (or 14 for Phase II) days after injection; Secondary \u2013 Safety up to 6 months and various immunogenicity indices up to 6 months for both Phase I and II trialsPartners: vaccine co-developed with Beijing Institute of Biotechnology; Academy of Military Medical Sciences. PLA of China Jiangsu Province Centers for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, Tongji Hospital);(ii) Jiangsu Provincial Center for Disease Control and Prevention; Canadian Immunization Research Network at the Canadian Center for Vaccinology; (iii) Canadian Center for Vaccinology (NCT04398147)Funding Partners: CanSinoManufacturing partners: CanSino, others (not known)Next stage: evaluate Phase II trial data and scale-up productionTimeline: preliminary data from Phase I just published (see below) but no exact timelines on production and scale-up reportedName: Ad26 SARS-CoV-2 (+ 2 back ups) Company (Country):Johnson and Johnson (USA)(iii) Antigen: undisclosedDetails of platform: Janssen's AdVac\u00ae and PER.C6\u00ae technologies allow for over a million doses to be produced from a 1000 liter bioreactor since the cells grow to high density in suspension culture; the non-replicating Ad26 vector (E1/E3 genes deleted) is likely better than Ad5 since less likelihood of preexisting antibodies to the vectorRoute/mode of administration: i.m. injection into deltoidSafety of Platform: their particular platform technology is used for an investigational Ebola vaccine in Africa and has also been used for their Zika, RSV and HIV vaccine candidates and appears to be safeAdvantages: well-tested vector in gene therapy and vaccination trials with transport/storage at 2-8 \u00b0C for 6 monthsClinical Trial Registration: not yet registered Start date: September 2020 projectedOfficial Name of Trial: not known yetPartners: Janssen Pharmaceutical Companies of Johnson & Johnson, Beth Israel Deaconess Medical Center; Operation Warp SpeedFunding Partners: BARDA cofunding $1 billion+Manufacturing partners: Emergent BioSolutions Inc., CatalentNext stage: Quick rollout of Phase I in September and EUA by early 2021Timeline: goal of providing global supply of more than one billion doses of a vaccine (unspecified timing)Viral Vector-Based (Replicating)Name: \u201cLead candidate\u201d Company (Country):Institut Pasteur (France)/Merck (USA)(i) Antigen: undisclosed Details of platform: measles vaccine vector exclusively licensed to Themis (purchased by Merck) from Institut Pasteur, with the capacity to insert multiple large recombinant protein antigens includes auto-adjuvant effect by live attenuated replicating vectorRoute/mode of administration: i.m. injection into deltoid presumablySafety of Platform: the technology that Themis uses to develop its vaccine candidates is based on the measles vaccine, which has been used for decades to immunize safely millions around the world; their approach was used to develop a vaccine candidate against SARS, and CEPI has previously partnered with Themis and Institut Pasteur to harness this technology to develop vaccine candidates against Chikungunya, MERS, and Lassa feverAdvantages: proven advanced development and manufacturing capabilities for this platformClinical Trial Registration: not yet registered Start date: September 2020 projectedOfficial Name of Trial: still in preclinical testing phasePartners: University of PittsburghFunding Partners: CEPI $4.9 MManufacturing partners: Merck/Themis/ABL EuropeNext stage: rollout of Phase I this yearTimeline: unspecified timingInactivated VirusName: CoronaVac (formerly PiCoVacc) Company (Country):Sinovac Biotech (China)(i) Antigen: whole virus, with initial reports that the RBD within the Spike protein is the main immunogen  Start date: April 16, 2020Official Name of Trial: A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 YearsStudy design: Phase I/II, randomized double-blinded, placebo-controlled with various groups of 18\u201359 y.o. volunteers, n=744 (n=144 for Phase I and n=600 for Phase II); Dosing Regimen: Dual dosing at Day 0 and Day 14 or 28 of medium dose or high dose or placebo in 0.5 ml; Endpoints: Primary \u2013 General safety including adverse events (AEs) to 28 days and immunogenicity indices compared between day 0 and day 28; Secondary: Safety and various immunogenicity indices up to Day 56Partners: Sinovac Research and Development Co., Ltd.Funding Partners: Advantech Capital and Vivo Capital ($15M)Manufacturing partners: partnering with Dynavax Technologies Corp for use of their adjuvant CpG 1018, which is currently used in an FDA-approved Hepatitis B Vaccine (Recombinant)Next stage: starting Phase III by end of 2020Timeline: 100 million doses/year projectedName: COVID-19 vaccine Company (Country):Sinopharm (China)(ii) Antigen: whole virusDetails of platform: The inactivated viral vaccine platform is straightforward and used extensively; no details on this particular vaccine could be foundRoute/mode of administration: i.m. injectionSafety of Platform: vaccines made from inactivated virus are used throughout the world with a generally excellent safety profileAdvantages: straightforward process; favorable safety and tolerability profileClinical Trial Registration: ChiCTR2000031809; ChiCTR2000032459* Start date: April 11, 2020Official Name of Trial: A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells)Study design: Phase I/II randomized, double-blinded, placebo-controlled conducted in Jiaozuo, Henan Province on healthy 6 y.o. and up; 96 volunteers injected by April 23; with n=216 to be injected with either low-, mid-, or hi-doses or placebo n=72 in Phase I; multiple groups in Phase II n=876 to be injected with either low-, mid-, or hi-doses or placebo n=292; Endpoints: Primary \u2013 adverse events; Secondary \u2013 Multiple safety and immunogenicity parameters up to 1 year post-injectionPartners: Wuhan Institute of Biological Products under the China National Pharmaceutical Group, Sinopharm, and the Wuhan Institute of Virology (WIV)/Beijing Institute of Biological Products*Funding Partners: not knownManufacturing partners: unknownNext stage: unknownTimeline: unknown*Two trials are registered in China with different clinical research groups but under \u201cSinopharm\u201d and it is unclear if they are using the same vaccine candidate*Live Attenuated Virus/OtherName: \u201cLead\u201d Organization (Country):University of Hong Kong (China)(i) Antigen: undisclosed which SARS-CoV-2 protein(s) usedDetails of platform: a weakened version of the flu virus adapted to express surface protein of the COVID-19 virusRoute/mode of administration: intranasalSafety of Platform: approach has been used previously to develop preclinical vaccine candidates against MERSAdvantages: straightforward process used for several licensed human vaccines; existing infrastructure can be usedClinical Trial Registration: not yet registered Start date: July 2020 projectedOfficial Name of Trial: still in preclinical phaseFunding Partners: CEPIManufacturing partners: dependent on mainland China for manufacturing, no specific partner mentionedNext stage: getting Phase I trials underway by summer 2020Timeline: unknownIn a May 18 press release of interim dataIn this preclinical trial , NHPs  and peer-reviewed publications  reached such exponential heights in such a short period with thousands of \u201call-things-considered\u201d COVID topics. Mobilization of data sharing and joint global efforts toward this vaccine goal are monumental. It is hoped that the collaborative framework  for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes and/or leveraging assets among various partners to rapidly respond to the COVID-19 and future pandemics will soon be a reality. However, a successful path forward will be challenging and is certainly not guaranteed. For instance, no efficacious and approved vaccine for HIV/AIDS has come forward in over 30 years. The main HIV surface protein for host cell entry is covered in sugars, as is the Spike protein of SARS-CoV-2, but to a lesser extent . Will thCF and AA conceived the design and concepts. CF wrote the manuscript. CL contributed key information for This research was funded by Queen's University Special Research Project 379415 (CDF).AA is the founder and managing director of Novateur Ventures, Inc. CL is a consultant with Novateur Ventures Inc. CF is a scientific advisor for Novateur Ventures Inc.CF declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}
+{"text": "This observational study aimed to examine the prognostic association of angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin receptor blockers (ARB) in different left ventricular ejection fraction (LVEF) categories.In 3717 patients enrolled in the KCHF Registry, a multicentre registry including consecutive patients hospitalized for acute heart failure (HF), we assessed patient characteristics and association between ACE-I/ARB and clinical outcomes according to LVEF. In the three LVEF categories , we compared the patients with ACE-I/ARB as discharge medication and those without, and assessed their 1-year clinical outcomes. We defined the primary outcome measure as a composite of all-cause death and HF hospitalization.interaction = 0.01).The 1-year cumulative incidences of the primary outcome measure were 36.3% in HFrEF, 30.1% in HFmrEF and 33.8% in HFpEF (log-rank P = 0.07). The adjusted risks of the ACE-I/ARB group relative to the no ACE-I/ARB group for the primary outcome measure were significantly lower in HFrEF and HFmrEF , but not in HFpEF . There was a significant interaction between the LVEF category and the ACE-I/ARB use on the primary outcome measure (PACE-I/ARB for patients who were hospitalized for acute HF was associated with significantly lower risk for a composite of all-cause death and HF hospitalization in HFrEF and HFmrEF, but not in HFpEF. ACE-I/ARB might be a potential treatment option in HFmrEF as in HFrEF. Previous randomized clinical trials have shown the prognostic and symptomatic benefits of angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) in heart failure with reduced ejection fraction (HFrEF) \u20135. On thThe ESC 2016 guideline recognizes the evidence gap between HFrEF and HF with preserved ejection fraction (HFpEF) , becauseIt would be intriguing to examine the treatment effect of RAS inhibitors in a large observational registry including all spectrum of LVEF, although large randomized controlled trials dedicated to HFmrEF are desirable , 19. ThiThe Kyoto Congestive Heart Failure registry is a physician-initiated, prospective, observational, multicenter cohort study enrolling the consecutive patients who were hospitalized for acute HF between October 2014 and March 2016 at 19 secondary and tertiary hospitals in Japan.The study was approved by the institutional review boards of Kyoto University Graduate School of Medicine ; Shiga General Hospital ; Tenri Hospital ; Kobe City Medical Center General Hospital ; Hyogo Prefectural Amagasaki General Medical Center ; National Hospital Organization Kyoto Medical Center ; Mitsubishi Kyoto Hospital (approved 11/12/2014); Okamoto Memorial Hospital ; Japanese Red Cross Otsu Hospital ; Hikone Municipal Hospital ; Japanese Red Cross Osaka Hospital ; Shimabara Hospital ; Kishiwada City Hospital ; Kansai Electric Power Hospital ; Shizuoka General Hospital ; Kurashiki Central Hospital ; Kokura Memorial Hospital ; Kitano Hospital ; and Japanese Red Cross Wakayama Medical Center . A waiver of written informed consent from each patient was granted by the institutional review boards of Kyoto University and each participating centre based on the Japanese guidelines for epidemiological study   . Thus, tACE-I/ARB for patients who were hospitalized for acute HF was associated with significantly lower risk for a composite of all-cause death and HF hospitalization in HFrEF and HFmrEF, but not in HFpEF. ACE-I/ARB might be a potential treatment option in HFmrEF as in HFrEF.S1 File(DOCX)Click here for additional data file.S1 Table(DOCX)Click here for additional data file.S2 Table(DOCX)Click here for additional data file.S3 Table(DOCX)Click here for additional data file.S4 Table(DOCX)Click here for additional data file.S5 Table(DOCX)Click here for additional data file.S6 Table(DOCX)Click here for additional data file.S1 Fig(DOCX)Click here for additional data file.S2 Fig(DOCX)Click here for additional data file.S3 Fig(DOCX)Click here for additional data file.S4 Fig(DOCX)Click here for additional data file."}
+{"text": "Scientific Reports 10.1038/s41598-019-49729-2, published online 19 September 2019Correction to: The Acknowledgements section in this Article is incomplete.\u201cThe authors recognize Wesley C. Van Voorhis MD, PhD of the University of Washington for his thoughtful discussions on the development of the models.\u201dshould read:\u201cThe authors recognize Wesley C. Van Voorhis MD, PhD of the University of Washington for his thoughtful discussions on the development of the models. This work was funded by Tres Cantos Open Lab Foundation (Grant: TC246).\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-019-38901-3, published online 22 February 2019Correction to: The Acknowledgements section in this Article is incomplete.\u201cWe would like to acknowledge Avril Robertson, The University of Queensland, for providing the supply of MCC950. We also acknowledge that this work was supported by BrAshA-T, Australia (RM2016001474), the A-T Children\u2019s Project, USA (RM2016000563) and the National Health and Medical Research Council, Australia (GNT1020028).\u201dshould read:\u201cWe would like to acknowledge Avril Robertson, The University of Queensland, for providing the supply of MCC950. We also acknowledge that this work was supported by BrAshA-T, Australia (RM2016001474), the A-T Children\u2019s Project, USA (RM2016000563), National Health and Medical Research Council, Australia (GNT1020028) and the Children\u2019s Hospital Foundation (RM2018002270).\u201d"}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-020-61161-5, published online 06 March 2020Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis study was funded by grants for the Swedish state under the agreement between the Swedish government and the county council, the ALF-agreement (ALFGBG-722391), the Swedish Research Council (621-2013-5895), Kung Gustav V:s 80-\u00e5rs foundation, Petrus and Augusta Hedlund\u2019s foundation (M-2016-0353), AFA insurance research fund (dnr 150150) and IngaBritt and Arne Lundberg Foundation. Sofa Grindberg and Paula-Terese Kelly Pettersson at Danderyd\u2019s Hospital and Lotta Falkendahl at University of Gothenburg are acknowledged for their assistance in collecting samples. Lubris BioPharma, LLC are acknowledged for providing rhPRG4. Prof Johan Bylund and Felix Klose at the Institute of Odontology, University of Gothenburg, are acknowledge for technical assistance in evaluating CG activity. Open access funding provided by University of Gothenburg.\u201dshould read:\u201cThis study was funded by grants for the Swedish state under the agreement between the Swedish government and the county council, the ALF-agreement (ALFGBG-722391), the Swedish Research Council (621-2013-5895), Kung Gustav V:s 80-\u00e5rs foundation, Petrus and Augusta Hedlund\u2019s foundation (M-2016-0353), AFA insurance research fund (dnr 150150) and IngaBritt and Arne Lundberg Foundation. Sofa Grindberg and Paula-Terese Kelly Pettersson at Danderyd\u2019s Hospital and Lotta Falkendahl at University of Gothenburg are acknowledged for their assistance in collecting samples. Lubris BioPharma, LLC are acknowledged for providing rhPRG4. Prof Johan Bylund and Felix Klose at the Institute of Odontology, University of Gothenburg, are acknowledge for technical assistance in evaluating CG activity. Prof Gregory D. Jay was supported by NIH 5P30GM122732. Open access funding provided by University of Gothenburg.\u201d"}
+{"text": "Following publication of the original article , the autThe content currently reads:This study funded by Taipei Medical University Hospital (108TMU-TMUH-16).The content should be changed to:This study funded by Taipei Medical University Hospital (109TMU-TMUH-10).The original article has been updated."}
+{"text": "In \u201cUse of an Electronic Clinical Decision Support System in Primary Care to Assess Inappropriate Polypharmacy in Young Seniors With Multimorbidity: Observational, Descriptive, Cross-Sectional Study\u201d :e14130) the authors noted one issue.In the Acknowledgments section of the paper, the statement:This study was financed by the Fondo de Investigaciones Sanitarias Coordinated project  from the Instituto de Salud Carlos IIIhas been removed and replaced by the following statement:This study was funded by National Institute for Health Research ISCIII (Grant numbers PI15/00276 (APT), PI15/00572 (ICG), PI15/00996 (JDPT), RD16/0001/0004 (ICG), RD16/0001/0005 (APT), RD16/0001/0006 (JDPT)) Co-funded by European Regional Development Fund, (ERDF) \u201cA way of shaping Europe\u201d. National Plan I+D+I 2013-2016.The correction will appear in the online version of the paper on the JMIR Publications website on November 19, 2020, together with the publication of this correction notice. Because this was made after submission to PubMed, PubMed Central, and other full-text repositories, the corrected article has also been resubmitted to those repositories."}
+{"text": "Scientific Reports 10.1038/s41598-020-69717-1, published online 18 August 2020Correction to: The original version of this Article contained errors in the spelling of the authors Maria Cywi\u0144ska, Jos\u00e9 \u00c1ngel Picazo-Bueno, Vicente Mic\u00f3 and Piotr Zda\u0144kowski, which were incorrectly given as Maria Cywinska, Jose-Angel Picazo-Bueno, Vicente Mico and Piotr Zdankowski.Furthermore, the Acknowledgements section was incomplete.\u201cWe would like to thank Prof. Bjorn Kemper for fruitful discussions. We acknowledge the support of Faculty of Mechatronics Warsaw University of Technology statutory funds (Dean\u2019s grant). Codes for VHQPI demodulation will be made available upon reasonable request. The study leading to the published manuscript has beed funded, in parts, by the\u00a0National Science Center Poland (NCN) (2017/25/B/ST7/02049), Polish National Agency for Academic Exchange (PPN/BEK/2018/1/00511), Spanish Ministerio de Econom\u00eda, Industria y Competitividad and the Fondo Europeo de Desarrollo Regional (FIS2017-89748-P), National Natural Science Foundation of China (61722506), Outstanding Youth Foundation of Jiangsu Province (BK20170034).\u201dnow reads:\u201cWe would like to thank Prof. Bjorn Kemper for fruitful discussions. We acknowledge the support of Faculty of Mechatronics Warsaw University of Technology statutory funds (Dean\u2019s grant). Codes for VHQPI demodulation will be made available upon reasonable request. The study leading to the published manuscript has beed funded, in parts, by the\u00a0National Science Center Poland (NCN) (2017/25/B/ST7/02049), Polish National Agency for Academic Exchange (PPN/BEK/2018/1/00511), Spanish Ministerio de Econom\u00eda, Industria y Competitividad and the Fondo Europeo de Desarrollo Regional (FIS2017-89748-P), National Natural Science Foundation of China (61722506), Outstanding Youth Foundation of Jiangsu Province (BK20170034). Studies were funded by FOTECH-1 project granted by Warsaw University of Technology under the program Excellence Initiative: Research University (ID-UB).\u201dThese errors have now been corrected in the PDF and HTML versions of the Article."}
+{"text": "BMJ 2020;370:m2215, doi:10.1136/bmj.m2215, published 1 July 2020), the funding statement was incomplete and should have included the following sentence in full: \u201cBSC is supported by UK Medical Research Council/Department for International Development (grant MR/K006924/1) and the UK Department of Health and Social Care using UK Aid funding managed by the National Institute for Health Research (grant PR-OD-1017-20006).\u201d Furthermore, in the summary box, the third point should read: \u201cPotential confounders should be prespecified in order to collect relevant and complete data from both adherent and non-adherent participants during the trial.\u201dIn this paper by Mo and colleagues ("}
+{"text": "Article title: Sensitive detection of Treponema pallidum DNA from the whole blood of patients with syphilis by the nested PCR assayAuthors: Wang, C., Cheng, Y., Liu, B., Wang, Y., Gong, W., Qian, Y., Guan, Z., Lu, H., Gu, X., Shi, M., & Zhou, P.Journal: Emerging Microbes & InfectionsDOI:https://doi.org/10.1038/s41426-018-0085-2This article was originally published with error in acknowledgement section. The correct version of the acknowledgement section is shown below:This work was supported by the National Natural Science Foundation of China [81371862 and 81572039], the Basic Research Project of Shanghai Science and Technology Commission [15JC1403000], the Shanghai Natural Science Foundation , Clinical Research Plan of SHDC [16CR1029B], and National megaproject on key infectious diseases [2017ZX10202102-001\u2013007]."}
+{"text": "Scientific Data 10.1038/s41597-019-0294-0, published online 22 November 2019Correction to: The spelling of King Abdullah University of Science and Technology has been corrected for author affiliations 1 and 2. This error has been corrected in both the HTML and PDF versions of this Data Descriptor."}
+{"text": "Correction to: BMC Genomics 2, 1005 (2019)https://doi.org/10.1186/s12864-019-6326-5After publication of this supplement article , it is rTherefore, the correct \u2018Funding\u2019 section in this article should read:This article has not received sponsorship for publication. We thank the National Science Foundation (NSF grant IIS-1902617) and the Data Science and Informatics Core for Cancer Research (CPRIT grant RP170668) for the financial support of ICIBM 2019, as well as the support from Cancer Prevention and Research Institute of Texas (RP180734)."}
+{"text": "Scientific Reports 10.1038/s41598-019-46387-2, published online 15 July 2019Correction to: This Article contains an error in the Acknowledgements section.\u201cThis project was supported by Award No. NIJ-2016-4305, awarded by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice and the National Institutes of Health Award No. P30DA033934.\u201dshould read:\u201cThis project was supported by Award No. 2016-DN-BX-0150, awarded by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice and the National Institutes of Health Award No. P30DA033934.\u201d"}
+{"text": "Correction to: BMC Microbiol 21, 25 (2021)https://doi.org/10.1186/s12866-020-02073-2Originally published Funding:Following publication of the original article , we wereCorrected Funding:\u201cThis work was supported by the Hunan Science and Technology Innovation Project, China (grant number 2017SK50122) and the Central South University New Medical Technology Project.\u201d\u201cThis work was supported by the Hunan Science and Technology Innovation Project, China (grant number 2017SK50122) and the New medical technology project of the Second Xiangya Hospital.\u201dSecondly, affiliation 1  should be removed for the author Chunmei Chen.The original article has been corrected."}
+{"text": "In the Funding statement, the author initials CK are missing from the funder the Foundation for Physical Therapy. The publisher apologizes for the error.The correct Funding statement is: This work was supported by NIH/NICHD : K12HD073945 (AE), F31HD087069 (RL), NIH/NIAMS  T32 AR050938, Musculoskeletal Training Grant , the Foundation for Physical Therapy , and the Minnesota Partnership for Biotechnology and Medical Genomics (MHP IF #14.02) (AE)."}
+{"text": "Scientific Reports 10.1038/srep39861, published online 03 January 2017Correction to: The Acknowledgements section in this Article is incomplete.\"We thank Nikon Instrument (Shanghai) CO., LTD. & Chansn Instrument (China) LTD. for technical support with super resolution microscopy. We also thank Dr. Matthew D. Weitzman for sharing reagents. This work was supported by grants from Chinese Academy of Sciences (KSCXZ-EW-BR-6), Startup fund from Kunming Institute of Zoology, Chinese Academy of Sciences (Y102421081), Grants from Yunnan Provincial Government , National Science Foundation of China (NSFC 81471966) to JZ, a NSFC grant to YX (31200964), a Common Project of Panzhihua, Science and Technology Bureau of China (2012CY-S-22(9)) to HH and a Visiting professorship for senior international scientist from CAS to NWF (2012T1S0001).\"should read:\"We thank Nikon Instrument (Shanghai) CO., LTD. & Chansn Instrument (China) LTD. for technical support with super resolution microscopy. We also thank Dr. Matthew D. Weitzman for sharing reagents. This work was supported by grants from National Science Foundation of China , Chinese Academy of Sciences (KSCXZ-EW-BR-6), Startup fund from Kunming Institute of Zoology, Chinese Academy of Sciences (Y102421081), Grants from Yunnan Provincial Government  to JZ, a NSFC grant to YX (31200964), a Common Project of Panzhihua, Science and Technology Bureau of China (2012CY-S-22(9)) to HH and a Visiting professorship for senior international scientist from CAS to NWF (2012T1S0001).\""}
+{"text": "Scientific Reports 10.1038/s41598-019-40114-7, published online 11 March 2019Correction to: The Acknowledgements section in this Article is incomplete.\u201cThe authors would like to thank Mrs Reyes Molina from the animal facility service at the Andalusian Centre for Nanomedicine & Biotechnology (BIONAND), Malaga, Spain. Mrs Ana Molina for the immunological analysis in IBIMA laboratories, Malaga, Spain and David Andreu from the Department of Experimental and Health Sciences, Universitat Pompeu Fabra of Barcelona for the synthesis of Prup3 T-cell peptide. The study was funded by the Institute of Health \u201cCarlos III\u201d of the Ministry of Economy and Competitiveness: PI12/02481, PI15/00559 and PI18/00288, RETICS ARADyAL  and Sara Borrell Program (CD14/00242). Andalusian Regional Ministry of Economy and Knowledge: CTS-7433), Nicolas Monardes Program (C-0044-2012 SAS2013) and the Spanish Ministry of Economy and Competitiveness  and a FPI grant (JRS). Grants were cofunded by the European Regional Development Fund (ERDF).\u201dshould read:\u201cThe authors would like to thank Mrs Reyes Molina from the animal facility service at the Andalusian Centre for Nanomedicine & Biotechnology (BIONAND), Malaga, Spain. Mrs Ana Molina for the immunological analysis in IBIMA laboratories, Malaga, Spain and David Andreu from the Department of Experimental and Health Sciences, Universitat Pompeu Fabra of Barcelona for the synthesis of Prup3 T-cell peptide. The study was funded by the Institute of Health \u201cCarlos III\u201d of the Ministry of Economy and Competitiveness co-founded by Fondo Europeo de Desarrollo Regional for the Thematic Networks and Co-operative Research Centres Una manera de hacer Europa: PI12/02481, PI15/00559 and PI18/00288, RETICS ARADyAL  and Sara Borrell Program (CD14/00242). Andalusian Regional Ministry of Health, Nicolas Monardes Program (C-0044- 2012 SAS2013). Andalusian Regional Ministry of Economy and Knowledge: CTS-7433), and the Spanish Ministry of Economy and Competitiveness  and a FPI grant (JRS). Grants were cofunded by the European Regional Development Fund (ERDF).\u201d"}
+{"text": "Interactions were evaluated using standard logistic regression and a newly developed case-only method for breast cancer risk overall and by estrogen receptor status. After accounting for multiple testing, we did not find evidence that per-standard deviation PRS313 odds ratio differed across strata defined by individual risk factors. Goodness-of-fit tests did not reject the assumption of a multiplicative model between PRS313 and each risk factor. Variation in projected absolute lifetime risk of breast cancer associated with classical risk factors was greater for women with higher genetic risk (PRS313 and family history) and, on average, 17.5% higher in the highest vs lowest deciles of genetic risk. These findings have implications for risk prevention for women at increased risk of breast cancer. We evaluated the joint associations between a new 313-variant PRS (PRS Precision prevention and early detection of cancer is a key aim of cancer research and uses tools such as risk prediction models for risk stratification ,2. Many 313) have a fourfold increased risk of breast cancer than women at population-average risk . This new PRS has been validated by prospective studies and shown to be more predictive than the previously reported 77-SNP PRS  can be summarized by a polygenic risk score (PRS); women in the top 1% of the newly derived 313-SNP PRS  using a tail-based test (313).Departure from the assumption of multiplicative combined effects of standardized PRSgression . Individsed test . Using tsed test , we proj313 and overall and ER-specific breast cancer risk are likely to be overestimated because there was substantial overlap between the SNP discovery samples and our dataset (Associations between PRSPint < .05/16\u2009=\u2009.003), none of the interactions between PRS313 and any classical risk factor was statistically significant except for family history    and conshistory) . However313 are based on a sample size 3 times larger than that used in previously published BCAC analyses , and by the European Communit\u00fds Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009\u2013223175) (COGS). The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report.Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Minist\u00e8re de l\u2019\u00c9conomie, Science et Innovation du Qu\u00e9bec through Genome Qu\u00e9bec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation. Funding for the iCOGS infrastructure came from: the European Community\u2019s Seventh Framework Programme under grant agreement n\u00b0 223175 (HEALTH-F2-2009\u2013223175) (COGS), Cancer Research UK , the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative , the Department of Defence (W81XWH-10\u20131-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, and Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The DRIVE Consortium was funded by U19 CA148065.The Australian Breast Cancer Family Study (ABCFS) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation  and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow. The ABCS study was supported by the Dutch Cancer Society . The Australian Breast Cancer Tissue Bank (ABCTB) was supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The AHS study is supported by the intramural research program of the National Institutes of Health, the National Cancer Institute (grant number Z01-CP010119), and the National Institute of Environmental Health Sciences (grant number Z01-ES049030). The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BCEES was funded by the National Health and Medical Research Council, Australia and the Cancer Council Western Australia and acknowledges funding from the National Breast Cancer Foundation (JS). The BREast Oncology GAlician Network (BREOGAN) is funded by Acci\u00f3n Estrat\u00e9gica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado FEDER; Acci\u00f3n Estrat\u00e9gica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Conseller\u00eda de Industria Programa Sectorial de Investigaci\u00f3n Aplicada, PEME I\u2009+\u2009D e I\u2009+\u2009D Suma del Plan Gallego de Investigaci\u00f3n, Desarrollo e Innovaci\u00f3n Tecnol\u00f3gica de la Conseller\u00eda de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigaci\u00f3n Cl\u00ednica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de Galicia, Spain. CBCS is funded by the Canadian Cancer Society (grant # 313404) and the Canadian Institutes of Health Research. The CECILE study was supported by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de S\u00e9curit\u00e9 Sanitaire, de l\u2019Alimentation, de l\u2019Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. The CNIO-BCS was supported by the Instituto de Salud Carlos III, the Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en C\u00e1ncer and grants from the Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer and the Fondo de Investigaci\u00f3n Sanitario (PI11/00923 and PI12/00070). The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort. The CTS was supported by the California Breast Cancer Act of 1993, the California Breast Cancer Research Fund (contract 97\u201310500) and the National Institutes of Health . Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. HAC receives support from the Lon V Smith Foundation (LVS39420). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G\u00e9n\u00e9rale de l\u2019Education Nationale, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council ; Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andaluc\u00eda, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK , Medical Research Council  (United Kingdom). The ESTHER study was supported by a grant from the Baden W\u00fcrttemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The GESBC was supported by the Deutsche Krebshilfe e. V. [70492] and the German Cancer Research Center (DKFZ). The KARMA study was supported by M\u00e4rit and Hans Rausings Initiative Against Breast Cancer. kConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command [DAMD17-01\u20131-0729], Cancer Council Victoria, Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, Cancer Council Tasmania and the National Health and Medical Research Council of Australia . G.C.T. and P.W. are supported by the NHMRC. RB was a Cancer Institute NSW Clinical Research Fellow. LMBC is supported by the \u2018Stichting tegen Kanker\u2019. DL is supported by the FWO. The MARIE study was supported by the Deutsche Krebshilfe e. V. , the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. The MCBCS was supported by the NIH grants CA192393, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. The MEC was support by NIH grants CA63464, CA54281, CA098758, CA132839 and CA164973. The MISS study is supported by funding from ERC-2011\u2013294576 Advanced grant, Swedish Cancer Society, Swedish Research Council, Local hospital funds, Berta Kamprad Foundation, Gunnar Nilsson. The MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286, and CA177150. The NBHS was supported by NIH grant R01CA100374. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The Northern California Breast Cancer Family Registry (NC-BCFR) and Ontario Familial Breast Cancer Registry (OFBCR) were supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The Carolina Breast Cancer Study was funded by Komen Foundation, the National Cancer Institute , and the North Carolina University Cancer Research Fund. The NHS was supported by NIH grants P01 CA87969, UM1 CA186107, and U19 CA148065. The NHS2 was supported by NIH grants UM1 CA176726 and U19 CA148065 and the Breast Cancer Research Foundation. The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health. PROCAS is funded from NIHR grant PGfAR 0707\u201310031. Prof. Dr D Gareth Evans is supported by the NIHR Biomedical Research Centre in Manchester (IS-BRC-1215\u201320007). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCS was supported by Sheffield Experimental Cancer Medicine Centre and Breast Cancer Now Tissue Bank. SEARCH is funded by Cancer Research UK  and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. The Sister Study (SISTER) is supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES049033). The SMC is funded by the Swedish Cancer Foundation and the Swedish Research Council (VR 2017\u201300644) grant for the Swedish Infrastructure for Medical Population-based Life-course Environmental Research (SIMPLER). The UKBGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The USRT Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The WHI program is funded by the National Heart, Lung, and Blood Institute, the US National Institutes of Health and the US Department of Health and Human Services . This work was also funded by NCI U19 CA148065-01.Role of the funder: The funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript.Disclosures: The authors declare no conflicts of interest.Acknowledgments: The authors thank all the researchers, clinicians, technicians, and administrative staff involved in the Breast Cancer Association Consortium. The authors would also like to thank all study participants, researchers, clinicians, technicians, and administrative staff who participated in the parent studies  and have enabled this work to be carried out. The authors thank the staff of the Center for Genetic Epidemiology Laboratory, the CNIO genotyping unit, the McGill University and G\u00e9nome Qu\u00e9bec Innovation Centre, and the Mayo Clinic Genotyping Core Facility. CPSII acknowledges the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, as well as cancer registries supported by the National Cancer Institute Surveillance Epidemiology and End Results program. The GENICA Network thanks Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of T\u00fcbingen, Germany, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), gef\u00f6rdert durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes und der L\u00e4nder - EXC 2180\u2013390900677, Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany, Institute of Pathology, University of Bonn, Germany, Molecular Genetics of Breast Cancer, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany, and Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Germany. KARMA and SASBAC studies thank the Swedish Medical Research Counsel. kConFab/AOCS wishes to thank all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study  for their contributions to this resource, and the many families who contribute to kConFab. NHS and NHS2 would like to thank the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. PROCAS thanks NIHR for funding. UKBGS thanks Breast Cancer Now and the Institute of Cancer Research for support and funding of the Breakthrough Generations Study. We acknowledge NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre.Author contributions:\u2002PMK: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Validation; Visualization; Writing\u2014original draft; Writing\u2014review & editing. NM: Data curation; Methodology; Validation; Writing\u2014review & editing. PPC: Methodology; Validation; Visualization; Writing\u2014review & editing. ANW: Methodology; Validation; Visualization; Writing\u2014review & editing. SL: Data curation; Writing\u2014review & editing. SB: Data curation; Writing\u2014review & editing. KM: Data curation; Writing\u2014review & editing. JD: Data curation; Writing\u2014review & editing. MKB: Data curation; Writing\u2014review & editing. QW: Data curation; Writing\u2014review & editing. AJ: Writing\u2014review & editing. ZA-F: Writing\u2014review & editing. TA: Writing\u2014review & editing. ILA: Data curation; Writing\u2014review & editing. HAC: Writing\u2014review & editing. VA: Writing\u2014review & editing. KJA: Writing\u2014review & editing. PLA: Writing\u2014review & editing. LEBF: Writing\u2014review & editing. HB: Data curation; Writing\u2014review & editing. MWB: Writing\u2014review & editing. AB-F: Writing\u2014review & editing. JB: Writing\u2014review & editing. LB: Writing\u2014review & editing. SEB: Writing\u2014review & editing. HB: Writing\u2014review & editing. TB: Writing\u2014review & editing. QC: Writing\u2014review & editing. DC: Writing\u2014review & editing. FC: Writing\u2014review & editing. AC: Writing\u2014review & editing. BDC: Writing\u2014review & editing. JEC: Writing\u2014review & editing. SJC: Writing\u2014review & editing. NC: Methodology; Writing\u2014review & editing. GC-T: Writing\u2014review & editing. CLC: Writing\u2014review & editing. FJC: Data curation; Writing\u2014review & editing. AC: Writing\u2014review & editing. SSC: Writing\u2014review & editing. KC: Writing\u2014review & editing. JYD: Writing\u2014review & editing. HSE: Writing\u2014review & editing. ABE: Writing\u2014review & editing. AHE: Writing\u2014review & editing. ME: Writing\u2014review & editing. DGE: Writing\u2014review & editing. PAF: Writing\u2014review & editing. JF: Writing\u2014review & editing. LF: Writing\u2014review & editing. MG: Writing\u2014review & editing. MG-D: Writing\u2014review & editing. CG: Writing\u2014review & editing. SMG: Writing\u2014review & editing. MMG: Writing\u2014review & editing. GGG: Writing\u2014review & editing. AG-N: Writing\u2014review & editing. PG: Writing\u2014review & editing. LH: Writing\u2014review & editing. CAH: Writing\u2014review & editing. NH: Writing\u2014review & editing. PH: Data curation; Writing\u2014review & editing. UH: Writing\u2014review & editing. SH: Writing\u2014review & editing. JH: Writing\u2014review & editing. BH: Writing\u2014review & editing. RNH: Writing\u2014review & editing. JLH: Writing\u2014review & editing. AH: Writing\u2014review & editing. DJH: Writing\u2014review & editing. EMJ: Writing\u2014review & editing. MEJ: Writing\u2014review & editing. RK: Writing\u2014review & editing. RK: Writing\u2014review & editing. CMK: Writing\u2014review & editing. Y-DK: Writing\u2014review & editing. SK: Writing\u2014review & editing. AWK: Writing\u2014review & editing. DL: Writing\u2014review & editing. LLM: Writing\u2014review & editing. EL: Writing\u2014review & editing. FL: Writing\u2014review & editing. ML: Writing\u2014review & editing. JL: Writing\u2014review & editing. AL: Writing\u2014review & editing. RJM: Writing\u2014review & editing. MEM: Writing\u2014review & editing. TM: Writing\u2014review & editing. CM: Writing\u2014review & editing. SLN: Writing\u2014review & editing. WGN: Writing\u2014review & editing. AN: Writing\u2014review & editing. KMO: Writing\u2014review & editing. AFO: Writing\u2014review & editing. JEO: Writing\u2014review & editing. HO: Writing\u2014review & editing. NO: Writing\u2014review & editing. CMP: Writing\u2014review & editing. GP: Writing\u2014review & editing. ECP: Writing\u2014review & editing. RLP: Writing\u2014review & editing. GR: Writing\u2014review & editing. HSR: Writing\u2014review & editing. KJR: Writing\u2014review & editing. DPS: Writing\u2014review & editing. CS: Writing\u2014review & editing. MJS: Writing\u2014review & editing. BS: Writing\u2014review & editing. FS: Writing\u2014review & editing. CS: Writing\u2014review & editing. RJS: Writing\u2014review & editing. X-OS: Writing\u2014review & editing. AS: Writing\u2014review & editing. MCS: Writing\u2014review & editing. JJS: Writing\u2014review & editing. JS: Writing\u2014review & editing. AJS: Writing\u2014review & editing. RMT: Writing\u2014review & editing. JAT: Writing\u2014review & editing. MAT: Writing\u2014review & editing. CMV: Writing\u2014review & editing. EmvV: Writing\u2014review & editing. XW: Writing\u2014review & editing. CRW: Writing\u2014review & editing. CW: Writing\u2014review & editing. WW: Writing\u2014review & editing. SJW: Writing\u2014review & editing. AW: Writing\u2014review & editing. XRY: Writing\u2014review & editing. WZ: Writing\u2014review & editing. AZ: Writing\u2014review & editing. AMD: Data curation; Funding acquisition; Project administration; Writing\u2014review & editing. PDPP: Data curation; Funding acquisition; Project administration; Writing\u2014review & editing. MKS: Data curation; Funding acquisition; Project administration; Writing\u2014review & editing. PK: Data curation; Funding acquisition; Methodology; Project administration; Writing\u2014original draft; Writing\u2014review & editing. DFE: Data curation; Funding acquisition; Project administration; Writing\u2014original draft; Writing\u2014review & editing. RLM: Conceptualization; Data curation; Funding acquisition; Project administration; Writing\u2014original draft; Writing\u2014review & editing. MG-C: Conceptualization; Data curation; Funding acquisition; Methodology; Project administration; Supervision; Validation; Visualization; Writing\u2014original draft; Writing\u2014review & editing.djaa056_Supplementary_DataClick here for additional data file."}
+{"text": "Scientific Reports 10.1038/s41598-020-76102-5, published online 11 November 2020Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis research was supported by a National Research Foundation of Korea (NRF) Grant funded by the Korean government (MSIT) (No. NRF-2019R1F1A1060353), Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2016M3C7A1913844), grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI19C1132), Fourth Stage of Brain Korea 21 Project in Department of Intelligent Precision Healthcare, National Research Council of Science & Technology (NST) grant by the Korea government (MSIP) (No. CRC-15-04-KIST) and Chonnam National University Hospital Biomedical Research Institute (BCRI20012).\u201dshould read:\u201cThis research was supported by a National Research Foundation of Korea (NRF) Grant funded by the Korean government (MSIT) (No. NRF-2019R1F1A1060353/NRF-2019R1A5A2027340), Research of Korea Centers for Disease Control and Prevention (No. 2018-ER6202-02), Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2016M3C7A1913844), grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI19C1132), Fourth Stage of Brain Korea 21 Project in Department of Intelligent Precision Healthcare, National Research Council of Science & Technology (NST) grant by the Korea government (MSIP) (No. CRC-15-04-KIST) and Chonnam National University Hospital Biomedical Research Institute (BCRI20012).\u201d"}
+{"text": "This article has been corrected: The Funding information has been updated. The complete Funding list is shown below:FUNDINGThis work was supported by the Karolinska Institutes KID funding (LP), the Seve Ballesteros Foundation to MS, the Marie Curie foundation (CIG-618751 MS), the Knut and Alice Wallenberg Foundation (KAW2014.273 TH), the Swedish Foundation for Strategic Research (RB13-0224 TH), the Swedish Cancer Society (TH), the Swedish Research Council (2015-00162 TH), the G\u00f6ran Gustafsson Foundation (TH), the Swedish Children\u2019s Cancer Foundation (to TH), the Swedish Pain Relief Foundation (PR20140048 TH), the Torsten and Ragnar S\u00f6derberg Foundation (TH), and the European Research Council (TAROX-695376).84671-84684. https://doi.org/10.18632/oncotarget.19404Original article: Oncotarget. 2017; 8:84671\u201384684."}
+{"text": "The article titled \u201cTumor-Derived CXCL1 Promotes Lung Cancer Growth via Recruitment of Tumor-Associated Neutrophils\u201d . The ediThe experiment was repeated by Dr. Mingyan Huang and supervised by Prof. Nan Li of the National Key Laboratory of Medical Immunology, Second Military Medical University. The corrected"}
+{"text": "The following information is missing from the Funding statement: Y.C. was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2019R1A2C1005380)."}
+{"text": "Correction to: BMC Public Health (2020) 20:880https://doi.org/10.1186/s12889-020-08975-0It was highlighted that the original article  containeAcknowledgmentswww.ace.soas.ac.ukAuthors acknowledge support from SamiunNazrinBente Kamal Tune, Senior Research Associate, BRAC James P. Grant BRAC School of Public Health, BRAC University for helping with organizing and formatting the references. This study is part of a large multi-country partnership, the SOAS Anti-Corruption Evidence (ACE) research consortium. For more information on SOAS-ACE visit: FundingThis publication is an output of the SOAS Anti-Corruption Evidence (ACE) research consortium funded by UK aid from the UK Government [Contract PO 7073]. The views presented are those of the author(s) and do not necessarily reflect the UK government\u2019s official policies or the views of SOAS-ACE or other partner organisations."}
+{"text": "Correction to: BMC Bioinformatics 21, 303 (2020)https://doi.org/10.1186/s12859-020-03591-6Following publication of the original article , the autThe sentence currently reads: Scientific research performed at the Computing Center of Research park of St. Petersburg State University.The sentence should read: Scientific research performed at the Computing Center of Research park of St. Petersburg State University. Development of the pipeline and publication of this supplement was funded by Russian Science Foundation grant #19\u201316-00049."}
+{"text": "Correction to: Arthritis Res Ther (2016):18, 264https://doi.org/10.1186/s13075-016-1159-yFollowing publication of the original article , the autAcknowledgementsThis research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C1277 and HI13C1754), SNUH research grant (number: 0420160770) and Rheumatology Research Foundation (RRF-2016-01)."}
+{"text": "There is information missing from the Funding statement. The complete, correct Funding statement is as follows: This research was funded by Universiti Putra Malaysia GP-IPS Research Grant (UPM/700-2/1/GP-IPS/2016/9492300) and Fundamental Research Grant Scheme under the Ministry of Higher Education Malaysia ."}
+{"text": "Correction to: Microbiome 8, 132 (2020)https://doi.org/10.1186/s40168-020-00909-7Following publication of the original article , it was FundingOpen access funding provided by Chalmers University of Technology.The project was funded by the Swedish Research Council  and the Swedish Research Council for Environment, Agricultural Sciences, and Spatial Planning . The original article  has been"}
+{"text": "Scientific Reports 10.1038/s41598-018-25636-w, published online 08 May 2018Correction to: This Article contains an error in the order of the Figures. Figures 1 and 3 were published as Figures 3 and 1 respectively. The correct Figures 1 and 3 appear below as Figures\u00a0In addition, the Acknowledgements section in this Article is incomplete.\u201cThis study was supported by the National Key Research Program of China (2017YFC0840100 and 2017YFC0840107) (L.C.); National Natural Science Foundation of China grant 81600858 (B.R.), and 81430011 (X.Z.); Recruitment Program for Young Professionals (M.F.) the Youth Grant of the Science and Technology Department of Sichuan Province, China 2017JQ0028 (L.C.). Innovative Research Team Program of Sichuan Province (L.C.).\u201dshould read:\u201cThis study was supported by the National Key Research Program of China (2017YFC0840100 and 2017YFC0840107) (L.C.); the Youth Grant of the Science and Technology, Department of Sichuan Province, China 2017JQ0028 (L.C.); National Natural Science Foundation of China grant 81870759 (L.C), 81600858 (B.R.), and 81430011 (X.Z.).\u201d"}
+{"text": "Communication, Collaboration and Care Coordination: The Three-Point Guide to Cancer Care Provision for Aboriginal and Torres Strait Islander Australians. International Journal of Integrated Care. 2020; 20(2): 10. DOI:"}
+{"text": "Scientific Reports 10.1038/s41598-020-58831-9, published online 25 February 2020Correction to: The Acknowledgements section in this Article was omitted. The Acknowledgements section should read:\u201cThe authors would like to acknowledge financial support from the European Commission, Future and Emerging Technology programme, through the projects RAMP (6112058) and SYNCH (824162) and from the Engineering and Physical Sciences Engineering Research Council programme FORTE (EP/R024642/1). All data are available at: 10.5258/SOTON/D1280\u201d"}
+{"text": "In this introduction article, we summarize the 2020 International Conference on Intelligent Biology and Medicine (ICIBM 2020) conference which was held on August 9\u201310, 2020 . We then briefly describe the nine research articles included in this supplement issue. ICIBM 2020 hosted four scientific sections covering current topics in bioinformatics, computational biology, genomics, biomedical informatics, among others. A total of 75 original manuscripts were submitted to ICIBM 2020. All the papers were under rigorous review (at least three reviewers), and highly ranked manuscripts were selected for oral presentation and supplement issues. This genomics supplement issue included nine manuscripts. These articles cover methods and applications for single cell RNA sequencing, multi-omics data integration for gene regulation, gene fusion detection from long-read RNA sequencing, gene co-expression analysis of metabolic pathways in cancer, integrative genome-wide association studies (GWAS) of subcortical imaging phenotype in Alzheimer\u2019s disease, as well as deep learning methods for protein structure prediction, metabolic pathway membership inference, and horizontal gene transfer (HGT) insertion sites prediction. The 2020 International Conference on Intelligent Biology and Medicine (ICIBM 2020), the official conference of the International Association for Intelligent Biology and Medicine (IAIBM), was successfully held virtually from August 9th to 10th, 2020 due to the coronavirus 2019 (COVID-19) outbreak. Since its inception in 2012, the goal of the ICIBM conference was to provide a forum that fosters interdisciplinary discussion, educational opportunities, and collaborative efforts among the fields of bioinformatics, systems biology, intelligent computing, and medical informatics, which are continuing to evolve at a rapid pace and having a significant impact in biomedical research and innovations.Building upon the successes of the conferences in the previous years \u20137, ICIBMBelow, we briefly summarize the scientific program of the ICIBM 2020 and provide an introduction to the nine research articles selected for this BMC Genomics supplement issue.Session I: Computational GenomicsSession II: Biomedical InformaticsSession III: Genomics and BeyondSession IV: BioinformaticsICIBM 2020 included four scientific sessions. Speakers in the regular sessions were chosen from those top ranked manuscripts after peer review. The topics in these sessions covered bioinformatics, genomics, systems biology, intelligent computing, data sciences, computational drug discovery, and biomedical informatics. The details of these sessions, including session chairs, authors, presenters, and the title and abstract of each talk were included on the conference website. The four session are:Here, we provide an editorial report of the supplements to BMC Genomics that include nine research papers selected from 75 manuscripts submitted to ICIBM 2020. Each manuscript was reviewed for two rounds. The first round of review was carried out by at least three reviewers and the manuscripts were substantially revised according to reviewers\u2019 critiques. The revision was further reviewed by at least two reviewers (most by three reviewers) before being accepted into the supplement issue. Other selected papers were accepted in other BMC journals: BMC Bioinformatics, BMC Medical Genomics, and BMC Medical Informatics and Decision Making.Below, we summarize the contribution of nine papers included in this supplement issue. These papers cover a wide spectrum of topics in bioinformatics and computational biology, and provide scalable techniques and algorithms for computational genomics.In the first paper, Cornish et al.  proposedintePareto, for the integrative analysis of RNA-seq and ChIP-seq data for different histone modifications. Specifically, the method can examine the abundance correlations of histone modification and gene expression. Then, it prioritizes genes with congruent changes in RNA-seq and ChIP-seq between two experimental conditions using Pareto optimization. The results show that integration of RNA-seq data and ChIP-seq data by Pareto optimization outperformed an unsupervised method based on Bayesian inference of a hierarchical model and a method using single omics data only.Multi-omics data integration has now become a routine technique to understand the mechanisms of gene regulation. Cao et al.  introducThe paper by Gao et al.  applied Long-read RNA-seq techniques are able to sequence full-length transcripts, so they are expected to overcome inherited limitations of short-read RNA-seq techniques. Liu et al.  introducHorizontal Gene Transfer (HGT) is generally defined as exchange of genetic materials between distant species that are not in a parent-offspring relationship. The HGT insertion sites are important to study the HGT mechanisms. Li et al.  introducThe paper by Zhang et al.  studied The paper by Cartealy et al.  proposedGenome-wide association studies (GWAS) can detect variants/genes associated with brain imaging quantitative traits (QTs) in Alzheimer\u2019s disease (AD). Meng et al.  applied To understand the biological function of proteins, it is important to accurately predict protein structure. Zhang et al.  proposedWe would like to express our sincere gratitude to the general chairs and the members of the steering, program, publication, publicity, award and trainee committees, as well as to all the reviewers, who spent their valuable time and effort on making ICIBM 2020 a success. The conference accomplishments are the results of support and hard work of all these people during the COVID-19 pandemic.Host: The International Association for Intelligent Biology and Medicine (IAIBM).General Chairs Kai Wang  and Zhongming Zhao .Steering Committee Yidong Chen , Xiaohua Tony Hu (Drexel University), Kun Huang (Indiana University), Sudhir Kumar (Temple University), Jason Moore (University of Pennsylvania), Yi Xing (University of Pennsylvania).Program Committee Co-Chairs: Xinghua (Mindy) Shi (Temple University), Li Shen (University of Pennsylvania). Members: Yongsheng Bai (University of Michigan) Xiao Chang , Bin Chen (Michigan State University), Li Chen (Indiana University School of Medicine), Yidong Chen , Jianlin Cheng (University of Missouri Columbia), Lijun Cheng (Ohio State University), Zechen Chong (The University of Alabama at Birmingham), Yulin Dai , Yang Ding , Abolfazl Doostparast , Lana Garmire (University of Michigan), Jun-Tao Guo (University of North Carolina at Charlotte), Yan Guo (University of New Mexico), Zhi Han (Indiana University School of Medicine), Matthew Hayes (Xavier University of Louisiana), Zhe He (Florida State University), Ting Hu , Heng Huang (University of Pittsburgh & JD Digits), Kun Huang (Indiana University School of Medicine), Tao Huang , Weichun Huang , Yufei Huang (University of Texas at San Antonio), Zhi-Liang Ji , Peilin Jia , Victor Jin , Yufang Jin (University of Texas at San Antonio), Travis Johnson (The Ohio State University), Dokyoon Kim (University of Pennsylvania), Rui Kuang (University of Minnesota Twin Cities), Aimin Li , Fuhai Li (Washington University School of Medicine) Jia Li (Texas A&M University), Tao Li , Li Liao (University of Delaware), Honghuang Lin (Boston University School of Medicine), Ke Liu (Michigan State University), Xiaoming Liu (University of South Florida), Yaping Liu , Zhandong Liu (Baylor College of Medicine), Shuang Luan (University of New Mexico), Qin Ma (The Ohio State University), Maciej Pietrzak (The Ohio State University), Mirjana Maletic-Savatic (Baylor College of Medicine), Patricio Manque , Huaiyu Mi , Nitish Mishra , Tabrez Anwar Shamim Mohammad (Greehey Children\u2019s Cancer Research Institute), Zhengqing Ouyang , Hatice Gulcin Ozer (The Ohio State University), Ranadip Pal (Texas Tech University), Jiang Qian (Johns Hopkins University), Guimin Qin , Boshu Ru (Merck & Co. Inc), Jianhua Ruan (The University of Texas at San Antonio), Wei Shao (Indiana University Bloomington), Yang Shen (Texas A&M University), Xiaofeng Song , Fengzhu Sun , Zhifu Sun (Mayo Clinic), Wing-Kin Sung , Manabu Torii (Kaiser Permanente), Fuchiang Rich Tsui , Jun Wan (Indiana University School of Medicine), Jiandong Wang (University of South Carolina), Jiayin Wang , Junbai Wang , Kai Wang , Yufeng Wang (University of Texas at San Antonio), Chaochun Wei , Lei Wei (Roswell Park Comprehensive Cancer Center), Yingying Wei , Jia Wen (University of North Carolina at Chapel Hill), Chunhua Weng (Columbia University), Huanmei Wu (Indiana University - Purdue University Indianapolis), Yonghui Wu (University of Florida), Junfeng Xia , Lei Xie (City University of New York), Hua Xu , Min Xu (Carnegie Mellon University), Jianhua Xuan (Virginia Tech), Yu Xue , Jingwen Yan (Indiana University - Purdue University Indianapolis), Sungroh, Yoon , Liang Zhan (University of Pittsburgh), Chi Zhang (Indiana University School of Medicine), Han Zhang , Rui Zhang (Michigan Tech), Shaojie Zhang , Wei Zhang , Ying Zhang (University of Rhode Island), Zuoyi Zhang (Indiana University), Zhongming Zhao , Jim Zheng , Wanding Zhou , Yunyun Zhou (University of Mississippi), Dajiang Zhu (University of Texas at Arlington).Publication Committee Co-Chairs: Yan Guo (University of New Mexico), Wei Zhang .Workshop/Tutorial Committee Chair: Yulin Dai .Publicity Committee Co-Chairs: Yu Xue , Kwangsik Nho (Indiana University).Award Committee Chair: Jinchuan Xing (Rutgers University).Trainee Committee Chair: James Havrilla .Local Organization Committee Co-Chairs: Dokyoon Kim (University of Pennsylvania), Wanding Zhou ."}
+{"text": "Euromed Research Center, National Institute of Applied Sciences, Euro-Mediterranean University of Fez, Morocco.a.arrahli@insa.ueuromed.org.\u2009 E-mail address: In the article titled \u201cValorization of Oued Sebou Natural Sediments (Fez-Morocco Area) as Adsorbent of Methylene Blue Dye: Kinetic and Thermodynamic Study\u201d , the autThe corrected list of affiliations is shown in the author information above."}
+{"text": "Respiratory syncytial virus (RSV) bronchiolitis (Br) is the leading cause of US infant hospitalizations and lower respiratory tract infections [1]. The historical seasonality of RSV in the US across all ages using passive laboratory surveillance has been described by the CDC (2014-17) [2] [3] and more recently by Staadegaard et al [4]. The objective of this analysis is to describe local variation in infant RSV-Br seasonality since the onset of COVID-19 in March 2020, across all facilities and all settings in four health systems across the US, and compare to trends from the recent pre-COVID-19 era.From October 2015-April 2023 we conducted real-time surveillance across all facilities and all settings in the State University of New York (SUNY) Upstate Medical University Health System in Syracuse, NY; the Duke University Health System (DUHS) in Durham, NC; the University of South Florida Health and Tampa General Hospital (TGH) in Tampa, FL; and the Renown Regional Medical Center Health System (Renown) in Reno, NV. We assessed electronic health records (EHR) of infants (0-11 months) using ICD-10 codes for Br and RSV-Br and laboratory testing data to describe infant RSV-Br encounters. For additional methods see Movva N et al [5].Figure 1). Onset and peak disease was earliest at TGH in the southeast and latest at Renown in the west. While occurring outside the historical seasonality timeframe, interseasonal 2021 and early seasonal 2022 infant RSV-Br was similar in duration and followed the same geographic pattern of onset to historical disease.During the recent pre-COVID-19 era, there was regional variation in seasonal onset and peak disease burden of infant RSV-Br (After the US onset of COVID-19 in March 2020, the geographic pattern of RSV-Br onset and peaks was preserved, despite the shift to interseasonal and early seasonal disease in 2021 and 2022, respectively. RSV surveillance is useful to determine whether RSV seasonality is returning to typical historic patterns. These results highlight the need for health system-level surveillance and can guide discussion regarding administration of candidate RSV vaccines and immunoprophylaxis and assessment of their impact.Mina Suh, MPH, International Health, AstraZeneca: Grant/Research Support|Sanofi: Grant/Research Support|Sobi: Grant/Research Support ZACHARY Wolf, MBA, MS, AstraZeneca: Grant/Research Support|Sanofi: Grant/Research Support Emory Waddell, n/a, Sanofi: Research support Christopher B. Nelson, PhD MPH, Sanofi: employee|Sanofi: employee|Sanofi: Stocks/Bonds|Sanofi: Stocks/Bonds"}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-023-43386-2, published online 26 September 2023Correction to: The Funding section in the original version of this Article was omitted.The Funding section now reads: \u201cThis work is the result of a commissioned research project supported by the affiliated institute of ETRI [2022-047], by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1G1A1095764), by the Hanbat National University Convergence Research, and by the research fund of Hanbat National University in 2021.\u201dThe original Article has been corrected."}
+{"text": "The COVID-19 pandemic has disrupted mental healthcare delivery in many countries. The restricted access to psychiatric services and double disasters (pandemic and earthquakes) coincided in Croatia, potentially placing people with severe mental illness (SMI) in a very vulnerable position.The aim of this study was to examine the changes in substance use in people with SMI in the first and the second COVID-19 wave and co-occurring earthquakes. The secondary aim was to explore whether the type of treatment  vs. treatment as usual) influenced those changes.This study was nested within the RECOVER-E project . The study involved 90 participants with SMI assessed at two time points: in May/June 2020 (during the first COVID-19 wave and after Zagreb earthquake) and in December 2020/January 2021 (during the second COVID-19 wave and after Petrinja earthquake). The changes in the use of psychoactive substances  were assessed using self-reported survey.The increase in tobacco smoking behavior and the use of sedatives was observed in both COVID-19 waves in people with SMI. No increase was reported in cannabis and other drugs use, while less than 5% of participants reported increase in alcohol consumption. Not receiving CMHT service predicted the increase in sedative use.Ensuring accessible mental health care provided by CMHT is recommended for counteracting the negative effect of external stressors (such as pandemic and co-occurring earthquakes) on the increased substance use among people with SMI.S. Levaj Grant / Research support from: Project RECOVER-E - European Union\u2019s Horizon 2020 research and innovation programme; Grant Agreement No 779362., S. Medved Grant / Research support from: Project RECOVER-E - European Union\u2019s Horizon 2020 research and innovation programme; Grant Agreement No 779362., J. Gerlach: None Declared, L. Shields-Zeeman Grant / Research support from: Project RECOVER-E - European Union\u2019s Horizon 2020 research and innovation programme; Grant Agreement No 779362., F. Bolinski Grant / Research support from: Project RECOVER-E - European Union\u2019s Horizon 2020 research and innovation programme; Grant Agreement No 779362., Z. Brada\u0161 Grant / Research support from: Project RECOVER-E - European Union\u2019s Horizon 2020 research and innovation programme; Grant Agreement No 779362., Z. Mad\u017earac Grant / Research support from: Project RECOVER-E - European Union\u2019s Horizon 2020 research and innovation programme; Grant Agreement No 779362., I. Rojni\u0107 Palavra: None Declared, M. Rojni\u0107 Kuzman Grant / Research support from: Project RECOVER-E - European Union\u2019s Horizon 2020 research and innovation programme; Grant Agreement No 779362."}
+{"text": "Scientific Reports 10.1038/s41598-022-25127-z, published online 21 March 2023Correction to: The original version of this Article contained an error in the Acknowledgments section.\u201cThe authors acknowledge the financial support provided by the Center of Excellence in Theoretical and Computational Science (TaCS-CoE), KMUTT. Moreover, this research project is supported by Thailand Science Research and Innovation (TSRI) Basic Research Fund: Fiscal year 2022 (FF65). The first author Muhammad Arif appreciate the support provided by Petchra Pra Jom Klao Ph.D. Research Scholarship (Grant No. 14/2562 and Grant No. 25/2563).\u201dnow reads:\u201cThe authors acknowledge the financial support provided by the Center of Excellence in Theoretical and Computational Science (TaCS-CoE), KMUTT. Moreover, this research project is supported by Thailand Science Research and Innovation (TSRI) Basic Research Fund: Fiscal year 2023 under project number FRB660073/0164. The first author Muhammad Arif appreciates the support provided by Petchra Pra Jom Klao Ph.D. Research Scholarship (Grant No. 14/2562 and Grant No. 25/2563).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-023-35433-9, published online 30 May 2023Correction to: The original version of this Article contained an error in the Acknowledgements section.\u201cThank you for the financial support from Henan Province Science and Technology Research Project (No. 212102310968), Key scientific research projects of colleges and universities in Henan Province (No. 21A410004), Henan Province Housing and Urban-Rural Construction Science and Technology Project (No. HNJS-2020-k25) and Post-doctoral research project of Henan Urban Planning Institute and Corporation.\u201d now reads:\u201cThank you for the financial support from Henan Province Science and Technology Research Project (No.222102320137), Key scientific research projects of colleges and universities in Henan Province (No. 21A410004), Henan Province Housing and Urban-Rural Construction Science and Technology Project (No. HNJS-2020-k25) and Post-doctoral research project (2022M721046).\"The original Article has been corrected."}
+{"text": "Learning Health Systems. An international, trans\u2010disciplinary, open access publication, the journal has advanced research and scholarship on learning health systems in partnership with our reviewers. With indexing in multiple major sources and the recent news that we have received our first official Impact Factor, we have achieved a publication milestone that signals a sustainable, positive trajectory. Articles from the journal were downloaded over 109,532 times in 2022.The publication of Issue 4 marks the completion of Volume 7 of Special Issues: \u201cPatient Empowerment and the Learning Health System\u201d (v.1); \u201cEthical, Legal, and Social Implications of Learning Health Systems\u201d (v.2); \u201cLearning Health Systems: Connecting Research to Practice Worldwide\u201d (v.3); \u201cHuman Phenomics and the Learning Health System\u201d (v.4); \u201cCollaborative Learning Health Systems: Science and Practice\u201d (v.5); and \u201cEducation To Meet the Multidisciplinary Workforce Needs of Learning Health Systems\u201d (v.6). \u201cTransforming Health Through Computable Biomedical Knowledge (CBK)\u201d (v.7). Our talented guest editors have been instrumental in helping these Special Issues come to fruition.The journal has now published seven We are keenly aware that these achievements would not have happened without the dedicated efforts and insightful comments of all those individuals who accepted invitations to review submitted articles. With busy schedules and full commitments, these individuals found the time and energy to contribute their expertise to our authors to help ensure that their papers met (and often exceeded) the journal's high standards for publication.Please accept our sincere gratitude for your outstanding efforts.Charles P. Friedman, Editor in Chief.Learning Health Systems Peer ReviewersNote: These are the Reviewers for articles published in all four issues of Volume 7 and for all articles currently published and posted online in Early View.Julia Adler\u2010Milstein (United States)Tesfa Michael Alaro (Ethiopia)Eta Berner (United States)Sarah Birken (United States)Juli Bollinger (United States)Nicholas Bowersox (United States)Erica Breuer Melinda Buntin (United States)Michael Cantor (United States)Jonathan Casey (United States)Harold Collard (United States)Marisa Conte (United States)Derek Corrigan (Ireland)Catherine Diederich (United States)Margo Edmunds (United States)Ayca Erdogan (United States)Amanuel Ergado (Ethiopia)Stephan Fihn (United States)Allen Flynn (United States)Thomas Foley (United Kingdom of Great Britain and Northern Ireland)Tina Foster (United States)Brandy Fureman (United States)Sarah Greene (United States)Robert Greenes (United States)Gary Groot (Canada)W. Ed Hammond (United States)Kevin Haynes (United States)Peter Kaboli (United States)Dipak Kalra (Belgium)Amy Kilbourne (United States)Martin Kohn (United States)Greg Koski (United States)Yong\u2010Hong Kuo (Hong Kong)Alison Laycock Xiaojuan Li (United States)Nancy Lorenzi (United States)Paula Lozano (United States)David McCallie (United States)Jamie McCusker (United States)Mark McGilchrist (United Kingdom of Great Britain and Northern Ireland)Scott Mahoney (South Africa)Brad Malin (United States)Teri Manolio (United States)Brian Martin (United States)Graham Martin (United Kingdom of Great Britain and Northern Ireland)Blackford Middleton (United States)Stephanie Morain (United States)Cheryl Moyer (United States)Mark Musen (United States)Brian Ostasiewski (United States)Gretchen Piatt (United States)Jodyn Platt (United States)Leon Pretorius (South Africa)Andrew Read (United States)Rachel Richesson (United States)Frank Rockhold (United States)Joshua Rubin (United States)Sameer Saini (United States)Lucy Savitz (United States)Philip Scott (United Kingdom of Great Britain and Northern Ireland)Jean Soler Matthew South (United Kingdom of Great Britain and Northern Ireland)Jessie Tenenbaum (United States)Alexandra Vinson (United States)Shyam Visweswaran (United States)Anita Walden (United States)Jim Walker (United States)Mark Weiner (United States)Berta Whitney (Canada)Jun Yasuda (Japan)Yili Zhang (United States)"}
+{"text": "Translational Psychiatry 13, 201 (2023); 10.1038/s41398-023-02508-0, published online 13 June 2023Correction to: The Acknowledgements section in this Article was incomplete.\u201cThis work was supported by Instituto de Salud Carlos III (PI18/00514 and PI21/00612) and by the Catalan Agency of Research and Universities . The PsyCourse study was supported by DFG .\u201dshould read:\u201cThis work was supported by Instituto de Salud Carlos III through the projects PI18/00514 and PI21/00612 and co-funded by the European Union, by the Catalan Agency of Research and Universities . The PsyCourse study was supported by DFG .\"The original article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-023-36589-0, published online 10 June 2023Correction to: The original version of this Article contained an error in the Funding section.\u201cOpen access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.\u201dnow reads:\u201cOpen access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This paper is based on work supported by a grant from the Science, Technology and Innovation Funding Authority (STDF).\u201dThe original Article has been corrected."}
+{"text": "In the published article, there was an error in the Funding statement (a project reference is missing from the funding statement):G. D. and D.B. were supported by the Spanish national research project (ref. PID2019-105772GB-I00AEI/10.13039/501100011033) funded by the Spanish Ministry of Science, Innovation and Universities (MCIU), State Research Agency (AEI).The correct Funding statement appears below.This work was funded by ICVS Scientific Microscopy Platform, member of the National infrastructure PPBI\u2013Portuguese Platform of Bioimaging (PPBI-POCI01 0145-FEDER-022122); by National funds, through the Foundation for Science and Technology (FCT)\u2013project UIDB/50026/2020 and UIDP/50026/2020; and by the project NORTE-01-0145-FEDER-000039, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). GD and DB were supported by the Spanish national research project (ref. PID2019-105772GB-I00/AEI/10.13039/501100011033) funded by the Spanish Ministry of Science, Innovation and Universities (MCIU) and State Research Agency (AEI).The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated."}
+{"text": "Correction: BMC Ophthalmol 23, 256 (2023)https://doi.org/10.1186/s12886-023-03001-4The original publication of this article  containeIncorrectClinical Research Program of 9th People\u2019s Hospital afliated to Shanghai Jiao Tong University School of Medicine(No.JYLJ201905).CorrectClinical Research Program of 9th People\u2019s Hospital afliated to Shanghai Jiao Tong University School of Medicine(No.JYLJ201904)."}
+{"text": "In \u201cA Personalized Ontology-Based Decision Support System for Complex Chronic Patients: Retrospective Observational Study\u201d :e27990) the authors made three changes.Affiliation 1 originally appeared as:Group of Research and Innovation in Biomedical Informatics, Biomedical Engineering and Health Economy, Institute of Biomedicine of Seville (IBiS), Virgen del Roc\u00edo University Hospital, University of Seville, Seville, SpainBut has been changed to:Computational Health Informatics Group, Institute of Biomedicine of Seville, Virgen del Roc\u00edo University Hospital, Consejo Superior de Investigaciones Cient\u00edficas, University of Seville, Seville, SpainAdditionally, the text under \u201cAcknowledgments\u201d has been changed from:This research was partly funded by the Innovation in Medical Technologies and Health  platform (code #PT13/0006/0036 and #PT17/0005/0036) and by the PITeS-TIiSS project (code #PI15/01213) from the Carlos III National Health Institute, both cofunded by the European Regional Development Fund (ERDF). We would like to thank Dr Rosario Villar\u00e1n Mart\u00ednez for the help during the validation phase of the PITeS-TIiSS tool.To read as follows:This research was partly funded by the Innovation in Medical Technologies and Health  platform (code #PT13/0006/0036 and #PT17/0005/0036) and by the PITeS-TIiSS project (code #PI15/01213) and Smart-PITeS project (code #PI18/00700) from the Carlos III National Health Institute, both cofunded by the European Regional Development Fund (ERDF). We would like to thank Dr Rosario Villar\u00e1n Mart\u00ednez for the help during the validation phase of the PITeS-TIiSS tool.The correction will appear in the online version of the paper on the JMIR Publications website on February 28, 2023, together with the publication of this correction notice. Because this was made after submission to PubMed, PubMed Central, and other full-text repositories, the corrected article has also been resubmitted to those repositories."}
+{"text": "Correction: European Journal of Medical Research (2023) 28:300 10.1186/s40001-023-01254-9In the Funding section of this article the grant number relating to Arak University of Medical Sciences given for Ali Khosrowbeygi was incorrectly given as 120 and should have been 6327. The original article ["}
+{"text": "Scientific Reports 10.1038/s41598-022-26813-8, published online 04 January 2023Correction to: The original version of this Article contained an error in the Funding section,\u201cThis work was supported by Basic Science Research Program through the Chungbuk Techno-Park funded by Chungcheongbuk-do, Korea. The funders had no role in the study design, analysis, decision to publish, or preparation of the manuscript.\u201dnow reads:\u201cThis research was supported by \u2018Regional Innovation Strategy (RIS)\u2019 through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (MOE) (2021RIS-001).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-023-34625-7, published online 16 May 2023Correction to: The original version of this Article contained an error in the Acknowledgements section.\u201cFinancial support for this study was provided by NIH Surveillance NOSI NOT-GM-21-031 and by the University of Idaho IIDS Genomics and Bioinformatics Resources Core, which is supported in part by NIH COBRE Phase III Grant P30GM103324.\u201dnow reads:\u201cThe project described was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grant #P20GM103408-21S1 and the University of Idaho IIDS Genomics and Bioinformatics Resources Core, which is supported in part by NIH COBRE Phase III Grant P30GM103324.\u201dThe original Article has been corrected."}
+{"text": "Correction to: BMC Public Health 23, 140 (2023)10.1186/s12889-023-15045-8The original publication of this article was missing the following affiliation for author Stephen O\u2019Neill:Centre for Economic and Social Research on Dementia, University of Galway, Galway, Ireland.The original article has been updated to correct this."}
+{"text": "Scientific Reports 10.1038/s41598-023-34721-8, published online 22 May 2023Correction to: The original version of this Article contained an error in the Acknowledgements section. The first grant number was incorrectly written.\u201cThe work at Texas Tech University was supported in part by grants from the Air Force Office of Scientific Research (No. FA9550-19-1-0056) and the Office of Naval Research (No. N00014-22-1-2483). The work at the University of New Mexico was supported by AFOSR MURI Grant FA9550-21-1-0367 via a subaward from Michigan State University and ONR Grant N00014-23-1-2072. We also acknowledge the generous amounts of computer time provided by Texas Tech University High Performance Computer Center.\u201dnow reads:\u201cThe work at Texas Tech University was supported in part by grants from the Air Force Office of Scientific Research (No. FA9550-22-1-0499) and the Office of Naval Research (No. N00014-22-1-2483). The work at the University of New Mexico was supported by AFOSR MURI Grant FA9550-21-1-0367 via a subaward from Michigan State University and ONR Grant N00014-23-1-2072. We also acknowledge the generous amounts of computer time provided by Texas Tech University High Performance Computer Center.\"The original Article has been corrected."}
+{"text": "Aspergillus spp. and non-tuberculous mycobacterium.Patients with pulmonary non-tuberculous mycobacteriosis (NTM) have been increasing in Japan in recent years. Furthermore, NTM cases complicated with pulmonary aspergillosis are associated with a poor prognosis. However, little is known about the interaction between A. fumigatus growth and gene expression, supernatants of M. avium (ATCC 700737) and M. abscessus (ATCC 19977) were added to A. fumigatus .To investigate the effect of NTM metabolites on A. fumigatus exposed to culture supernatant of each NTM were significantly increased compared to the control . The expression of genes involved in the synthesis of secondary metabolites of A. fumigatus, such as gliotoxin, was decreased after the exposure to supernatant by RNA sequencing analysis .The biofilms and biomass of A. fumigatus while suppressing the production of some secondary metabolites. We are now trying to reproduce this phenotype in mouse model and to identify the causative agent from NTM culture supernatant and elucidate the mechanism further.Our results suggest that exposure to culture supernatant of NTM may support the growth of Masato Tashiro, MD, PhD, Asahi Kasei Pharma Corporation: Advisor/Consultant|Asahi Kasei Pharma Corporation: Honoraria|Sumitomo Pharma Co., Ltd.: Honoraria Koichi Izumikawa, M.D., Ph.D., Asahi Kasei Pharma Corporation: Grant/Research Support|Asahi Kasei Pharma Corporation: Honoraria|Astellas Pharma Inc.: Honoraria|DAIICHI SANKYO COMPANY, LIMITED: Grant/Research Support|DAIICHI SANKYO COMPANY, LIMITED: Honoraria|KYORIN Pharmaceutical Co., Ltd.: Honoraria|Merck & Co., Inc.: Honoraria|Pfizer Japan Inc.: Honoraria|Shionogi & Co., Ltd.: Grant/Research Support|Shionogi & Co., Ltd.: Honoraria|Sumitomo Pharma Co., Ltd.: Grant/Research Support|Sumitomo Pharma Co., Ltd.: Honoraria|TAIHO PHARMACEUTICAL CO., LTD.: Grant/Research Support"}
+{"text": "Correction: Journal of Orthopaedic Surgery and Research (2023) 18:554https://doi.org/10.1186/s13018-023-04033-8Following publication of the original article , the affThe author would like to update the funding information as \u201cFujian Provincial Clinical Medical Research Center for First Aid and Rehabilitation in Orthopaedic Trauma (2020Y2014)\u201d."}
+{"text": "Correction: Cancer Cell International (2023) 23:24 https://doi.org/10.1186/s12935-022-02837-yThe research is supported by the Science and Technology Research Project from the Education Department of Jilin Province, Based on the NF-\u03baB mediated inflammatory corpuscle and PI3K/AKT signaling pathway research puerarin drug mechanism of nanometer fiber membrane on the skin wound healing (No. JJKH20210413KJ).In this article , the gra"}
+{"text": "Nature Communications 10.1038/s41467-021-25564-w, published online 06 September 2021Correction to: The original version of this Article omitted the following from the Acknowledgements: \u201cThis research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science user facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.\u201d This has now been corrected in both the PDF and HTML versions of the Article."}
+{"text": "Correction to: BMC Health Services Research (2023) 23:37610.1186/s12913-023-09242-9Following publication of the original article , the autThe statement in the \u2018Funding\u2019 section originally read: This study was funded by National Institute for Health Research (NIHR) Policy Research Programme (PRP) (Award ID: NIHR200718).The statement in the \u2018Funding\u2019 section should read: This study was funded by National Institute for Health Research (NIHR) Policy Research Programme (PRP) (Award ID: NIHR200718). This is study was supported by the NIHR Applied Research Collaboration (ARC) WestMidlands, NIHR Community Healthcare MedTech and IVD Cooperative (MIC) and NIHR Oxford Biomedical Research Centre (BRC) through funding to DL.The original article  has been"}
+{"text": "Correction: Journal of Orthopaedic Surgery and Research (2023) 18:328https://doi.org/10.1186/s13018-023-03633-8Following publication of the original article , the autThe correct funding note is given below.This work was supported by: (1) National Natural Science Foundation of China (No. 81972983); (2) National Key Research and Development Program of China (2022YFC2503101).The original article  has been"}
+{"text": "Correction: Journal of Nanobiotechnology (2023) 21:65https://doi.org/10.1186/s12951-023-01808-3Following publication of the original article , the aut12272071) and the Key and Postdoctoral Projects of Natural Science Foundation of Chongqing (cstc2019jcyj-zdxmX0009 and cstc2020jcyj-bsh0139).This research was supported by the National Natural Science Foundation of China (12032007, 32171334, The original article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-023-41364-2, published online 29 August 2023Correction to: The Acknowledgements section in the original version of this Article was incomplete.\u201cThe work was part funded by the IVCC and Medical Research Council (Grant Ref: MR/V001264/1).\u201dnow reads:\u201cThe work was funded by the IVCC (supported by the Bill and Melinda Gates Foundation under Grant Number OPP1148615), and Medical Research Council (Grant Ref: MR/V001264/1).\u201dThe original Article has been corrected."}
+{"text": "An additional affiliation is missing for author Adam R. Ferguson, who is also affiliated with San Francisco Veterans Affairs Healthcare System, San Francisco, California, United States of America.http://doi.org/10.34945/F5KG6Z).The following information is missing from the Data Availability statement: Source data has been deposited to the Open Data Commons for Spinal Cord Injury  under the accession number ODC-SCI:727 ("}
+{"text": "Scientific Reports 10.1038/s41598-023-43760-0, published online 03 October 2023Correction to: The original version of this Article omitted an affiliation, Shenzhen Research Institute, for Hongfeng Yang. The correct affiliations are listed below.1Earth and Environmental Sciences Programme, The Chinese University of Hong Kong, Shatin, Hong Kong2Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China3Institute of Environment, Energy and Sustainability, The Chinese University of Hong Kong, Shatin, Hong KongIn addition, the Acknowledgements section was incorrect.\u201cWe appreciate constructive comments and suggestions from two anonymous reviewers.\u00a0We thank E.M. Dunham from Stanford University for insightful discussions. Y.Y. is supported by the Research Grants Council Postdoctoral Fellowship, University Grants Committee, Hong Kong (PDFS2223-4S08). H.Y. is supported by the Research Grants Council, University Grants Committee, Hong Kong (No.\u00a014303721) and the National Natural Science Foundation of China (U2139203). All authors are supported by the Faculty of Science at the Chinese University of Hong Kong.\u201dnow reads:\u201cWe appreciate constructive comments and suggestions from two anonymous reviewers. We thank E.M. Dunham from Stanford University for insightful discussions. H.Y. is supported by the National Natural Science Foundation of China (No. U2139203) and the Research Grants Council, University Grants Committee, Hong Kong (No. 14303721). Y.Y. is supported by the Research Grants Council Postdoctoral Fellowship, University Grants Committee, Hong Kong (PDFS2223-4S08). J.Z. is supported by the Hong Kong PhD Fellowship Scheme. All authors are supported by the Faculty of Science at the Chinese University of Hong Kong.\u201dThe original Article has been corrected."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-023-39542-3, published online 01 August 2023Correction to: In the original version of this Article, Weixiong Peng, Yue Gao and Yang Mu were incorrectly affiliated with \u2018Clinical Research Center (CRC), Medical Pathology Center (MPC), Cancer Early Detection and Treatment Center (CEDTC), Translational Medicine Research Center (TMRC), Chongqing University Three Gorges Hospital, Chongqing University, Wanzhou, Chongqing, China\u2019. The correct affiliation is listed below.\u2018Hunan Zixing Artificial Intelligence Technology Group Co., Ltd., Hunan Province, Changsha City, China\u2019The original Article has been corrected."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-023-34296-4, published online 04 May 2023Correction to: The Acknowledgments section in the original version of this Article was omitted. The Acknowledgments section now reads:\u201cThis work was supported by the Zhejiang Basic Public Welfare Research Project (LGF20H260013), the Initial Scientific Research Fund for PhD from Taizhou Hospital of Zhejiang Province (2018BSKYQDJJ15) and the Taizhou Science and Technology Planning Project (1802ky01).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-023-29359-5, published online 01 March 2023Correction to: The original version of this Article contained an error in the order of the Figures. Figure 1 was published as Figure 3, Figure 3 was published as Figure 1, Figure 4 was published as Figure 8, Figure 5 was published as Figure 7, Figure 7 was published as Figure 5, and Figure 8 was published as Figure 4. The Figure legends were correct.The original Figures\u00a0In addition, the Funding section contained an error.\u201cThis research was funded by the National Key Research and Development Program of China [2017YFA0604902], The Scientific Research Foundation of the Third Institute of Oceanography, MNR , China APEC Foundation [HV01-190101(1)], Xiamen, and Marine and Fishery Development Special Foundation [19CZP011HJ08].\u201dnow reads:This research was funded by the National Key Research and Development Program of China [2017YFA0604902], The Scientific Research Foundation of the Third Institute of Oceanography, MNR , the High-level Foreign Experts Funding Program of China (G2021055005L), China APEC Foundation [HV01-190101(1)], Xiamen, and Marine and Fishery Development Special Foundation [19CZP011HJ08].The original Article has been corrected."}
+{"text": "Cell Death and Disease 10.1038/s41419-023-05715-1, published online 28 March 2023Correction to: In this article the funding note has been given erroneously:This study was supported by grants: (I) Youth Scientific Reseach Project of Fujian Province Health Commission (2020QNA05*2*);But should be read:This study was supported by grants: (I) Youth Scientific Reseach Project of Fujian Province Health Commission (2020QNA05*1*);The original article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-26637-6, published online 04 January 2023Correction to: The Funding section in the original version of this Article was incomplete.\u201cThis work was supported by ICGEB, Cape Town Component, Medical Research Council (MRC) South Africa as well as support by the South African National Research Foundation (NRF) Research Chair initiative (SARChi) and Wellcome Trust CIDRI-Africa (203135Z/16/Z) to FB. SH is supported by NRF Thuthuka Grant (117721), NRF Competitive Support for Unrated Researcher (138072), MRC South Africa under a Self-initiated grant. MS was supported by ICGEB Arturo Falaschi PhD Fellowship NM was supported by South African MRC PhD Fellowship. AN was supported by NRF MSc Scholarship.\u201dnow reads:\u201cThis work was supported by ICGEB, Cape Town Component, Medical Research Council (MRC) South Africa as well as support by the South African National Research Foundation (NRF) Research Chair initiative (SARChi) and Wellcome Trust CIDRI-Africa (203135Z/16/Z) to FB. SH is supported by NRF Thuthuka Grant (117721), NRF Competitive Support for Unrated Researcher (138072), MRC South Africa under a Self-initiated grant. MS was supported by ICGEB Arturo Falaschi PhD Fellowship NM was supported by South African MRC PhD Fellowship. AN was supported by NRF MSc Scholarship. This research was funded in whole, or in part, by the Wellcome Trust [Grant number 203135Z/16/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-023-37973-6, published online 03 July 2023Correction to: The original version of this Article contained an error in the Acknowledgements section.\u201cThe author (Z. Raizah) extends her appreciation to the Deanship of Scientific Research at King Khalid University, Abha, Saudi Arabia, for funding this work through the Research Group Project under Grant Number (RGP.1/334/43).\u201dnow reads:\u201cThe author (Z. Raizah) extends her appreciation to the Deanship of Scientific Research at King Khalid University, Abha, Saudi Arabia, for funding this work through the Research Group Project under Grant Number (RGP.1/300/44).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-023-32307-y, published online 09 May 2023Correction to: The Funding section in the original version of this Article was incomplete.\u201cThis study received funding from the Korean Fund for Regenerative Medicine (KFRM), a Grant funded by the Korean government  (21A0101L0). Additionally, partial support was provided by a Grant from the Korea Research Institute of Standards and Science (KRISS-2022-GP2022-0002-11).\u201dnow reads:\u201cThis study received funding from the Korean Fund for Regenerative Medicine (21C0721L1) funded by Ministry of Science and ICT and Ministry of Health and Welfare, and from the Technology Innovation Program  funded by the Ministry of Trade, Industry & Energy. Additionally, partial support was provided by a Grant from the Korea Research Institute of Standards and Science (KRISS-2022-GP2022-0002-11)\u201d.The original Article has been corrected."}
+{"text": "Biomarker Research (2023) 11:6210.1186/s40364-023-00499-0The original article  mistakenFunding:This work was funded by National Natural Science Foundation of China , National Health Commission Science Research Fund-Zhejiang Provincial Health Key Science and Technology Plan Project (WKJ-ZJ-2117), Leading Talents in Scientific and Technological Innovation from Zhejiang Provincial Ten Thousand Talents Plan , Zhejiang Province Health Leader Talent (Zjwjw2021-40), and Major Training Personnel from Zhejiang Provincial Program for Training and Development Project for 151 Talents (Zjhrss2014-150)."}
+{"text": "Scientific Reports 10.1038/s41598-017-06410-w, published online 20 July 2017Correction to: This Article contains an error in the Acknowledgements section.\u201cWe thank Beth Cadugan for editing the manuscript, Dr. Zhiyong Guo  for generously sharing the Foxp3(GFP) knock-in mice, and Mr. Xiaobo Li for providing the technical support of cell sorting. This study partially fulfills the requirement of the Ph.D. degree at the Graduate School of Sun Yat-sen University School of Medicine for Qi Wang and Jianwei He. This work is supported in part by the 985 project grant from Sun Yat-sen University, Guangdong Province Innovative Research Program Project 2011Y035, PRC; National Institutes of Health grants P50 CA177444, P30 CA016359, P50 CA17744415 and P30 CAO16359, and an endowment from the United Technologies Corporation, USA.\u201dshould read:\u201cWe thank Beth Cadugan for editing the manuscript, Dr. Zhiyong Guo  for generously sharing the Foxp3(GFP) knock-in mice, and Mr. Xiaobo Li for providing the technical support of cell sorting. This study partially fulfills the requirement of the PhD degree at the Graduate School of Sun Yat-sen University School of Medicine for Qi Wang and Jianwei He. This work is supported in part by the 985-project grant from Sun Yat-sen University, Guangdong Province Innovative Research Program Project 2011Y035, PRC; National Institutes of Health grants P50 CA177444, P30 CA016359, and an endowment from the United Technologies Corporation, USA.\u201d"}
+{"text": "Pagiophloeus tsushimanus (Coleoptera: Curculionidae) larvae, Journal of Insect Science, Volume 23, Issue 2, March 2023, 14, https://doi.org/10.1093/jisesa/iead019This is a correction to: Heng Qiao and others, Isolation and characterization of gut bacteria associated with the degradation of host-specific terpenoids in Funding statement. This should read additionally: \u201c[...]the Shanghai Landscaping & City Appearance Administrative Bureau (Grant number G161206), Postgraduate Research & Practice Innovation Program of Jiangsu Province (Grant number KYCX23_1236), and National natural science foundation of China (Grant number 32271884).\u201d instead of \u201c[...]and the Shanghai Landscaping & City Appearance Administrative Bureau (Grant number G161206).\u201dIn the originally published version of this manuscript, details were missing from the This error has been corrected in the article."}
+{"text": "The new Cystic Fibrosis (CF) transmembrane conductance regulator modulator therapy combination  has significantly improved the quality of life of children with CF and decreased the rate of pulmonary exacerbations (PEx). The focus of our study was to examine the infection characteristics of PEx in children with CF before the availability of ETI (2018) and following ETI approval and during emergence from COVID-19 (2022).We conducted a multicenter (5 sites) retrospective review collecting data on children with CF over 12-month periods in 2018 and in 2022 who were hospitalized for PEx and treated with IV antibiotics. We analyzed the number of PEx, bacterial and fungal organisms identified by CF respiratory cultures and IV antibiotics used empirically at hospital admission.The number of hospitalizations for PEx decreased from 414 in 2018 to 163 in 2022. The most common organisms identified in all centers were Pseudomonas aeruginosa (Pa), Staphylococcus aureus (Sa) and Candida species, with no apparent overall difference in the relative percentages of pathogens isolated between 2018 and 2022 (figure 1), although fewer children were infected with methicillin-resistant S. aureus (MRSA) in 2022 (2.7%) than in 2018 (10%) (p=0.014). There was variability in the type of antipseudomonal agents and antistaphylococcal agents used empirically both within and between the different centers (figure 2).Pathogens isolated from respiratory culture associated with PEx demonstrated similar rates of isolation of pathogens in the 2 time periods, consistent with historical CF pathogen isolation. The decreased number of PEx in 2022 compared to 2018 is consistent with the widespread use of ETI. The variability of usage antipseudomonal agents between centers and between years of data collection requires further investigation.Andrea Hahn, MD, MS, TGV Dx: Advisor/Consultant Antonio C. Arrieta, MD, FIDSA, FPIDS, Astellas Pharma Global Development, Inc.: Advisor/Consultant|Astellas Pharma Global Development, Inc.: Grant/Research Support|Astellas Pharma Global Development, Inc.: Honoraria|Cumberland Pharmaceutical: Grant/Research Support|IDbyDNA: Advisor/Consultant|IDbyDNA: Grant/Research Support|Melinta: Grant/Research Support|Merck: Advisor/Consultant|Merck: Grant/Research Support|Nabriva: Grant/Research Support|Paratek Pharmaceuticals: Grant/Research Support|Pfizer, Inc: Advisor/Consultant|Pfizer, Inc: Grant/Research Support|Roche/Genentech: Grant/Research Support|The Medicine Company: Grant/Research Support"}
+{"text": "Funding statement. One of the funding references was displayed as \u201cEXPL/BIA-EVL/1562/2021\u201d and should have been displayed as \u201cEXPL/BIA-EVL/1045/2021\u201d. The correct Funding statement appears below.In the published article, there was an error in the via the projects PTDC/ASP-PES/28053/2017 \u2013 POCI-01-0145-FEDER-028053 co-funded by FEDER Funds through the Operational Competitiveness Factors Program COMPETE and by national funds through the Foundation for Science and Technology and EXPL/BIA-EVL/1045/2021, supported by the Foundation for Science and Technology. PE and AV, were supported by Portuguese funds through Portuguese Foundation for Science and Technology Contracts: CEECIND/CP1601/CT0005 (to PE) and DL57/2016 (to AV).\u201d\u201cThis work was co-funded by the European Regional Development Fund (FEDER) and Norte Portugal Regional Operational Programme (NORTE2020), under the PORTUGAL 2020 Partnership Agreement, and by the project NORTE-01-0246-FEDER-000063. The authors also acknowledge research support The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated."}
+{"text": "Correction to: BMC Public Health (2023) 23:99310.1186/s12889-023-15803-8The original publication of this article contained an incorrect funding section. The incorrect and correct information is listed in this correction article, the original publication has been updated.IncorrectThis work was support by Science and Technology Commission Shanghai Municipality (No. 20JC1410204) for the Seroepidemiological Study of Novel Coronavirus Pneumonia in Key Populations.CorrectThis work was support by the Shanghai Municipal Health Commission [grant numbers GWV-10.1-XK18]\u00a0and Science and Technology Commission Shanghai Municipality (No. 20JC1410204) for the Seroepidemiological Study of Novel Coronavirus Pneumonia in Key Populations."}
+{"text": "Molecular Neurodegeneration (2023) 18:4110.1186/s13024-023-00630-7.The original article [1] contained errors in the Funding section. The correct Funding information can be viewed ahead:FundingThis work was supported by the National Research Foundation of Korea (NRF) grants funded by the Ministry of Science, ICT and Future Planning (MSIP) , the Korea Dementia Research Project (HU21C0071 to Y.H.S.), and the Ministry of Education (RS-2023-00243474 to E.J.B.). This work was also supported by Korea Drug Development Fund (KDDF) (RS-2022-00166787 to K.W.S.)."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-023-43778-4, published online 05 October 2023Correction to: The original version of this Article contained an error in the Funding section.\u201cThis research was funded by grants to Chang (Grant Number 2022IL0031-1) and Jung (Grant Number 2023IL0020-1) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.\u201dnow reads:\u201cThis research was funded by grants to Chang (Grant Number 2022IL0031-1) and Jung (Grant Number 2023IP0123) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-020-61437-w, published online 16 March 2020Correction to: The original version of this Article contained an error in the Acknowledgements section. The last digit of the RETICS was incomplete.\u201cThis study was funded by the Spanish Ministry of Science and Innovation (MICINN) and Carlos III Health Institute (ISCIII)/European Regional Development Fund (ERDF), (RETICS: RD16/0007). The authors declare no conflicts of interest.\u201dnow reads:\u201cThis study was funded by the Spanish Ministry of Science and Innovation (MICINN) and Carlos III Health\u00a0Institute (ISCIII)/European Regional Development Fund (ERDF), (RETICS: RD16/0007/0015). The authors declare no conflicts of interest.\u201dThe original Article has been corrected."}
+{"text": "Correction:J Exp Clin Cancer Res42, 309 (2023)10.1186/s13046-023-02899-4Following publication of the original article , authorsThe sentence currently reads:This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2019M3A9H2032425). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2020R1I1A306655012). This work was supported by the Ministry of Science and ICT, (Project Number: (2022) ERIC07_1_1) and Commercialization Promotion Agency for R&D Outcomes (COMPA).The sentence should read:This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2019M3A9H2032425). This research was supported by the Commercialization Promotion Agency for R&D Outcomes(COMPA) funded by the Ministry of Science and ICT(MSIT) .This work was supported by the Korea Medical Device Development Fund grant funded by the Korea government  (project number: RS_2023-00255627).The correction does not affect the overall result or conclusion of the article. The original article has been corrected."}
+{"text": "Correction to: BMC Women\u2019s Health (2023) 23:49110.1186/s12905-023-02646-zIn this article , \u201cLan LiUnder funding information section, a funder name and an institution \u201cNatural Science Foundation of Ningxia Province (2022AAC03143)\u201d needs to be added. So the Funding information should read as \u201cThe research was supported by National Key Research and Development Program of China (2017YFC0907204), the Key Research and Development Program of Ningxia (2021BEG02026) and Natural Science Foundation of Ningxia Province (2022AAC03143)\u201d.The original article has been corrected."}
+{"text": "Correction to: Journal of Assisted Reproduction and Genetics10.1007/s10815-022-02689-5In this article the affiliation details for author Claudia Raperport should have been \u201cWomen\u2019s Health Research Unit, Wolfson Institute for Population Health, Queen Mary University of London.\u201dThe original article has been corrected."}
+{"text": "Correction:BMC Musculoskelet Disord24, 380 (2023)10.1186/s12891-023-06474-yFollowing publication of the original article [1], the authors would like to make the following changes to affiliations:Department of Radiology, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea\u201dAffiliation 2 should be changed to \u201cDepartment of Orthopaedic surgery, Seoul National University College of Medicine, Seoul, Republic of Korea)Additional affiliation to Dr. Moon Seok Park (The affiliations have been updated above and the original article  has been"}
+{"text": "The first paragraph of the Acknowledgments section should read as follows: \u201cThis research was supported by the Chung-Ang University Research Grants in 2019 and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R1A2C2007712).\u201dVolume 10, no. 5, e03305-22, 2022,"}
+{"text": "Correction: BMC Oral Health 23, 695 (2023)https://doi.org/10.1186/s12903-023-03431-yIn the original publication of the article , the autThis work was supported by Japan Agency for Medical Research and Development (AMED) Grant No. 16lm0103007j0005 and a Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research\u2009<\u2009KAKENHI\u2009>\u2009."}
+{"text": "Scientific Repots 10.1038/s41598-023-31706-5, published online 05 April 2023Correction to: The Acknowledgements section in the original version of this Article was incomplete.\u201cThe author (PF) was supported by an OTKA Grant (FK 135870). The author (ZTK) was supported by an OTKA Grant (K 139415).\u201dnow reads:\u201cThe author (SIA) was supported by the \u00daNKP-22-3-SZTE-232 New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund. The author (PF) was supported by an OTKA Grant (FK 135870). The author (ZTK) was supported by an OTKA Grant (K 139415).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-023-30309-4, published online 25 February 2023Correction to: The Acknowledgements section in the original version of this Article was incomplete.\u201cPrincess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2022R161), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. The authors would like to thank the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by Grant Code: (22UQU4310373DSR40).\u201dnow reads:\u201cPrincess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2023R161), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. This study is supported via funding from Prince Sattam bin Abdulaziz University project number (PSAU/2023/R/1444). The authors would like to thank the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by Grant Code: (22UQU4310373DSR62). The Authors would like to thank the Deanship of Scientific Research at Majmaah University for supporting this work under Project No. R-2023-68.\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-05479-2, published online 08 February 2022Correction to: The original version of this Article contained an error in the Acknowledgements section.\u201cThis work was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI20C1456 and HI19C0655), and by a grant from the SNUBH Research Fund (14-2017-012). T.E.M was supported from Seoul National University Hospital Biomedical Research Institute.\u201dnow reads:\u201cThis work was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI19C0655), by the Korea Medical Device Development Fund grant funded by the Korean government (Project Number: RS-2020-KD000229), and by a grant from the SNUBH Research Fund (14-2017-012). T.E.M. was supported by Seoul National University Hospital Biomedical Research Institute.\u201dThe original Article has been corrected."}
+{"text": "Correction: Journalof Translational Medicine (2023) 21:294\u00a010.1186/s12967-023-04133-3Following publication of the original article , we haveThis study was supported by National Research Council of Thailand (NRCT) and Mahidol University (Grant No. N42A650369).The original article  has been"}
+{"text": "Scientific Reports 10.1038/s41598-022-25763-5, published online 07 December 2022Correction to: The original version of this Article contained an error in the Acknowledgements section, where the grant number of the Program Management Unit for Human Resources and Institutional Development, Research and Innovation was incorrect.\u201cThe Program Management Unit for Human Resources and Institutional Development, Research and Innovation (B16F630071), National Science and Technology Development Agency through the Southeast Asia-Europe Joint Funding Scheme for Research and Innovation (FDA-CO-2563-11897-TH), and the Energy Storage Cluster, Chulalongkorn University are acknowledged.\u201dnow reads:\u201cThe Program Management Unit for Human Resources and Institutional Development, Research and Innovation (B16F640166), National Science and Technology Development Agency through the Southeast Asia-Europe Joint Funding Scheme for Research and Innovation (FDA-CO-2563-11897-TH), and the Energy Storage Cluster, Chulalongkorn University are acknowledged.\u201dThe original article has been corrected."}
+{"text": "In the Funding section, funding sources were omitted. The correct Funding Statement is: This work was supported by grants to C. V. F. Carrington from The University of the West Indies\u2014Trinidad &Tobago Research Development Impact Fund (No. 26607\u2013447524), Pan American Health Organization / World Health Organisation , Government of the Republic of Trinidad and Tobago Ministry of Health (He: 10/45/35 Vol 1) and the AHF Global Public Health Institute, and in-kind support from PAHO/WHO and the Caribbean Public Health Agency. Also, a Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0) and a Wellcome Trust and Royal Society  to N. Faria. S. C. Hill acknowledges support of a Sir Henry Wellcome Postdoctoral Fellowship (Wellcome Trust grant number 220414/Z/20/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."}
+{"text": "Scientific Reports 10.1038/s41598-023-33968-5, published online 19 May 2023Correction to: The original PDF version of this Article contained formatting errors in Equation\u00a010.now reads:Additionally, the Funding section in the original version of this Article was omitted. The Funding section now reads:\u201cThis research was funded by the Health Research Council of New Zealand (programme grant 17/608) and National Heart Foundation of New Zealand (project 1834).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-023-32507-6, published online 31 March 2023Correction to: The original version of this Article contained an error in the Acknowledgements section.\u201cThis work was supported by the National Natural Science Foundation of China (Grant No. 8206040058); and the Natural Science Foundation of Jiangxi Province, China (Grant No. 20202BABL206064).\u201dnow reads:\u201cThis work was supported by the National Natural Science Foundation of China (Grant No. 82060186); and the Natural Science Foundation of Jiangxi Province, China (Grant No. 20202BABL206064).\u201dThe original article has been corrected."}
+{"text": "Blood Cancer Journal 10.1038/s41408-022-00739-w, published online 04 October 2022Correction to: In this article, Acknowledgements section was incorrectly given. It should have read as below.This work was supported in part by National Institutes of Health, National Heart, Lung, and Blood Institute grant R01 HL141336, R01 CA248149, a Research Scholar grant (RSG-19-036-01-LIB) from the American Cancer Society, the Gehr Family Center for Leukemia Research (LL) and the Vera and Joseph Dresner Foundation for established investigator award (LL and GM).The original article has been corrected."}
+{"text": "Prospective randomized control trial\u201d Saudi Med J 2021; Vol. 42 (10): 1065-1071 doi: The affiliation should appeared as: From the Department of Anesthesiology ; from the Department of Orthopedic Surgery (Aljurayyan), College of Medicine, King Saud Universityahaji@ksu.edu.saThe e-mail should appear as:"}
+{"text": "Scientific Reports 10.1038/s41598-023-40904-0, published online 24 August 2023Correction to: The original version of this Article omitted an affiliation for Yousef Mubarak. The correct affiliations are listed below:Department of Geosciences, College of Petroleum Engineering and Geosciences, King Fahd University of Petroleum and Minerals, Dhahran, Saudi ArabiaSaudi Aramco, 31311, Dhahran, Saudi ArabiaAlso there was an error in the acknowledgements section. The last digit of the Grant number was incorrect.\u201cThe author acknowledged contribution from King Fahd University of Petroleum and Minerals, Saudi Arabia in providing the facilities to perform this study under a Research Grant from the SDAIA-KFUPM Joint Research Centre for Artificial Intelligence (CAI02564) awarded to A.K.\u201dnow reads:\u201cThe author acknowledged contribution from King Fahd University of Petroleum and Minerals, Saudi Arabia in providing the facilities to perform this study under a Research Grant from the SDAIA-KFUPM Joint Research Centre for Artificial Intelligence (JRCAI-RG-05) awarded to A.K.\u201dThe original Article has been corrected."}
+{"text": "This article has an addendum: Acknowledgements - To the Experimental Research Group and the Laboratory of Histopathology of the State University of Par\u00e1 (CESUPA) for the technical assistance provided and to the Laboratory of Human Cytogenetics of the Federal University of Par\u00e1 (LCH/UFPA). This study was also supported in part by scholarships for postgraduate students of Coordination for the Improvement of Higher Education Personnel - Brazil (CAPES) - Finance Code 001. To the support of PROPESP/UFPA (PAPQ) (23073.074981/2022-97).23-39. https://doi.org/10.18632/oncotarget.28338Original article: Oncotarget. 2023; 14:23\u201339."}
+{"text": "Correction: Genome Med 14, 67 (2022)https://doi.org/10.1186/s13073-022-01071-5The original publication of this article  containeIncorrectCamille and Henry Dreyfus Foundation and R35 GM13779501 from the National Institutes of Health (NIH) USA to S. ChandrasekaranCorrectCamille and Henry Dreyfus Foundation and startup funds from the University of Michigan to S. Chandrasekaran."}
+{"text": "Correction: Journal of Cheminformatics (2023) 15:26 https://doi.org/10.1186/s13321-023-00693-0Following publication of the original article , the autFundingThis work was supported by National Research Foundation of Korea (NRF) Grants funded by the Korean government (MSIT) . This work was also supported by the Korea Environment Industry & Technology Institute (KEITI) through the Technology Development Project for Safety Management of Household Chemical Products, funded by the Korea Ministry of Environment (MOE) (KEITI:2020002960002 and NTIS:1485017120 to U.V.U. and J.L.).The original article has been corrected."}
+{"text": "The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy By Zhao Z, Dong S, Sun T, Han K, Huang X, Ma M, Yang S and Zhou Y. (2023) Front. Cardiovasc. Med. 10:1115142. doi: 10.3389/fcvm.2023.1115142A Corrigendum on Incorrect FundingIn the published article, there was an error in the Funding statement. The correct Funding statement appears below.FUNDINGThis work was supported by grants from the National Key Research and Development Program of China (2017YFC0908800), Pilot Projects for Public Welfare Development of Beijing Municipal Medical Institute \u201cPrecise medicine and interventional diagnosis and treatment platform for coronary heart disease\u201d (2019-3), Capital's Funds for Health Improvement and Research (CFH 2020-2-2063) and Beijing Municipal Natural Science Foundation (7202041).The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated."}
+{"text": "Scientific Reports 10.1038/s41598-023-30411-7, published online 10 March 2023Correction to: The Acknowledgements section in the original version of this Article was incomplete. It now reads:\u201cWe thank the following colleagues for their support and valuable suggestions: Dr Ang Siang Yun, Dr Keith Tan, Dr Kwa Mei Qi, Alvin Tan, and Dr Ivo De Vos. We thank the AMPL/Histology facility for performing Masson\u2019s trichrome staining. This work was supported by Biomedical Research Council (BMRC), Agency for Science, Technology, and Research in Singapore (A*STAR); BMRC-A*STAR-EDB IAF-PP for the Skin Research Institute of Singapore (H17/01/a0/004), Acne and Sebaceous Gland Program (H17/ H17/01/a0/008), and National Medical Research Council Clinician-Scientist Individual Research Grant MOH-CIRG20nov-0009.\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-020-64679-w, published online 08 May 2020Correction to: The Acknowledgements section in the original version of this Article was incomplete.www.gemma-project.eu. The Cell line and DNA bank of Rett Syndrome, X-linked mental retardation and other genetic diseases, member of the Telethon Network of Genetic Biobanks (project no. GTB18001), funded by Telethon Italy, and of the EuroBioBank network, provided us with specimens. We thank John Hatton of the Institute of Biomedical Technologies (CNR-ITB) for proofreading the manuscript.\u201d\u201cGrants received in support of research work: Italian Ministry of Health (GR-2009-1570296); Italian Flagship-project InterOmics (PB05); European Union\u2019s Horizon 2020 GEMMA project (grant agreement No 825033), now reads:www.gemma-project.eu. The Cell line and DNA bank of Rett Syndrome, X-linked mental retardation and other genetic diseases, member of the Telethon Network of Genetic Biobanks (project no. GTB18001), funded by Telethon Italy, and of the EuroBioBank network, provided us with specimens. We thank John Hatton of the Institute of Biomedical Technologies (CNR-ITB) for proofreading the manuscript. Two of several authors of this publication are members of the European Reference Network for rare malformation syndromes and rare intellectual and neurodevelopmental disorders, ERN-ITHACA.\u201d\u201cGrants received in support of research work: Italian Ministry of Health (GR-2009-1570296); Italian Flagship-project InterOmics (PB05); European Union\u2019s Horizon 2020 GEMMA project (grant agreement No 825033), The original Article has been corrected."}
+{"text": "The current funding information is incorrect. The full, correct funding statement can be found below.http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap) for The Atherosclerosis Risk in Communities (ARIC) Study through accession number phs000090.v1.p1. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. O.H is supported by the National Institute of Drug Abuse (DA027995) and the Barnes-Jewish Hospital Foundation.OZALC-NAG is supported by National Institutes of Health Grants DA012854, AA07535, AA07728, AA13320, AA13321, AA14041, AA11998, AA17688 and DA019951; by grants from the Australian National Health and Medical Research Council ; by grants from the Australian Research Council ; and by the 5th Framework Programme (FP-5) GenomEUtwin Project (QLG2-CT-2002-01254). Genome-wide association study genotyping at the Center for Inherited Disease Research was supported by a grant to the late Richard Todd, M.D., Ph.D., former Principal Investigator of grant AA13320. Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment and Health Initiative [GEI] (U01 HG004422). SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies (GENEVA) under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism , the Collaborative Genetic Study of Nicotine Dependence , and the Family Study of Cocaine Dependence . Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH contract \"High throughput genotyping for studying the genetic contributions to human disease\" (HHSN268200782096C). Data were obtained from dbGaP (The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."}
+{"text": "There were errors in the Funding section. The correct funding information is as follows: This work is supported by Hong Kong Baptist University (FRG2/11-12/009), Environment and Conservation Fund (ECF Project 3/2010), Centre for Cancer and Inflammation Research, School of Chinese Medicine , the Health and Medical Research Fund (HMRF/11101212), the Research Grants Council (HKBU/201811), the University of Macau -ICMS12-LCH and MYRG121(Y1-L2)-ICMS12-LCH), and Special Equipment Grant (SEG_PolyU01) of the University Grants Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."}
+{"text": "An affiliation of the first author was incorrectly omitted. Philip C. Higgins is notonly affiliated with institutions numbers 1-3, but also Department of CareCoordination, Brigham & Women's Hospital and the Dana-Farber/Brigham & Women'sCancer Center."}
+{"text": "There was an error in the Funding Information. The correct Funding Information is as follows:The study was funded by the United States Department of State (U.S. Foreign Ministry); the U.S. Embassy, Quito; the U.S. Department of Agriculture (USDA-ARS); the Instituto Nacional Autonomo de Investigaciones Agropecuarias (INIAP-Ecuador); and the Centre de Coop\u00e9ration Internationale en Recherche Agronomique pour le D\u00e9veloppement (CIRAD-France)."}
+{"text": "The image and legend for Figure 1 is incorrect. The correct image can be found at the following URL:The correct legend is as follows:Figure 1. Maximum likelihood phylogeny of contemporary DENV strainsRepresentative DENV strains from currently circulating genotypes considered for primer and probe modifications. Full genome sequences were used. Each taxa is labeled: country of origin, year of isolation, and GenBank accession number. Due to figure space limitations, only a representative subset of strains were used to generate these ML trees. DENV-1 Asian (I), South Pacific (II), and American-African (III) genotypes [55], DENV-2 Asian I (IIIa), American-Asian (IIIb), and Cosmopolitan (IV) genotypes [42], DENV-3 South Pacific (I), Thailand (II), and Indian Subcontinent (III) genotypes , DENV-4 Southeast (I) and Indonesian (II) genotypes [56]."}
+{"text": "The first paragraph of the Conclusion section of the article should have included a citation to the following publication in American Board of Family Medicine. 66. Legendre CM, Charpentier-Cote C, Drouin R, Bouffard C (2011) Neurofibromatosis type 1: Persisting misidentification with \"the Elephant Man\" disease. J Am Board Fam Med 24: 112-114."}
+{"text": "Several funding sources were missing from the financial disclosure information. The authors would like to add the following to their funding information: \"The research team of A-M Vandamme has received funding from the Interuniversity Attraction Poles Programme, Belgian State, Belgian Science Policy (IAP-VI P6/41), from the FWO (grant G.0611.09), and from the AIDS Reference Laboratory of Leuven that receives support from the Belgian Ministry of Social Affairs through a fund within the Health Insurance System.The European Community's Seventh Framework Programme (FP7/2007-2013) under the project \"Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN),\" - grant agreement n\u00b0 223131.\""}
+{"text": "An additional affiliation for the eighth author was incorrectly omitted from the byline. In addition to institution number 6, Edward S. Buckler is also affiliated with the following institution: USA Department of Agriculture (USDA) - Agricultural Research Service (USDA-ARS)."}
+{"text": "There were errors in the Funding section. The correct funding information is asfollows: This work was supported by the Korea Research Foundation Grant funded bythe Korean Government (MOEHRD) (KRF-2007-532-C00017) and by the National ResearchFoundation of Korea Grant funded by the Korean Government (NRF-2009-353-C00061).Supercomputing resources were supported by the Korea Institute of Science andTechnology Information (KISTI) (KSC-2010-S00-0016 & PLSI). The funders had no rolein study design, data collection and analysis, decision to publish, or preparationof the manuscript."}
+{"text": "In a response to our article \u201cTreatment compliance and effectiveness in complex PTSD patients with personality disorders (\u2026)\u201d  over TAU could be considered as \u2018placebo effects\u2019\u201d, since our design did not include a comparison to a gold standard treatment or placebo  evidence-based stabilizing treatments (Cloitre et al., In conclusion, the findings in our paper \u201cTreatment compliance and effectiveness in complex PTSD patients with co-morbid personality disorder\u201d (Dorrepaal et al., Ethy DorrepaalDepartment of Psychiatry VU University Medical Center Amsterdam, The Netherlands EMGO Institute VU University Medical Center Amsterdam, The Netherlands PsyQ, Parnassiagroep The Hague, The Netherlands Email: e.dorrepaal@psyq.nlKathleen Thomaes GGZ inGeest Amsterdam, The Netherlands Department of Psychiatry VU University Medical Center Amsterdam, The Netherlands Email: k.thomaes@vumc.nlJohannes H. Smit GGZ inGeest Amsterdam, The Netherlands Department of Psychiatry VU University Medical Center Amsterdam, The Netherlands EMGO Institute VU University Medical Center Amsterdam, The NetherlandsDick J. Veltman GGZ inGeest Amsterdam, The Netherlands Department of Psychiatry VU University Medical Center Amsterdam, The NetherlandsAdriaan W. Hoogendoorn GGZ inGeest Amsterdam, The Netherlands Department of Psychiatry VU University Medical Center Amsterdam, The NetherlandsAnton J. L. M. van Balkom GGZ inGeest Amsterdam, The Netherlands Department of Psychiatry VU University Medical Center Amsterdam, The Netherlands EMGO Institute VU University Medical Center Amsterdam, The NetherlandsNel Draijer GGZ inGeest Amsterdam, The Netherlands Department of Psychiatry VU University Medical Center Amsterdam, The Netherlands EMGO Institute VU University Medical Center Amsterdam, The Netherlands"}
+{"text": "Information was missing from the Funding section. The funding section should read: \"This work was supported by grants from ExCell Therapeutics LLC, the Nora Eccles Treadwell Foundation, and BD Biosciences (to D.A.H.) and National Institutes of Health Grant R01 AR059103, ACR Research and Education Foundation's Within Our Reach, Arthritis Foundation, Outstanding Youth Scientist Investigator Award from National Natural Science Foundation of China (30728007) and East Shanghai Scientific Foundation (PKJ2009-Y41) (to S.G.Z)."}
+{"text": "A following funder was erroneously omitted:Jacobs University Bremen [2140/90140].The correct financial disclosure is: This work has been generously supported by grants from South-East regional health authorities , The Norwegian Research Council under the Functional Genomics Program , S\u00f8ren and Jeanette Bothners legacy and the Norwegian Cancer Society [#PR-2006-0272], Jacobs University Bremen [2140/90140], Deutscher Akademischer Austausch Dienst (DAAD) [A/11/95548], The University of Oslo, Anders Jahres foundation for the Promotion of Science, Astrid and Birger Torsteds Foundation, and the Nansen Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."}
+{"text": "In the Funding Statement, the name of a funding organization was given incorrectly. The Funding Statement should read:\"Graydon B. Gonsalvez was supported by grants from the American Cancer Society (123887-RSG-13-006-01-CCG) and the National Institutes of Health (1R01GM100088-01A1). Simon Bullock was supported by MRC core funding (U105178790) and a Lister Institute Research Prize. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\""}
+{"text": "After publication of this work , we noteThe authors received funding from the Australian National Health and Medical Research Council (APP1055319) and EU FP7 Project (HEALTH.2012.2.1.1-1-C): RD Connect: An integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. The authors wish to acknowledge their involvement in the International Rare Disease Research Consortium."}
+{"text": "The third affiliation should be: \"NPC Consortium for Community-Based Assessment of Patient Records, Notre Dame, Indiana.\""}
+{"text": "AbstractEchinodermata: Crinoidea) PageBreakPromachocrinus kerguelensis  from the Southern Ocean, documents biodiversity associated with the specimens sequenced in http://www.boldsystems.org/index.php/IDS_OpenIdEngine). This dataset can be used by studies dealing with, among other interests, Antarctic and/or crinoid diversity , biogeography or habitat / ecological niche modeling. This dataset is accessible through the GBIF network at http://ipt.biodiversity.aq/resource.do?r=proke.This circumpolar dataset of the comatulid ( Project title: Comprehensive sampling reveals circumpolarity and sympatry in seven mitochondrial lineages of the Southern Ocean crinoid species Promachocrinus kerguelensis (Echinodermata)Personnel: Lena\u00efg G. HemeryFunding: French ANR ANTFLOCKS (n\u00b0 07-BLAN-0213-01); MNHN Paris intern grants .Study area descriptions/descriptor: The 1307 specimens in this dataset were collected from the Southern Ocean, south of the Sub-Antarctic Front (SAF): Kerguelen Plateau (Kerguelen and Heard islands), Davis Sea, Dumont d\u2019Urville Sea, Ross Sea, Amundsen Sea, West Antarctic Peninsula, East Weddell Sea and Scotia Arc (from the tip of the Antarctic Peninsula and the Bransfield Strait to the South Georgia island). The bathymetric range extended from 65 to 1162 meters deep.Design description: This dataset was gathered to conduct a circumpolar phylogeographic study of the crinoid species PageBreakPromachocrinus kerguelensis , were provided by several taxonomists and benthologists from different institutions. Specimen identifications during the sampling cruises were conducted to a higher level allowed by the taxonomic skills of the collectors then checked principally at the Mus\u00e9um national d\u2019Histoire naturelle, Paris by taxonomists trained to deal with Antarctic crinoids. The Cytochrome c Oxydase subunit I (COI) was successfully sequenced for 1307 of these specimens. Both collection data and produced sequences were digitized in appropriate databases, used or ready to be used for publishing purpose Collection name: Echinodermes (MNHN-IE)Collection identifier: Marc El\u00e9aumeSpecimen preservation method: AlcoholMethod step description: See sampling description below and graphic summary in Study extent description: The specimens were collected during 17 cruises in the Southern Ocean, from 1996 to 2010 (Polarstern (1996) in the East Weddell Sea, 53 from EASIZ III (ANT XVII/3) onboard the RV Polarstern (2000) in the East Weddell Sea and the Scotia Arc, 12 from ANDEEP I&II (ANT XIX/3&4) and 25 from LAMPOS (ANT XIX/5) onboard the RV Polarstern (2002) in the Scotia Arc, 43 from BENDEX (ANT XXI/2) onboard the RV Polarstern (2003-2004) in the East Weddell Sea, 15 from ITALICA 2004 onboard the RV Italica (2004) in the Ross Sea, 106 from TAN0402 onboard the RV Tangaroa (2004) in the Ross Sea, 12 from ANDEEP III (ANT XXII/3) onboard the RV Polarstern (2005) in the East Weddell Sea, 14 from BIOPEARL I (JR144) onboard the RV James Clark Ross (2006) in the Scotia Arc, 418 from CEAMARC (2007/08 V3) onboard the RV Aurora Australis (2007-2008) in the Dumont d\u2019Urville Sea, 17 from BIOPEARL II (JR179) onboard the RV James Clark Ross (2008) in the Amundsen Sea, 2 from HIMI-SC50 onboard the FV Southern Champion (2008) on the Kerguelen Plateau (Heard island), 148 from TAN0802 onboard the RV Tangaroa (2008) in the Ross Sea, 68 from AMLR 2009 Leg II onboard the RV Yuzhmorgeologiya (2009) in the Scotia Arc and the West Antarctic Peninsula, 26 from BASWAP (JR230) onboard the RV James Clark Ross (2009) in the West Antarctic Peninsula, 184 from BR09 onboard the RV Aurora Australis (2009-2010) in the Davis Sea, and 111 from POKER II onboard the FV Austral (2010) on the Kerguelen Plateau (Kerguelen island). to 2010  and 3: 5Sampling description: The specimens were sampled using several sampling gears, depending on the cruise: agassiz trawls, beam trawls, bottom trawls, box corers, epibenthic sledges (PageBreakcruise reports. The molecular data (barcoding) were generated following the protocols described in  sledges . During Quality control description: The initial geo-referencing was done by means of the vessel onboard GPS systems. Samples identification was supervised and checked by Marc El\u00e9aume, crinoid taxonomist at the Mus\u00e9um national d\u2019Histoire naturelle, Paris, following http://www.boldsystems.org/index.php/IDS_OpenIdEngine). All sequences, specimen occurrences and identifications are linked together through unique numbers in BOLD under the public project name PROKE.Dataset description: This dataset has been generated for a molecular study of the Antarctic comatulid species Promachocrinus kerguelensis, improving the geographic coverage of the previous study by Object name: Darwin Core Archive Circumpolar dataset of sequenced specimens of Promachocrinus kerguelensis Character encoding: UTF-8Format name: Darwin Core Archive formatFormat version: 1.0Distribution:http://ipt.biodiversity.aq/archive.do?r=prokePublication date of data: 2012-03-01Language: EnglishMetadata language: EnglishDate of metadata creation: 2012-04-25Hierarchy level: DatasetPageBreak"}
+{"text": "International Journal of Environmental Research and Public Health [Page 11692, the abstract, line 15, the data collection for \u201cAwareness of e-cigarettes\u201d in Brazil should be 37%, and the data for \u201cTrial of Electronic Cigarettes\u201d in Brazil should be 8%. The correct sentence should be \u201cThere was considerable cross-country variation by year of data collection and for awareness of e-cigarettes (Netherlands (2013: 88%), Republic of Korea (2010: 79%), United States (2010: 73%), Australia (2013: 66%), Malaysia (2011: 62%), United Kingdom (2010: 54%), Canada (2010: 40%), Brazil (2013: 37%), Mexico (2012: 34%), and China (2009: 31%)), in self-reports of ever having tried e-cigarettes , Malaysia (19%), Netherlands (18%), United States (15%), Republic of Korea (11%), United Kingdom (10%), Brazil (8%), Mexico (4%), Canada (4%), and China (2%)), and in current use , Republic of Korea (7%), Australia (7%), United States (6%), United Kingdom (4%), Netherlands (3%), Canada (1%), and China (0.05%))\u201d.Page 11696, Table 1, the data for Brazil are corrected. There are no changes in the data of any of the other countries. The corrected The authors wish to make the following amendments to their paper published in c Health . These aThe authors would like to apologize for any inconvenience caused to readers by these changes."}
+{"text": "Scientific Reports5: Article number: 986510.1038/srep09865; published online: 05142015; updated: 10092015This Article contains errors in the Acknowledgements section:\u201cThis work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government ; the National Nuclear R&D Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (No. 2012M2A2A7014020); a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111345); grant no. RTI04-01-01 from the Regional Technology Innovation Program of the Ministry of Knowledge Economy (MKE) and the Kyungpook National University Research Fund (2013); a grant from the Medical Cluster R&D Support Project of Daegu Gyeongbuk Medical Innovation Foundation, Republic of Korea and by the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MSIP)(2014R1A1A1003323); a grant from Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C0001).\u201dshould read:\u201cThis work was supported by National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIP) , a grant of the Korea Health Technology R&D Project, Ministry of Health & Welfare (HI11C1300), National Nuclear R&D Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education, Science and Technology (No.2012M2A2A7014020), a grant from the Medical Cluster R&D Support Project through the Daegu-Gyengbuk Medical Innovation Foundation(DGMIF), funded by the Ministry of Health & Welfare (grant number:HT13C0002), BK21 PlusKNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, National Research Foundation of Korea(NRF) Grant funded by the Korea Government(MSIP) (No.2014R1A1A1003323), a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (grant number : HI15C0001), and the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIP) (No. NRF-2015M2A2A7A01045177). Radioactive sodium iodide (Na124I) was provided by MC-50 cyclotron in Molecular Imaging Research Center, KIRAMS (2015038444).\u201d"}
+{"text": "The funding section is incorrect. The correct funding statement is as follows: This work was supported by the Special Research Grant\u2014BOF grant of Ghent University (01N02712); Research Foundation Flanders (FWO) (1.8.020.09.N.00); King Baudouin Foundation (2014-J1820640-201991); and the European Strategic Research Agenda for HIV/AIDS- HIVERA (B/14167). MK received travel grant for long stay abroad (V427314N) from the Research Foundation\u2014Flanders (FWO). WDS is a post-doctoral fellow at FWO, grant number 12G9716N. LV is a Senior Clinical Investigator at the FWO, grant number 1802014N.MLis supported by NIH grants AI106468 and AI098487. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."}
+{"text": "Scientific Reports5: Article number: 1551210.1038/srep15512; published online: 10222015; updated: 04132016The Acknowledgements section in this Article is incomplete.\u201cThis study was supported by National 973 Program (2012CBA01305); National Science Fund for Outstanding Young Scholars (81322039); National Natural Science Foundation (31371524); Distinguished Young Scholars of Jiangsu Province (BK20130041); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); New Century Excellent Talents in University (NCET-13-0870) and the California Tobacco-Related Disease Research Program (TRDRP) Grant 19XT-0070 (to B.H.) under U.S. Department of Energy (Contract no. DE-AC02-05CH11231).\u201dshould read:\u201cThis study was supported by National 973 Program (2012CBA01305); National Science Fund for Outstanding Young Scholars (81322039); National Natural Science Foundation (31371524); Distinguished Young Scholars of Jiangsu Province (BK20130041); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); New Century Excellent Talents in University (NCET-13-0870) and the California Tobacco-Related Disease Research Program (TRDRP) Grant 19XT-0070 (to B.H.) under U.S. Department of Energy (Contract no. DE-AC02-05CH11231); The California Consortium on Thirdhand Smoke, California Tobacco-Related Disease Research Program (trdrp.org) grant 20PT-0184 and California Tobacco-Related Disease Research Program grant 21 ST-011).\u201d"}
+{"text": "The Funding section should read as follows: The study presented herein was made possible by the University of Malaya Higher Impact Research (HIR) Grant: UM.C/HIR/MOHE/ENG/57 and University of Malaya Research Grant (UMRG): RP004C-13AET. The authors would like to acknowledge the support.The publisher apologizes for this error."}
+{"text": "There are errors in the Funding section. The complete, correct Funding section is as follows:The work was partially supported by grants from the Instituto de Salud Carlos III (Spanish Government)  and from the Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca\u2014Generalitat de Catalunya  , European Regional Development fund (FEDER) \"A way to build Europe\". The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Health Research Fund (FIS) of the Spanish Ministry of Health (Exp P10710130), Regional Governments of Andaluc\u00eda, Asturias, Basque Country, Murcia (no. 6236), Navarra and the Catalan Institute of Oncology, La Caixa (BM 06\u2013130), RTICC-RD06/10091 (Spain); Danish Cancer Society (Denmark); Ligue contre le Cancer, Institut Gustave Roussy, Mutuelle G\u00e9n\u00e9rale de l'Education Nationale, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Italian Association for Research on Cancer (AIRC) and National Research Council ; Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) and Statistics Netherlands (The Netherlands); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Sk\u00e5ne and V\u00e4sterbotten (Sweden); Cancer Research UK, Medical Research Council (United Kingdom); Norwegian Research Council, Norwegian Cancer Society, University of Tromso (Norway). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."}
+{"text": "Scientific Reports5: Article number: 1244110.1038/srep12441; published online: 07282015; updated: 08232016In this Article, there is a typographical error in the Acknowledgments section.\u201cThis work was supported by grants from National Natural Science Foundation of China , National Basic Research Program , FPI fellowship from the Spanish Ministerio de Econom\u00eda y Competitividad (Grant no. BES-2011-047557) and China-UK Cooperation Programme in Global Priorities \u201d.should read:\u201cThis work was supported by grants from National Natural Science Foundation of China , National Basic Research Program , FPI fellowship from the Spanish Ministerio de Econom\u00eda y Competitividad (Grant no. BES-2011-047557) and China-UK Cooperation Programme in Global Priorities \u201d."}
+{"text": "Scientific Reports5: Article number: 1286710.1038/srep12867; published online: 08112015; updated: 10012015This Article contains a typographical error in the grant number in the Acknowledgements section.\u201cThis work is supported by Samsung Electronics, and the Ministry of Trade, Industry and Energy under the contract for the MLC-PRAM project , the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean government (MSIP) (Grant No. 2011-0028570), and KIST internal projects (Grant No. 2E25372 & 2E373)\u201d.should read:\u201cThis work is supported by Samsung Electronics, and the Ministry of Trade, Industry and Energy under the contract for the MLC-PRAM project , the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean government (MSIP) (Grant No. 2011-0028570), and KIST internal projects (Grant No. 2E25372 & 2E25373)\u201d."}
+{"text": "Scientific Reports5: Article number: 16498;10.1038/srep16498 Published online: 11132015; Updated: 06022016The Acknowledgements section in this Article is incomplete.\u201cThis work was supported by the European Research Council (FP7 ERC-Synergy Nexus1492 project grant number 319209) and the US National Institutes of Health (R01 GM089886), the BBVA Foundation , the Generalitat Valenciana (VALi+d APOSTD/2014/123 and GV/2015/060), the European Union , and the Centre for Chronic Diseases and Disorders (C2D2) Research Priming Fund grant to CFS. C2D2 is part-funded by the Wellcome Trust (ref: 097829). The authors thank Joaqu\u00edn Lomba for his assistance with obtaining samples; Amanda Henry for providing helpful comments on the manuscript; Jacqueline Eng for providing osteological data for the Samdzong sample; Mar\u00eda Haber and Azucena Avil\u00e9s for providing osteological data for the Camino del Molino sample; Malin Holst for providing osteological data for the Tickhill samples; and also Matthias Garn & Partner, the Parish Church Council for St. Mary\u2019s Church, Tickhill, South Yorkshire, and Wiles & Maguire, Ltd., for assistance with sample provisioning.\u201dshould read:\u201cThis work was supported by the European Research Council (FP7 ERC-Synergy Nexus1492 project grant number 319209), the US National Science Foundation (BCS-1516633) and the US National Institutes of Health (R01 GM089886), the BBVA Foundation , the Generalitat Valenciana (VALi+d APOSTD/2014/123 and GV/2015/060), the European Union , and the Centre for Chronic Diseases and Disorders (C2D2) Research Priming Fund grant to CFS. C2D2 is part-funded by the Wellcome Trust (ref: 097829). The authors thank Joaqu\u00edn Lomba for his assistance with obtaining samples; Amanda Henry for providing helpful comments on the manuscript; Jacqueline Eng for providing osteological data for the Samdzong sample; Mar\u00eda Haber and Azucena Avil\u00e9s for providing osteological data for the Camino del Molino sample; Malin Holst for providing osteological data for the Tickhill samples; and also Matthias Garn & Partner, the Parish Church Council for St. Mary\u2019s Church, Tickhill, South Yorkshire, and Wiles & Maguire, Ltd., for assistance with sample provisioning.\u201d"}
+{"text": "Nature Communications 6: Article number: 7718 (2015); 10.1038/ncomms8718 Published: 07272014; Updated: 08212015.The financial support for this Article was not fully acknowledged. The second sentence of the Acknowledgements should have read: This research was supported by grants from NIH/NINDS (R01 NS054941), the March of Dimes Foundation and the Christopher and Dana Reeve Foundation (to S.-K.L.), NIH/NIDDK (R01 DK064678) (to J.W.L.), NIH/NIDDK , NIH/NIMH  and National Research Foundation of Korea (NRF) grants for Basic Science Research Program (2012R1A1A1001749), the Bio & Medical Technology Development Program (2012M3A9C6050508) funded by the Korean government (MEST) and for the Global Core Research Center (GCRC) funded by the Korean government (MSIP)(2011-0030001) and Aspiring Researcher Program of Seoul National University in 2014 (to S.L.)."}
+{"text": "Scientific Reports5: Article number: 11798; 10.1038/srep11798 published online: 07022015; updated: 03172016The Acknowledgements section in this Article is incomplete.\u201cThe authors acknowledge EPSRC (EP/J004863/1 and EP/I035307/1), NSF (DMR-1107894), the Penn State Materials Research Science and Engineering Center (NSF DMR-0820404), and the Air Force Research Laboratory (FA8650-10-C-1902) for financial support. The data for this work is accessible through the University of Southampton Institutional Research Repository (doi: 10.5258/SOTON/376815).\u201dshould read:\u201cThe authors acknowledge EPSRC (EP/J004863/1 and EP/I035307/1), NSF (DMR-1107894), the Penn State Materials Research Science and Engineering Center (NSF DMR-0820404), and the Air Force Research Laboratory (FA8650-10-C-1902) for financial support. The data for this work is accessible through the University of Southampton Institutional Research Repository (doi: 10.5258/SOTON/376815). This work was also supported by the Center for Nanoscale Science, an NSF Materials Research Science and Engineering Center, under the award DMR-1420620 to JVB.\u201d"}
+{"text": "There are errors in the Funding section. The correct funding information is as follows: This study was supported by grants from Taiwan National Health Research Institutes (NHRI-EX100-9838PI) and Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002)."}
+{"text": "The following information is missing from the Funding section: This research was supported by a National Institutes of Health (NIH) grant, 3R01CA165076-03S2, Research Supplement to Promote Diversity in Health-Related Research, to Hassan M. Shaleh."}
+{"text": "Scientific Reports6: Article number: 20314;10.1038/srep20314 published online: 02012016; updated: 03042016The Acknowledgements section in this Article is incomplete.\u201cThe authors would like to thank all the laboratory coordinators from Shanghai Institute of Rheumatology: Ms. Ye Ping, Ms. Song Rui, Ms. Wang Zhenni and Mr. Zhu Haoming. Dr. Qu Bo and Dr. Han Xiao from Institute of Health Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine provided kind support on data analysis and animal experiments. Dr. Xiao Chun-yuan, Dr. Zhou Ying-ying and Ms. Sun Shu-hui from Institute of Rheumatology, Shanghai Renji Hospital helped in laboratory techniques.\u201dshould read:\u201cThe authors would like to thank all the laboratory coordinators from Shanghai Institute of Rheumatology: Ms. Ye Ping, Ms. Song Rui, Ms. Wang Zhenni and Mr. Zhu Haoming. Dr. Qu Bo and Dr. Han Xiao from Institute of Health Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine provided kind support on data analysis and animal experiments. Dr. Xiao Chun-yuan, Dr. Zhou Ying-ying and Ms. Sun Shu-hui from Institute of Rheumatology, Shanghai Renji Hospital helped in laboratory techniques.This study was supported by the Natural Science Foundation of China (30901306 and 81471596), Shanghai Rising-Star Program (11QA1404200), Science and Technology Fund of Shanghai Jiaotong University School of Medicine and National key clinical center construction Program of China.\u201d"}
+{"text": "W81XWH-13-1-0193 (DCA), and by a Post-Doctoral Research Fellowship from the Italian Association for Cancer Research to M.T. and by a Post-Doctoral Research Fellowship from the American Italian Cancer Foundation to C.F. Research in this publication includes work carried out using the Sidney Kimmel Cancer Center Bioimaging Facility and the Translational Research & Pathology Shared Resource, which are supported in part by NCI Cancer Center Support Grant P30 CA56036 (RGP). This project is also funded, in part, under a Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health (H.R.); the Department specifically disclaims responsibility for any analyses, interpretations or conclusions.Corrected:GRANT SUPPORTNIH-P01140043, NIH-R01CA109874 (LRL), NIH-R01CA089720 (LRL), NIH-R01CA086072 (RGP); the Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program under Award No. W81XWH-13-1-0193 (DCA), and by a Post-Doctoral Research Fellowship from the Italian Association for Cancer Research to M.T. and by a Post-Doctoral Research Fellowship from the American Italian Cancer Foundation to C.F. Research in this publication includes work carried out using the Sidney Kimmel Cancer Center Bioimaging Facility and the Translational Research & Pathology Shared Resource, which are supported in part by NCI Cancer Center Support Grant P30 CA56036 (RGP). This project is also funded, in part, under a Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health (H.R.); the Department specifically disclaims responsibility for any analyses, interpretations or conclusions.This work was supported by NIH ,"}
+{"text": "Scientific Reports6: Article number: 23271; 10.1038/srep23271 published online: 04162016; updated: 04292016.In the HTML version of this Article, Gottfried Schlaug is incorrectly listed as being affiliated with \u2018Department of Physical Therapy and Rehabilitation Sciences Institute University of Toronto Toronto, Ontario, Canada\u2019. The correct affiliation is listed below:Department of Neurology; Neuroimaging and Stroke Recovery Laboratory Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA."}
+{"text": "Archives administrator Mrs. Yolette D\u00e9lius works with paper files for information provision in the Archives of the Ophthalmology Department of State University Hospital Haiti on January 26, 2016. The existing data management architecture is unable to provide reliable indicators for data-driven management and policy due to the lack of financing, digital technologies, adequate human resources, and technical expertise . This caYuri Zelenski Faculty of Medicine and Pharmacy State University of Port-au-Prince Port-au-Prince, Haiti Foundation in Support of the Ophthalmology Department Hospital Albert Schweitzer Haiti Chur, Switzerland DGZ International Ottawa, Canada Email: yuri.zelenski@gmail.comDieter Eisenmann Foundation in Support of the Ophthalmology Department Hospital Albert Schweitzer Haiti Chur, Switzerland Faculty of Medicine and Pharmacy State University of Port-au-Prince Port-au-Prince, Haiti Kantonsspital Graub\u00fcnden Chur, Schweiz Email: dr.d.eisenmann@gmail.com"}
+{"text": "Obesity and metabolic syndrome are associated with increased risk of cardiovascular disease. Research suggests that altered cardiac mechanics  are present in obesity; yet, the causes of this mechanical dysfunction and its relationship to other sequelae of obesity  are not well understood. We hypothesize that diet-induced obesity in mice leads to reductions in measures of left ventricular (LV) mechanics, which develop in acute response to the onset of hyperglycemia, hypertension, and ventricular remodeling.Twenty 4-week-old C57BL/6J mice were randomized (n = 10 per group) to either a high-fat  or sucrose-matched low-fat  diet for 28 weeks. After 4 weeks and every 6 weeks thereafter, LV mechanics were quantified using cine displacement encoding with stimulated echoes (DENSE) on a 7T ClinScan MRI  with a 4-element phased array cardiac coil. Three short-axis and two long-axis slices were acquired with 13-20 frames per cardiac cycle. Semi-automated post-processing was performed using custom software in MATLAB . Additionally, systolic blood pressure (via tail cuff measurement) and fasting blood glucose were assessed every 4 weeks on staggered schedules.Mice on the high-fat diet became obese relative to the low-fat controls , the NIH Director's Early Independence Award (1DP5OD012132-01), a pilot grant from an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the NIH (8 P20 GM103527-05), the University of Kentucky Cardiovascular Research Center, grant number UL1RR033173  from the National Center for Research Resources (NCRR), funded by the Office of the Director, National Institutes of Health (NIH) and supported by the NIH Roadmap for Medical Research, and contributions made by local businesses and individuals through a partnership between Kentucky Children's Hospital and Children's Miracle network."}
+{"text": "Scientific Reports6: Article number: 25392; 10.1038/srep25392 published online: 05042016; updated: 07272016.This Article contains errors in the Acknowledgements section.\u201cThis work was supported by research grants from the National Research Foundation (NRF) of Korea (2010-0029132 and 2011-0031638).\u201dshould read:\u201cThis work was supported by the Center for Advanced Soft-Electronics funded by the Ministry of Science, ICT and Future Planning as Global Frontier Project (CASE-2011-0031638).\u201d"}
+{"text": "The following information is missing from the Funding section: This work was supported by the Ministry of Higher Education of Malaysia under the HIR (H21001-F00033), UM.C/HIR/MOHE/SC/33 and UMRG grant (RP008-13AFR).The complete, correct funding information is: This work is supported by Peruntukan Penyelidikan Pascasiswazah (PPP) of University Malaya Grant No.: PS212/2009A and UMRG Grant No.: RG247-12AFR, as well as by the Ministry of Higher Education of Malaysia under the HIR (H21001-F00033), UM.C/HIR/MOHE/SC/33 and UMRG grant (RP008-13AFR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.The publisher apologizes for this error."}
+{"text": "Scientific Reports5: Article number: 1779210.1038/srep17792; published online: 12072015; updated: 02252016The Acknowledgements section in this Article is incomplete.\u201cWe thank Dr. Richard Schlegel for providing the 3T3-J2 cells, Dr. Kalenic and the House Research Institute for providing the HEI-OC1 cells, Dr. Guillermo Oliver for the MEFs, Dr. Suzanne Baker for the NIH 3T3 cells, and Drs. Stefan Heller and Kazuo Oshima for help on isolation of otic-spheres, and Dr. Yannan Ouyang for help on confocal microscope imaging.\u201dshould read:\u201cWe thank Dr. Richard Schlegel for providing the 3T3-J2 cells, Dr. Kalenic and the House Research Institute for providing the HEI-OC1 cells, Dr. Guillermo Oliver for the MEFs, Dr. Suzanne Baker for the NIH 3T3 cells, and Drs. Stefan Heller and Kazuo Oshima for help on isolation of otic-spheres, and Dr. Yannan Ouyang for help on confocal microscope imaging.This research was supported by funding from the National Institutes of Health grants (R01DC006471 (J.Z.), R21DC013879 (J.Z.), F32DC013832 (W.L), P30CA21765 (St. Jude)), American Lebanese Syrian Associated Charities (ALSAC) of St. Jude Children\u2019s Research Hospital, the Office of Naval Research grants ), the Hearing Health Foundation , the National Organization for Hearing Research (NOHR) Foundation (Bradley J. W.), and The Hartwell Foundation .\u201d"}
+{"text": "The following information is missing from the Funding section: Portuguese Foundation of Science and Technology (FCT) (PTDC/MHC-PCN/4842/2012 to SCS)."}
+{"text": "In 2013, the percentage of physicians using an EHR system was higher than the national average (78%) in seven states  (range = 87%\u201394%) and was lower than the national average in New Jersey (66%).Source: NCHS Research Data Center: what\u2019s new? Winter 2014. National Electronic Health Records Survey (NEHRS). Survey data available through the NCHS Research Data Center at http://www.cdc.gov/rdc/leftbrch/whatnew.htm.Reported by: Esther Hing, MPH, ehing@cdc.gov, 301-458-4271; Chun-Ju Hsiao, PhD."}
+{"text": "An affiliation for the first author is not indicated. Uzma Bashir Aamir is also affiliated with #2: Atta-ur-Rehman School of Applied BioSciences (ASAB), National University of Science & Technology (NUST), Islamabad, Pakistan."}
+{"text": "Correction: Genome Med 14, 64 (2022)https://doi.org/10.1186/s13073-022-01063-5Following publication of the original article , an erroThe section currently reads:https://eveappeal.org.uk). Additional aspects of the study were supported by the Swedish Research Council Grant # 2017-00932, 2012-02961, Region Stockholm and Karolinska Institutet (ALF), Cancerfonden (Grant no. CAN 2016/696), and Radiumhem- mets Forskningsfonder  as well as by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). The work carried out by TEB was supported by MRC grant MR/P014070/1.This study was funded by the European Union\u2019s Horizon 2020 European Research Council Programme, H2020 BRCA-ERC under Grant Agreement No. 742432 as well as the charity The Eve Appeal . Additional aspects of the study were supported by the Swedish Research Council Grant # 2017-00932, 2012-02961, Region Stockholm and Karolinska Institutet (ALF), Cancerfonden (Grant no. CAN 2016/696), and Radiumhem- mets Forskningsfonder  as well as by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). The work carried out by TEB was supported by MRC grant MR/P014070/1. Clinical trial 3 was supported by Breast Cancer Now [Grant Ref no: 2014May-CR003]\u201dThis study was funded by the European Union\u2019s Horizon 2020 European Research Council Programme, H2020 BRCA-ERC under Grant Agreement No. 742432 as well as the charity The Eve Appeal (The original article  has been"}
+{"text": "Correction: BMC Neurol 22, 321 (2022)https://doi.org/10.1186/s12883-022-02813-zFollowing publication of the original article , the autbold.The updated Funding is provided below and the changes have been highlighted in Dominik Stelzle was supported by the German Federal Ministry of Education and Research, Grant 01KA2112B, within the Cysticercosis Network of Sub-Saharan Africa (CYSTINET-Africa). The funders had no role in the detailed study design, data collection and analysis, decision to publish, or preparation of the manuscript.Open Access funding enabled and organized by Projekt DEAL. This study was funded by the German Research Foundation (DFG) within the research grant (WI 3427/1\u20131) \u201cNeurocysticercosis in sub-Saharan Africa\u201d and by the Bill and Melinda Gates Foundation within the research grant (1017886) \u201cIntegrated Control of Cysticercosis in sub-Saharan Africa\u201d. The original article  has been"}
+{"text": "Leukemia (2021) 36:1088\u20131101 10.1038/s41375-021-01475-z, published online 27 January 2022Correction to: The Acknowledgments section of this article was incomplete in the initial publication. it should read as follows:Acknowledgments: We thank Catherine A. Nicholas for her help with preliminary experiments and Morgan F. O\u2019Keefe for manuscript proofreading. This work was supported by the National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant P50100707 and P01 CA155258; as well as by the Adelson Medical Research Foundation and the Paula and Rodger Riney Foundation."}
+{"text": "Funding statement. We failed inadvertently to acknowledge one of our funding bodies in the \u201cFunding\u201d section. The Funding statement read as \u201cThis work was supported by a grant from Stavros Niarchos Foundation (ST and MZ), by RSF (Grant No. 16-14-00215) (VT and II), by RFBR (Grant No. 18-04-01366) (IK) and by BioStruct-X (Contract No. 283570/3521).\u201dIn the published article, there was an error in the The correct statement is: \u201cThis work was supported by a grant from Stavros Niarchos Foundation (ST and MZ), by RSF (Grant No. 16-14-00215) (VT and II), by RFBR (Grant No. 18-04-01366) (IK), by the Hellenic Foundation for Research and Innovation (HFRI) and the General Secretariat for Research and Technology (PG),  and by BioStruct-X (Contract No. 283570/3521).\u201dThe authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated."}
+{"text": "Correction: BMC Cancer 21, 409 (2021)https://doi.org/10.1186/s12885-021-08134-7Following publication of the original article , the autThis research was funded by National Science Foundation of China (81802652), Research Fund of Hubei Province Health Bureau (WJ2015MB144) and Research Fund of Wuhan Public Health Bureau (WX15A12 and WX18Y11). The funders had no role in the design of the study, data collection, analysis, interpretation of data, or in writing the manuscript."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-022-26145-7, published online 23 December 2022Correction to: The Funding section in the original version of this Article was omitted.The Funding section now reads: \u201cThis study was supported by grants  from the Chonnam National University Hospital Biomedical Research Institute to DWK, ISJ and HJC, by Chonnam National University (2021-2443 and 2022-3856-01) to DWK and HJC. This study was also supported by grants from National Research Foundation  to DWK, ISJ and HJC.\u201dThe original Article has been corrected."}
+{"text": "Correction to: BMC Public Health 21, 1866 (2021)https://doi.org/10.1186/s12889-021-11924-0In the original publication  there waIncorrect fundingThis study was funded under the Singapore-Australia Bilateral Program on Innovations in Food for Precision Health 2019.Correct fundingThis study was funded under the Singapore-Australia Bilateral Program on Innovations in Food for Precision Health 2019. BPC Smith was supported by a National Research Foundation Singapore Whitespace grant (grant no. W20W3D0002) and Health and Biomedical Sciences Industry Alignment Fund Pre-positioning grant (H1801a0\u2013014) administered by the Agency for Science, Technology & Research."}
+{"text": "Scientific Reports 10.1038/s41598-022-21836-7, published online 09 November 2022Correction to: The Funding section in the original version of this Article was omitted. The Funding section now reads:\u201cThis research was supported by the Kasetsart University Research and Development Institute, KURDI (R-M 52.63), Bangkok, and the Health Systems Research Institute (HSI), Thailand.\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-22159-3, published online 03 November 2022Correction to: The Funding section in the original version of this Article was incomplete.\"This work was supported by the National Science Centre [grant number 2016/21/D/NZ8/01306 (IN)]; the Ministry of Science and Higher Education [grant number IdP2011000161 (GJ)]; and the Ella & Georg Ehrnrooth Foundation (MB).\"now reads:\u201cThis work was supported by the National Science Centre [grant number 2016/21/D/NZ8/01306 (IN)]; the Ministry of Science and Higher Education [grant number IdP2011000161 (GJ)]; and the Ella & Georg Ehrnrooth Foundation (MB). Publication of this article was funded by the Priority Research Area qLife under the program \u201cExcellence Initiative \u2013 Research University\u201d at the Jagiellonian University in Krakow (06/IDUB/2019/94).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-16028-2, published online 16 July 2022Correction to: The Acknowledgments section in the original version of this Article was incomplete.\u201cThis work was supported by Medical Scientist Training Program T32GM008152, National Institutes of Health grants U54CA193419, R01 CA228272, R01CA225002, and National Science Foundation grants EFMA-1830961 and EFMA-1830969. This work made use of the BioCryo facility of Northwestern University\u2019s NUANCE\u00a0Center, which has received support from the SHyNE Resource (NSF ECCS-2025633), the International Institute for Nanotechnology (IIN), and Northwestern's MRSEC program (NSF DMR-1720139). The imaging methodology is partially based on research sponsored by the Air Force Research laboratory under agreement number FA8650-15-2-5518. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of Air Force Research Laboratory or the U.S. Government.\u201dnow reads:\u201cThis work was supported by Medical Scientist Training Program T32GM008152, National Institutes of Health grants U54CA268084, U54CA261694, R01CA228272, R01CA225002, and National Science Foundation grants EFMA-1830961 and EFMA-1830969. This work made use of the BioCryo facility of Northwestern University\u2019s NUANCE\u00a0Center, which has received support from the SHyNE Resource (NSF ECCS-2025633), the International Institute for Nanotechnology (IIN), and Northwestern's MRSEC program (NSF DMR-1720139). The imaging methodology is partially based on research sponsored by the Air Force Research laboratory under agreement number FA8650-15-2-5518. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of Air Force Research Laboratory or the U.S. Government.\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-09323-5, published online 31 March 2022Correction to: The original version of this Article contained errors.Shahzaib Ashraf was incorrectly affiliated with \u2018Department of Mathematics and Statistics, Bacha Khan University, Charsadda, KPK, Pakistan\u2019. The correct affiliation is listed below.Department of Mathematics, Khawaja Farid University of Engineering and Information Technology, Rahim Yar Khan, PakistanIn the Acknowledgements section,\u201cMuhammad Naeem would like to thank the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by Grant Code: (22UQU4310396DSR02).\u201dnow reads:\u201cMuhammad Naeem would like to thank the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by Grant Code: (22UQU4310396DSR06).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-13132-1, published online 03 June 2022Correction to: The Funding section in the original version of this Article was incomplete.\u201cGrant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology 19K09003.\u201dnow reads:\u201cThis study was funded by Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology 19K09003 and Medtronic\".The original Article has been corrected."}
+{"text": "In the article titled Acceleration of Mesenchymal-to-Epithelial Transition (MET) during Direct Reprogramming Using Natural Compounds, the funding acknowledgment was partially incorrect as published.Original versionAcknowledgmentsThis research was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R111A1A01048981) and the Korea government  (NRF-2017R1C1B5077043).Corrected versionAcknowledgmentsThis research was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R111A1A01048981) and the National Research Foundation (NRF) grant funded by the Korea government (MSIT) (NRF-2020R1C1C1014148)."}
+{"text": "DOI: 10.1039/C9RA08707ACorrection for \u2018Boron-doped few-layer graphene nanosheet gas sensor for enhanced ammonia sensing at room temperature\u2019 by Shubhda Srivastava  The authors regret that affiliation b was incorrectly provided as Academy of Scientific and Innovative Research (AcSIR), CSIR-National Physical Laboratory Campus, Dr K S Krishnan Road, New Delhi 110012, India.The correct details are provided in the Affiliations section of this document.The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers."}
+{"text": "Correction to: BMC Health Serv Res 22, 568 (2022)https://doi.org/10.1186/s12913-022-07922-6Following publication of the original article , the autH21C0059).The statement in the \u2018Funding\u2019 section originally read: This research was supported by a grant of Patient-Centered Clinical Research Coordinating Center funded by the Ministry of Health & Welfare, Republic of Korea .The statement in the \u2018Funding\u2019 section should read: This research was supported by a grant of Patient-Centered Clinical Research Coordinating Center funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI19C0481, The original article  has been"}
+{"text": "Scientific Reports 10.1038/s41598-020-69403-2, published online 23 July 2020Correction to: The original version of this Article contained an error in Affiliation 2, which was incorrectly given as \u2018Academy of Scientific and Innovative Research (AcSIR), New Delhi 110025, India\u2019. The correct affiliation is listed below:Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, IndiaThe original Article has been corrected."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-022-24021-y, published online 02 December 2022Correction to: The original version of this Article contained an error in the spelling of the author Rizwan Ali which was incorrectly given as Ali Rizwan.In addition, Rizwan Ali was incorrectly affiliated with \u2018Light and Electron Microscopy Unit, Medical Core Facility and Research Platforms, King Abdullah International Medical Research Centre, National Guard Health Affairs, Mail Code 1515, P.O. Box 3660, Riyadh 11481, Saudi Arabia\u2019. The correct affiliation is listed below.King Abdullah International Medical Research Center (KAIMRC), Medical Research Core Facility and Platforms (MRCFP), King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs (MNGHA), Riyadh 11481, Saudi Arabia.The original Article has been corrected."}
+{"text": "Correction to: BMC Public Health 22, 760 (2022)https://doi.org/10.1186/s12889-022-13152-6In the original publication  there waIncorrect fundingThis research does not receive any funding.Correct fundingThis work was funded by the National Natural Science Foundation of China  and the National Key Research and Development Program of China (Grant No. 2018YFC1315302)."}
+{"text": "Nature Communications 10.1038/s41467-022-34062-6, published online 25 October 2022Correction to: In this article the affiliation \u2018Institute of Materials Research and Engineering, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore\u2019 for Jie Yin was missing. The original article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-25027-2, published online 01 December 2022Correction to: The original version of this Article contained an error in the Acknowledgements section.\u201cThis work was partially funded by the Project TAMI\u2014Transparent Artificial Medical Intelligence (NORTE-01-0247-FEDER-045905) financed by ERDF\u2014European Regional Fund through the North Portugal Regional Operational Program\u2014NORTE 2020 and by the Portuguese Foundation for Science and Technology\u2014FCT under the CMU\u2014Portugal International Partnership, and also by the Portuguese Foundation for Science and Technology\u2014FCT within PhD grants SFRH/BD/139468/2018 and 2020.06434.BD. The authors thank the Swiss National Science Foundation grant number 198388, as well as the Lindenhof foundation for their grant support.\u201dnow reads:\u201cThis work was supported by National Funds through the Portuguese Funding Agency, FCT\u2013Foundation for Science and Technology Portugal, under Project LA/P/0063/2020, and also by the Portuguese Foundation for Science and Technology - FCT within PhD grants SFRH/BD/139468/2018 and 2020.06434.BD. The authors thank the Swiss National Science Foundation grant number 198388, as well as the Lindenhof foundation for their grant support.\u201dThe original Article has been corrected."}
+{"text": "Correction: Trials 23, 459 (2022)https://doi.org/10.1186/s13063-022-06377-8Following publication of the original article , the aut1 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Road, Shanghai 200437, ChinaThe affiliation of Jing Zhao was incorrect upon publication. Jing Zhao is affiliated to Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Road, Shanghai 200437, China.Further to this, the funding section has been updated as follows:This project is funded by Shanghai '13th five-year plan' key clinical specialty (TCM gynecology department) (shslczdzk04501) and General program of clinical research of Shanghai Municipal Health Commission (202140173).The original article  has been"}
+{"text": "Cellular & Molecular Immunology 10.1038/s41423-022-00928-4, published online 27 October 2022Correction to: In this article the statement in the Acknowledgements section was incorrectly given as \u201cMRB and IIS are supported by the NIH R01GM080139 grant (to IIS), the Welch Foundation Research Grant AU-2014-20190331 (to IIS), and the American Heart Association grant 18CDA34110086 (to MRB)\u201d and should have been, \u201cMRB and IIS are supported by the NIH R01GM072804 grant (to IIS), the Welch Foundation Research Grant AU-2014-20190331 (to IIS), and the American Heart Association grant 18CDA34110086 (to MRB).\u201dThe original article has been corrected."}
+{"text": "Correction: Ann Clin Microbiol Antimicrob (2023) 22:5 https://doi.org/10.1186/s12941-023-00553-7Following publication of the original article , the autFundingThis work was supported by the National Natural Science Foundation of China , the Natural Science Foundation of Jiangsu Province (Grant No. BK20201129), the Wuxi City Health Committee top-notch talent (Grant No. BJ2020077).The original article has been corrected."}
+{"text": "The funding statement for this article should read as follows:https://ec.europa.eu/research/mariecurieactions/), grant number 750835. GP received support from the Austrian Science Fund (FWF) (https://fwf.ac.at/en/); grant number PI2760-B30. PL holds a Wellcome Trust Senior Research Fellowship (209450/Z/17/Z) and is supported by BHF [PG/16/75/32383]. SAN is supported by NIH R01-HL152256, ERC PREDICT-HF 453 (864055), BHF (RG/20/4/34803), EPSRC (EP/P01268X/1). This work was supported by the Wellcome/EPSRC Centre for Medical Engineering [WT 203148/Z/16/Z]. This work made use of ARCHER (http://www.archer.ac.uk/), the UK national high-performance computing service located at the University of Edinburgh and funded by the Office of Science and Technology through Engineering and Physical Sciences Research Councils High-End Computing Programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\u201d\u201cCR and MM have received funding from the European Union\u2019s Horizon 2020 Research and innovation programme under the Marie Sklodowska-Curie Grant Agreement No 764738. MS was supported by an unrestricted Abbott educational grant through the Centre for Doctoral Training in Medical Imaging at King\u2019s College London. CA received support from the Marie Sklodowska-Curie fellowship ("}
+{"text": "Volume 6 of Learning Health Systems. An open access publication, the journal has advanced research and scholarship on learning health systems in partnership with our reviewers. With indexing in multiple major sources and the recent news that we will have an official impact factor next year, we believe the journal is now on a sustainable, positive trajectory.The publication of Issue 4 marks the completion of We were also delighted to learn that articles from the journal were downloaded over 100\u2009000 times in 2021.Special Issues: \u201cPatient Empowerment and the Learning Health System\u201d (v.1); \u201cEthical, Legal, and Social Implications of Learning Health Systems\u201d (v.2); \u201cLearning Health Systems: Connecting Research to Practice Worldwide\u201d (v.3); \u201cHuman Phenomics and the Learning Health System\u201d (v.4); \u201cCollaborative Learning Health Systems: Science and Practice\u201d (v.5); and \u201cEducation To Meet the Multidisciplinary Workforce Needs of Learning Health Systems\u201d (v.6). Our talented guest editors have been instrumental in helping these Special Issues come to fruition.The journal has also published six We are keenly aware that these achievements would not have happened without the dedicated efforts and insightful comments of all those individuals who accepted invitations to review submitted articles. With busy schedules and full commitments in the midst of the Covid\u201019 pandemic, these individuals found the time and energy to contribute their expertise to our authors to help ensure that their papers met (and often exceeded) the journal's high standards for publication.Please accept our sincere gratitude for your outstanding efforts.Charles P. Friedman, Editor in ChiefREVIEWERS FOR VOLUME 6 LHS JOURNALIncludes reviewers of rejected manuscriptsJulia Adler\u2010Milstein (United States)Joan Ash (United States)Mark Ashworth (United Kingdom of Great Britain and Northern Ireland)Ross Bailie Eta Berner (United States)Jeff Brown (United States)Michael Cantor (United States)Jim Cimino (United States)Derek Corrigan (Ireland)Vasa Curcin (United Kingdom of Great Britain and Northern Ireland)Brendan Delaney (United Kingdom of Great Britain and Northern Ireland)Catherine Diederich (United States)Deborah Dinardo (United States)Gerry Douglas (United States)Archie Drake (United Kingdom of Great Britain and Northern Ireland)Christine Dymek (United States)Margo Edmunds (United States)Jordan Everson (United States)Stephan Fihn (United States)Erin P. Finley (United States)Allen Flynn (United States)Thomas Foley (United Kingdom of Great Britain and Northern Ireland)Emily Ginier (United States)Shaun Grannis (United States)Sarah Greene (United States)Jeanne\u2010Marie Guise (United States)W. Ed Hammond (United States)Kristi Holmes (United States)Kelli Johnson (United States)Owen Johnson (United Kingdom of Great Britain and Northern Ireland)Dipak Kalra (Belgium)Amy Kilbourne (United States)Rebecca Kush (United States)Elyse Lasser (United States)Harold Lehmann (United States)Christopher Longhurst (United States)Nancy Lorenzi (United States)David McCallie (United States)Mark McGilchrist (United Kingdom of Great Britain and Northern Ireland)Marianne McPherson (United States)Brad Malin (United States)Kenneth Mandl (United States)Erik Mayer (United Kingdom of Great Britain and Northern Ireland)Daniella Meeker (United States)Paul Meissner (United States)Michelle Mengeling (United States)Blackford Middleton (United States)Tara Montgomery (United States)David Mosen (United States)Cheryl Moyer (United States)Mark Musen (United States)Paige Nong (United States)Sally Okun (United States)Nancy Pandhi (United States)Gareth Parry (United States)Niels Peek (United Kingdom of Great Britain and Northern Ireland)Jodyn Platt (United States)Rachel Richesson (United States)Jamie Roberts (United States)Joshua Rubin (United States)Philip Scott (United Kingdom of Great Britain and Northern Ireland)Ruth Simmons (United States)Karandeep Singh (United States)Carolynn Smith Jean Soler Caren Stalberg (United States)Zachary Strasser (United States)Ndidi Unaka (United States)Kim Unerti (United States)Barbara Van de Castle (United States)Robert Verheij (Netherlands)Sam Volchenboum (United States)Jim Walker (United States)Denise Warzel (United States)Terrie Wheeler (United States)Paul Wicks (United States)"}
+{"text": "The funding statement for this article should read as follows:\u201cJ.L., H.Y. and D.R-G. acknowledge partial funding from the National Science Foundation- Division of Mathematical Sciences (NSF-DMS) grants DMS-1953410, DMS-1714973 and DMS-1763272/Simons Foundation  for the Center for Multiscale Cell Fate Research at UC Irvine. M.W acknowledge partial funding from NSF-DMS-2012330. JL additionally acknowledges partial funding from the National Institutes of Health (NIH) grant 1U54CA217378- 01A1 for a National Center in Cancer Systems Biology at the UC Irvine , and from NIH grant P30CA062203 for the Chao Family Comprehensive Cancer Center at UC Irvine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-022-26284-x, published online 16 December 2022Correction to: The Acknowledgements section in the original version of this Article was omitted. The Acknowledgements section now reads:\u201cThis work was supported by the Interdisciplinary Research Center for Renewable Energy and Power Systems at King Fahd University of Petroleum & Minerals (KFUPM) under Project INRE2221.\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-17759-y, published online 05 September 2022Correction to: The original version of this Article contained an error in the Acknowledgments section.\u201cThis work was supported by the National Natural Science Foundation of China (Grant Nos. 11975176), the Natural Science Basic Research Plan in Shaanxi Province of China (Grant No. 2019JM-139), the Key Research and Development Program of Shaanxi Province (No. 2020KW-011), the Fundamental Research Funds of Shaanxi Key Laboratory of Artificially-Structured Functional Materials and Devices (No. AFMD-KFJJ-21207).\u201dnow reads:\u201cThis work was supported by the National Natural Science Foundation of China (Grant No. 11975176), the Key Research and Development Program of Shaanxi Province (No. 2020KW-011), the Fundamental Research Funds of Shaanxi Key Laboratory of Artificially-Structured Functional Materials and Devices (No. AFMD-KFJJ-21207) and Natural Science Foundation of Shaanxi (2022JQ-660).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-022-20995-x, published online 06 October 2022Correction to: The Acknowledgements section in the original version of this Article was incomplete.\u201cThis research was supported by the Kumoh National Institute of Technology (2019-104-044) and the Hustar Medical Industry Innovation University Project and Nano-Material Technology Development Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF2021M3H4A407927511 and 2021M3H4A4079264).\u201dnow reads:\u201cThis research was supported by the Kumoh National Institute of Technology (2019-104-044) and the Hustar Medical Industry Innovation University Project, S3310771  and Nano-Material Technology Development Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF2021M3H4A407927511 and 2021M3H4A4079264) and Nanomedical Devices Development Project of NNFC in 2022.\"The original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-13662-8, published online 10 June 2022Correction to: The Funding section in the original version of this Article was incomplete.\"NHMRC  project grant (application ID 1063608). This project received seed funding from a Pfizer Neuroscience Research Grant (2011) (application ID WS1931543). Chris Moran was supported by a NHMRC-ARC  Dementia Research Fellowship (application ID 1109482).\"now reads:\u201cNHMRC  project grant (application ID 1063608). This project received seed funding from a Pfizer Neuroscience Research Grant (2011) (application ID WS1931543). Chris Moran was supported by a NHMRC-ARC  Dementia Research Fellowship (application ID 1109482). The Australian Twin Registry  receives support from the National Health and Medical Research Council through a Centre of Research Excellence Grant, which is administered by the University of Melbourne.\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-14259-x, published online 16 June 2022Correction to: The original version of this Article contained an error in the Acknowledgments section.\"The authors would like to thank the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by Grant Code: 22UQU4331317DSR14. The authors acknowledge the financial support provided by the Center of Excellence in Theoretical and Computational Science (TaCS-CoE), KMUTT. Kamel SMIDA would like to express his gratitude to AlMaarefa University, Riyadh, Saudi Arabia, for providing funding (TUMA-2021-17) to do this research.\u00a0Moreover, this research project is supported by Thailand Science Research and Innovation (TSRI) Basic Research Fund: Fiscal year 2022 under project number FRB650048/0164.\"now reads:\"The authors would like to thank the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by Grant Code: 22UQU4331317DSR16. The authors acknowledge the financial support provided by the Center of Excellence in Theoretical and Computational Science (TaCS-CoE), KMUTT. Kamel SMIDA would like to express his gratitude to AlMaarefa University, Riyadh, Saudi Arabia, for providing funding (TUMA-2021-17) to do this research.\u00a0Moreover, this research project is supported by Thailand Science Research and Innovation (TSRI) Basic Research Fund: Fiscal year 2022 under project number FRB650048/0164.\"The original Article has been corrected."}
+{"text": "Functional mobility training with a powered knee and ankle prosthesis by Finucane SB, Hargrove LJ and Simon AM (2022). Front. Rehabilit. Sci. 3:790538. doi: 10.3389/fresc.2022.790538A corrigendum on Incorrect FundingIn the published article, there was an error in the Funding statement. The funding statement was missing an additional funding source as listed below. Original text: Funding for this report was provided by the US Army's Telemedicine and Advanced Technology Research Center (TATRC) contract WW81XWH-09-2-0020, the US Army's Joint Warfighter Program contract W81XWH-14-C-0105, and the National Institute of Health NIH R01 HD079428-02.The correct Funding statement appears below.FundingFunding for this report was provided by the US Army's Telemedicine and Advanced Technology Research Center (TATRC) contract WW81XWH-09-2-0020, the US Army's Joint Warfighter Program contract W81XWH-14-C-0105, the National Institute of Health (NIH) R01 HD079428-02 and the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR grant number 90REGE0003. NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this article do not necessarily represent the policy of NIDILRR, ACL, or HHS, and you should not assume endorsement by the Federal Government.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated."}
+{"text": "Correction: Respiratory Research (2022) 23:309 https://doi.org/10.1186/s12931-022-02113-7Following publication of the original article , the autIt has been updated in this correction.The updated Funding section should read as below:FundingThis study was supported by the National Natural Science Foundation of China (61976238); Shanghai Municipal Science and Technology Commission (21Y11910500); Shanghai Municipal Health Commission (20204Y0299); Medical Imaging Key Program of Wise Information Technology of 120, Health Commission of Shanghai 2018ZHYL0103 (ML), \u201cFuture Star\u201d of famous doctors\u2019 training plan of Fudan University. This study was also supported by the Shanghai Municipal Science and Technology Commission (20Y11902900).The original article has been corrected."}
+{"text": "T. N. Nha et al., RSC Adv., 2021, 11, 30054\u201330068. DOI: 10.1039/D1RA03216JCorrection for \u2018Sensitive MnFe The authors regret that an incorrect grant number was shown in the acknowledgements section of the published article. The corrected section should read:This work was supported by the Vietnam Academy of Science and Technology (VAST) by Program of Development in the field of Physics by 2020 under grant number KHCBVL.02/20-21, and partly by AOARD Award No. FA2386-17-1-4042.The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers."}
+{"text": "Correction: BMC Health Services Research 22, 1591 (2022)https://doi.org/10.1186/s12913-022-08991-3Following publication of the original article , the autThe incorrect author name is: John D. PowersThe correct author name is: John H. PowersIn addition, the authors identified an error in the affiliation of John H. Powers (affiliation 4): it was corrected from \u2018Clinical Research Directorate, Frederick National Laboratory for Cancer Research\u2019 to \u2018George Washington University School of Medicine\u2019.The author group and list of affiliations has been updated above and the original article  has been"}
+{"text": "Scientific Reports 10.1038/s41598-022-22644-9, published online 28 October 2022Correction to: The Funding section in the original version of this Article was omitted. The Funding section now reads:\u201cWe would like to thank the School of Information Technology and Engineering, Vellore Institute of Technology, Vellore, India \u2212 632014 for paying APC for this study.\u201dThe original Article has been corrected."}
+{"text": "Correction to: Journal of Immigrant and Minority Health10.1007/s10903-022-01402-zThe original version of this article unfortunately missed to include Acknowledgement section.Therefore, the complete section is given here:Acknowledgements: This work was supported by Promoting Grants for Research Toward Resilient Society 2021 (Tohoku University) and Ensemble Grants for Early Career Researchers 2021 (Tohoku University).The original article has been corrected."}
+{"text": "Correction to: BMC Medical Imaging (2022) 22:153https://doi.org/10.1186/s12880-022-00874-7Following the publication of the original article , we wereThe statement \"This study was supported by the National Natural Science Foundation of China [81771834] and the Natural Science Foundation of Beijing [Z181100001718017]\" should be replaced by \"None\".The original article has been revised as above."}
+{"text": "BioMed Research International has retracted the article titled \u201cClinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis\u201d [Following an investigation conducted by the Hindawi Research Integrity team , signifiThe authors do not agree to the retraction."}
+{"text": "Correction: Biotechnol Biofuels (2020) 13:73 10.1186/s13068-020-01714-yFollowing publication of the original article , the autFundingThis work is partially supported by grants from National Key R&D Program of China (2018YFA0902500), National Youth Thousand Talents Program of China and Peking University CCUS project supported by BHP Billiton.The original article  has been"}
+{"text": "Jung, E. S., Suh, K., Han, J., Kim, H., Kang, H.\u2010S., Choi, W.\u2010S., & Mook\u2010Jung, I. (2022).Aging Cell, 21, e13623. https://doi.org/10.1111/acel.13623In Jung et al. (2022), the authors would like to correct the grant numbers listed under funding information section. The revised funding information should read as follows:Funding informationHU20C0187 and HU20C0198).This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and Korea Dementia Research Center (KDRC), funded by the Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea (grant numbers The authors would like to apologize for the inconvenience caused."}
+{"text": "Correction: BMC Health Serv Res 22, 586 (2022)https://doi.org/10.1186/s12913-022-07936-0Following publication of the original article , the autThe sentence originally read:years  and 49 years  respectively and they ranged between 13 and 50 months for PD and one and 21 years for HD.The median dialysis vintage of PD and HD patients were 36 The sentence should read:months  and 49 months  respectively and they ranged between 13 and 50 months for PD and one and 21 years for HD.The median dialysis vintage of PD and HD patients were 36 The original article  has been"}
+{"text": "Signal Transduction and Targeted Therapy 10.1038/s41392-022-00970-8, published online 27 May 2022Correction to: In this article, the funding from \u201cNational Natural Science Foundation of China to YR (Grant# 82125034), National Key R&D Program of China .\u201d was omitted.The original article has been corrected."}
+{"text": "Page 1: The title should appear as given in this Erratum.Volume 9, no. 3, 2021, Page 12, Acknowledgments: The first paragraph should read as follows. \u201cThis work was supported by the Natural Science Foundation of Guangdong Province, China (2022A1515011532), Foundation for Innovative Research Groups of the National Natural Science Foundation of China (32121004), Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2019BT02N054), and Innovation Team Project of Guangdong University (2019KCXTD001).\u201d"}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-022-16984-9, published online 27 July 2022Correction to: The original version of this Article contained an error in the Methods section.In the Methods section, under the subheading \u2018Study design\u2019,\u201cThis study was approved by the Research Ethics Committee Office of National Taiwan University Hospital (No. 201803013RINA).\u201dnow reads:\u201cThis study was approved by the Research Ethics Committee Office of National Taiwan University Hospital (No. 201803013RINA) and the Institutional Review Board (IRB) of Chang Gung Memorial Hospital (IRB No. 201800767B0C501).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-20348-8, published online 06 October 2022Correction to: The original version of this Article contained an error in the Author Information section.\u201cThese authors contributed equally: Hae-Yeon Park, DoGyeom Park, Seungchul Lee and Sun Im.\u201dnow reads:\u201cThese authors contributed equally: Hae-Yeon Park and DoGyeom Park.These authors jointly supervised this work: Seungchul Lee and Sun Im.\u201dIn addition, the Article contained an error in the Funding section.\u201cThis work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (no. 2020R1F1A106581412), the by the Po-Ca Networking Groups funded by The Postech-Catholic Biomedical Engineering Institute (No. 5-2020-B0001-00050) and by Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R1A6A1A03047902).\u201dnow reads:\u201cThis work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (no. 2020R1F1A106581413), by the Po-Ca Networking Groups funded by The Postech-Catholic Biomedical Engineering Institute (No. 5-2020-B0001-00050) and by the Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R1A6A1A03047902).\u201dThe original Article and accompanying Supplementary Information file have been corrected."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-021-93742-3, published online 12 July 2021Correction to: The original version of this Article contained an error in the Funding section.https://www.jpnd.eu\u00a0 and Economic and Social Research Council (ES/L008238/1)) and through the Motor Neurone Disease Association. This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London.\u201d\u201cThis work was funded by the Motor Neurone Disease Association (Grant: Jones/Oct15/958-799) and the ALS Association (Grant: 18-LGCA- 394 \"HERV-K molecular studies in ALS\").\u00a0AAC is an NIHR Senior Investigator. This is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND -\u00a0now reads:https://www.jpnd.eu\u00a0 and Economic and Social Research Council (ES/L008238/1)) and through the Motor Neurone Disease Association. This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London.\u201d\u201cThis work was funded by the Motor Neurone Disease Association (Grant: Jones/Oct15/958-799), the ALS Association (Grant: 18-LGCA- 394 \"HERV-K molecular studies in ALS\") and MND Scotland . AAC is an NIHR Senior Investigator. This is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND -\u00a0The original Article has been corrected."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-023-28294-9, published online 21 January 2023Correction to: The original version of this Article contained an error in the Funding section.\u201cThis study was supported by a grant from Shaanxi Provincial Key Research and Development Project (CN) (grant no. 2021SF-224) and Xi\u2019an Health Scientific Research Talent Project (CN) (grant no. J202102038). The authors have no conflicts of interest to declare.\u201dnow reads:\u201cThis study was supported by a grant from the Clinical Medical Research Center Projects - Innovation Capability Support Program of Shaanxi Province (2020LCZX-030). The authors have no conflicts of interest to declare.\u201dThe original Article has been corrected."}
+{"text": "Funding statement. \u201cThis work was supported by National Key Programs of China during the 13th Five-Year Plan Period (2018ZX09711001-002-012) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZY2017202).\u201d The correct Funding statement appears below.In the published article, there was an error in the Funding\u201cThis work was supported by National Key Programs of China during the 13th Five-Year Plan Period (2018ZX09711001-002-012) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD20001).\u201dThe authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated."}
+{"text": "After publication of this article , the autM. Saruta has received consulting and lecture fees from Abbvie GK., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd, EA Pharma Co., Ltd., and Gilead K.K; and research grants from EA Pharma Co., Ltd., EP-CRSU Co., Ltd., Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co., Ltd., and Zeria Pharmaceutical Co., Ltd.The other authors have no conflicts of interest related to this article.The original article  has been"}
+{"text": "Prisons are high-risk environments for the transmission of drug related infections, due to over-incarceration of people who inject drugs; often inadequate healthcare, substandard prison conditions; and others. An overview of the availability and coverage of prison-based harm reduction interventions in Europe is presented.National Focal Points of the EMCDDA (30) collected 2019 data, which were integrated with findings from the European funded project HA-REACT (Joint Action on HIV and Co-infection Prevention and Harm Reduction).Prison based harm reduction interventions are available in European countries, but only few of them are available in most countries and often with a low coverage (e.g. less than 10% of prison population in Opioid Substitution Treatment (OST) in most countries). Interventions available in most countries (20 or more) include: HIV, HBV, HCV testing (29), OST continued from community (29), Referral to HIV treatment upon release (28), HIV treatment (27), Referral to HCV treatment upon release (25), HCV antiviral treatment (25), Testing for TB (23), HBV antiviral therapy (25), OST initiated in prison (22), Treatment for TB (21), Vaccination for HBV (20). Interventions available in 10 to 19 countries are: condom distribution (19), OST (re)initiated before release (17), prison/community guidelines for implementation of OST (13). Interventions provided in < 10 countries include: distribution of disinfectant (9), condom with lubricant (9), take-home naloxone (5), needles and syringes programs (3).Compared to the community, the availability and coverage of harm reduction interventions in European prisons are limited and large information gaps exist. Scaling up harm reduction in prison can achieve important individual and public-health benefits."}
+{"text": "Correction to: Trials 23, 162 (2022)https://doi.org/10.1186/s13063-022-06083-5Following the publication of the original article , we wereOriginally published sections:Funding: \u201cThe Wushu Research Institute of the State Sports General Administration (WSH2018A005).Authors\u2019 contributions: \u201cLYK was involved in the conception and design of the research. LYH obtained ethics approval. LYH drafted the manuscript. All authors edited and revised the manuscript. All authors approved the final version of the manuscript.\u201dCorrected sections:Funding: \u201cFund Project: Zhejiang Provincial Department of Education College Teacher Professional Development Project (FX2018064); Zhejiang Provincial Department of Education University Scientific Research Program Project (Y201533645)\u201dAuthors\u2019 contributions: \u201cLXW was involved in the conception and design of the research. LXW obtained ethics approval. LYH drafted the manuscript. All authors edited and revised the manuscript. All authors approved the final version of the manuscript.\u201dThe original article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-25099-0, published online 01 December 2022Correction to: The original version of this Article contained an error in the Funding section.\u201cThis study was supported by the Polish National Science Center, grant number: 2016/23/B/HS6/03843. N.K-G was supported by the Foundation of Polish Science (FNP) and the Kosciuszko Foundation.\u201dnow reads:\u201cThis study was supported by the Polish National Science Center, grant number: 2016/23/B/HS6/03843. N.K-G was supported by the Foundation of Polish Science (FNP) and the Kosciuszko Foundation. Open access was funded by SWPS University Research Development.\u201dThe original Article has been corrected."}
+{"text": "Humanities and Social Sciences Communications 10.1057/s41599-022-01338-7, published online 26 September 2022.Correction to: In this article the funding from the French government under the \u201cFrance 2030\u201d investment plan managed by the French National Research Agency (reference: ANR-17-EURE-0020) and from Excellence Initiative of Aix-Marseille University - A*MIDEX.\u201d and Federal funds from the National Institutes of Health, Department of Health and Human Services, under Contract No. 75N91020C00039 was omitted. The original article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-022-07773-5, published online 08 March 2022Correction to: The original version of this Article omitted an affiliation for Yoon\u2011Sang Oh and Sang\u2011Won Yoo. Their correct affiliation is listed below:Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaThe original Article has been corrected."}
+{"text": "The authors regret that the funding information was not included in the acknowledgements in the original article. The following acknowledgements should have been included:This work was supported in part by the Engineering and Physical Science Research Council (EPSRC) through Engineering Fellowship for Growth\u2014PRINTSKIN (EP/M002527/1) and neuPRINTSKIN (EP/R029644/1) and EPSRC ORCA \u2013 Partnership Resource Fund Project MUSES (EP/R026173/1). In addition, this work received support from the European Union\u2019s Horizon 2020 Research and Innovation Programme (AQUASENSE Project) under the Marie Sk\u0142odowska-Curie grant agreement No: H2020-MSCA-ITN-2018-813680.The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers."}
+{"text": "Nature Communications 10.1038/s41467-022-30236-4, published online 19 May 2022.Correction to: The original version of this Article contained an error in Acknowledgements, which incorrectly read \u2018We thank Edward Owusu-Ansah, Alex Whitworth, Ronald Davis, and the Bloomington Drosophila Stock Center at Indiana University (supported by NIH P40OD018537) for fly stocks, Michael Ryan for the NDUFB10KO, NDUFS4KO, and control cell lines, David Clapham for other HEK293T cell lines, John Elrod, Ronald Kahn, and Nils-G\u00f6ran Larsson for mouse lines, James Marvin and Flow Cytometry Core staff at the University of Utah (supported by NIH P30CA042014), Small Animal Ultrasound Core staff at the University of Utah, and Derek Warner and DNA Sequencing Core staff at the University of Utah.\u2019 The correct version states \u2018We thank Edward Owusu-Ansah, Alex Whitworth, Ronald Davis, and the Bloomington Drosophila Stock Center at Indiana University (supported by NIH P40OD018537) for fly stocks, Vamsi Mootha for multiple plasmids and MCU knockout cell lines, Michael Ryan for the NDUFB10KO, NDUFS4KO, and control cell lines, David Clapham for other HEK293T cell lines, John Elrod, Ronald Kahn, and Nils-G\u00f6ran Larsson for mouse lines, James Marvin and Flow Cytometry Core staff at the University of Utah (supported by NIH P30CA042014), Small Animal Ultrasound Core staff at the University of Utah, and Derek Warner and DNA Sequencing Core staff at the University of Utah\u2019. This has been corrected in both the PDF and HTML versions of the Article."}
+{"text": "Scientific Reports 10.1038/s41598-021-85630-7, published online 24 March 2021Correction to: The Acknowledgements section in this Article is incorrect.\u201cThis study was supported by 2021 the RDA Fellowship Program of National Institute of Animal Science, Rural Development Administration, Republic of Korea.\u201dshould read:\u201cThis research was funded by Rural Development Administration, Korea (grant number: PJ0147962021).\u201d"}
+{"text": "Pseudomonas aeruginosa has become one of the most common pathogens associated with nosocomial infections. A series of susceptibility studies was designed to evaluate the activity of tebipenem against a panel of P. aeruginosa isolates known to have alterations in efflux pumps, outer-membrane porins, and expression of AmpC beta-lactamase enzymes compared to a subset of wild-type organisms.SPR994 is an orally bioavailable pivoxil hydrobromide prodrug of tebipenem, a novel oral carbapenem with activity against Gram-positive and -negative bacteria currently under development for the treatment of urinary tract infections (UTI). P. aeruginosa isolates was subjected to tebipenem and five other challenge compounds  in order to determine minimum inhibitory concentration (MIC) values, in triplicate, using standard agar dilution methodologies. P. aeruginosa ATCC 27853 was used as an internal control and all reported MIC values represented the modal value.A panel of 20 Table 1) and were similar to those found for meropenem and ertapenem with MIC values ranging from \u22640.03 to 16 mg/L and \u22640.25 to 128 mg/L, respectively. The deletion of MexB decreased the carbapenem MIC values by 2 to 4x while deletion of MexCD-OprJ and MexXy did not. Simultaneous deficiencies in MexAB, CD, EF, and XY did not decrease MIC values in comparison with the deletion of MexAB alone. Isolates possessing a derepressed AmpC showed no significant elevation in MIC value compared to wild-type isolates while those known to have lost OprD resulted in carbapenem MIC values increasing by ~4 to 32x. The combined loss of OprD and overexpression of AmpC resulted in the highest carbapenem MIC values (\u226516 mg/L). Levofloxacin, tetracycline, and carbenicillin MIC values ranged from \u22640.06 to 16 mg/L, 0.5 to 64 mg/L, and \u22640.125 to >128 mg/L, respectively. All MIC values determined for the internal control were within Clinical Laboratory Standard Institute reported values.Tebipenem MIC values ranged from 0.25 to >64 mg/L for the 20 isolates evaluated Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Haley Conde, B.S., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Nicole Cotroneo, Spero Therapeutics  Ian A. Critchley, Ph.D., Spero Therapeutics  Thomas R. Parr, Ph.D., Spero Therapeutics  Paul G. Ambrose, Pharm.D., FIDSA, 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Research Grant or Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support)"}
+{"text": "Enterobacterales (CREs). Carbapenemase-negative (CN) CRE isolates have been reported, but the activity of newer agents against these isolates is still not well understood. We evaluated the activity of MVB against CN-CRE collected during 6 years of surveillance in US hospitals.Meropenem-vaborbactam (MVB) is an important addition to the armamentarium to treat infections caused by carbapenem-resistant Enterobacterales isolates collected in US hospitals from 2014-2019 were susceptibility tested by reference broth microdilution methods. Results were interpreted using CLSI 2020 breakpoints. CRE isolates were submitted to PCR/sequencing (2014-2015) or whole genome sequencing  for characterization of carbapenemase genes. Isolates from 2016-2019 were evaluated for other beta-lactam resistance mechanisms.A total of 27,968 K. pneumoniae (16 isolates) followed by E. cloacae (9), E. coli (8), and K. aerogenes (8). MVB was the most active agent tested against these isolates, inhibiting 47/48 (97.9%) of the isolates tested. The only isolate displaying a resistant MIC for MVB was a P. mirabilis  collected in 2015. Meropenem alone inhibited only 2.1% of the isolates. Other beta-lactams inhibited 4.2 to 14.6% of the isolates. Among non-beta-lactam comparator agents, tigecycline and amikacin inhibited 93.8 and 91.7% of the isolates, respectively, when applying CLSI or US FDA breakpoints. A total of 89.6% of the isolates had intermediate colistin MIC values. Among the 27 isolates collected from 2016-2019 that were submitted to WGS, 15 harbored CTX-M encoding genes. K. aerogenes and E. cloacae isolates (3 each) overexpressed AmpC. OmpC/K36 was disrupted in 20 isolates and OmpF/K35 was disrupted in 8 isolates.Among 357  CRE isolates identified during 6 years of surveillance, 48 (13.4% of the CRE) isolates did not produce known carbapenemases. The CN-CRE collection included 7 bacterial, species, or species complex. The top four most common species in the collection were MVB displayed good activity against CN-CRE isolates from US hospitals. This combination agent could be a good option to treat infections caused by these isolates.Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Timothy B. Doyle, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Valerie Kantro, n/a, Melinta Therapeutics, Inc. (Research Grant or Support) Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)"}
+{"text": "This article has been corrected: The authors have found a typing mistake in the FUNDING section: Zhejiang Provincial Natural Science Foundation (No.Y19H270018) should be (No.LY19H270004). The correct section is presented below.Zhejiang Provincial Natural Science Foundation . Special project for the modernization of traditional Chinese medicine in Zhejiang Province (No. 2020ZX007). National TCM clinical research base construction project (No. 2015H0105). National Natural Science Foundation of China (No. 81800138)."}
+{"text": "Scientific Reports 10.1038/s41598-021-01185-7, published online 05 November 2021Correction to: The Acknowledgments section in the original version of this Article was incomplete.\u201cThis study was funded by core research grant from National Institute of Plant Genome Research. MI acknowledges CSIR, India for Senior Research Associateship (CSIR Pool Number: 8862-A).\u201dnow reads:\u201cThis study was funded both by core research grant from National Institute of Plant Genome Research and Department of Biotechnology, Ministry of Science and Technology, Government of India. MI acknowledges CSIR, India for Senior Research Associateship (CSIR Pool Number: 8862-A).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-019-47651-1, published online 05 August 2019Correction to: The Acknowledgements section in the original version of this Article was incomplete.\u201cThis work was based on work supported by the National Science Foundation through Grant CHE 1607949 (TGIII).\u201dnow reads:\u201cThis work was based on work supported by the National Science Foundation through Grant CHE 1607949 (TGIII). This material is based upon work supported by the Air Force Office of Scientific Research under award number FA9550-17-1-0457.\"The original Article has been corrected."}
+{"text": "In the original publication  there waIncorrect fundingThis research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number HI20C1496), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. NRF-2018R1A2B6007291) and (No. NRF-2018R1C1B6005889).Correct fundingThis research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea , the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. NRF-2018R1A2B6007291) and (No. NRF-2018R1C1B6005889)."}
+{"text": "Staphylococcus aureus (SA) bacteremia (SAB), including right-sided infective endocarditis (IE), used in addition to standard-of-care antibiotics. CF-301 in vitro activity was determined against SA isolates reflecting the Phase 3 target patient SAB population, including IE.Exebacase (CF-301) is a lysin (peptidoglycan hydrolase enzyme) with anti-staphylococcal activity. CF-301 is in Phase 3 of clinical development for the treatment of 666 SA recovered from blood (3% from known IE) of patients hospitalized in 29 centers located in 9 Census regions were included as part of the SENTRY Antimicrobial Surveillance Program for 2020. Identification was confirmed by MALDI-TOF. Susceptibility to 12 comparators used reference broth microdilution (BMD), whereas CF-301 used a modified BMD method with cation-adjusted Mueller-Hinton broth (CAMHB) supplemented with 25% horse serum and 0.5 mM DL-dithiothreitol according to CLSI. MIC interpretation for comparator agents used CLSI criteria, including determination of multidrug-resistant (MDR) phenotype (non-susceptible to \u22653 classes of antibiotics).50, MIC90 and modal MIC values of 0.5 mg/L. CF-301 MIC results  against methicillin-susceptible (MSSA) and -resistant  SA were identical. Many comparators had activity against MSSA; among drugs indicated for treating SAB caused by MRSA, daptomycin and vancomycin were active (100% susceptible) against all isolates. A total of 62.3% of MRSA isolates were categorized as MDR, and CF-301 showed equal MIC50 and MIC90 results against MDR  and non-MDR  populations. Daptomycin and vancomycin were active (100% susceptible) against MDR MRSA isolates.Against all SA tested CF-301 had an MIC range of 0.06-1 mg/L, with MICCF-301 was uniformly active against contemporary SA isolates responsible for bloodstream infections in the US in 2020. CF-301 activity was consistent, regardless of resistance phenotype . Surveillance data presented here further support the clinical development of CF-301 as a promising option for treatment of SAB, including those caused by MDR MRSA isolates.Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Jill Lindley, Bravos Biosciences (Research Grant or Support)ContraFect Corporation (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support) Nabina Gurung, n/a, ContraFect Corporation (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Ray Schuch, PhD, ContraFect Corporation (Employee) Jane E. Ambler, PhD, ContraFect Corporation (Employee)"}
+{"text": "The section should read: ``German Federal Ministry of Research and Education (01ZZ1802); Physician-Scientist Program of the University of Heidelberg, Faculty of Medicine, DKTK (German Cancer Consortium) School of Oncology and the Cancer Core Europe TRYTRAC program (to A.M.); MTB-Report project (VolkswagenStiftung ZN3424) (to J.H.).'' instead of ``German Federal Ministry of Research and Education (01ZZ1802); University of Heidelberg, Faculty of Medicine (to A.M.); Volkswagen Foundation (to J.H.).'' This has now been corrected."}
+{"text": "Correction to:Health Justice9, 27 (2021).https://doi.org/10.1186/s40352-021-00150-wThere are multiple, repeated references for \u2018United Nations Office on Drugs and Crime\u2019 in the reference list.(2 instances) United Nations Office on Drugs and Crime (UNODC). (2015). The United Nations Standard Minimum Rules for the Treatment of Prisoners (the Nelson Mandela Rules). Retrieved from https://www.unodc.org/documents/justice-and-prison- reform/Nelson_Mandela_Rules-E-ebook.pdf(2 instances) United Nations Office on Drugs and Crime (UNODC). (2020). COVID-19 prevention and control among people working in prisonThese include:In the reference list, \u2018Retrieved from\u2019 still remains in many instances where there is no URL; we had asked for these to be removed prior to publication.Supplementary appendix Following the publication of the original article (Pearce et al., The original article (Pearce et al., Additional file 1: Appendix S1. List of recommendations by domain and sub-domain."}
+{"text": "Scientific Reports 10.1038/s41598-021-86146-w, published online 23 March 2021Correction to: The original version of this Article contained an error in the Acknowledgments section. \u201cThis research was supported by the following grants: National Natural Science Foundation of China (NSFC) No. 81671909 and 8190195, Zhejiang Provincial Natural Science Foundation of China under Grants No. LY18H150004, LY19H150004 and LY20H150010, and Key Research and Development Project of Sichuan Science and Technology Department No. 2018SZ0380.\u201dnow reads:\u201cThis research was supported by the following grants: National Natural Science Foundation of China (NSFC) No. 81671909 and 81901958, Zhejiang Provincial Natural Science Foundation of China under Grants No. LY18H150004, LY19H150004 and LY20H150010, and Key Research and Development Project of Sichuan Science and Technology Department No. 2018SZ0380.\u201dThe original Article has been corrected."}
+{"text": "Page 15: The following should be added to Acknowledgments after paragraph 2.Volume 95, no. 17, e01868-20, 2021, This work is based on research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences, National Institutes of Health (grant P30 GM124165). The Eiger 16M detector on the 24-ID-E beamline is funded by an NIH-ORIP HEI grant (S10OD021527). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by the Argonne National Laboratory under contract no. DE-AC02-06CH11357."}
+{"text": "Scientific Reports 10.1038/s41598-021-98627-z, published online 29 September 2021Correction to: The Acknowledgements section in the original version of this Article was incomplete.\u201cThe authors thank Kezhong Zhang of Wayne State University for providing the anti-CREB3L3 antibody. The work was supported by R00 DK090210, R01 DK109015, University of Chicago DRTC (DK020595) Pilot & Feasibility award, Central for Society for Clinical and Translational Research Early Career Development Award and UIC Startup fund (C.W.L.); M.A.M. was supported by an American Heart Association Predoctoral Fellowship (Grant No. 16PRE30190011). M.B. was funded by the Deutsche Forschungsgemeinschaft: Collaborative Research Center SFB1052, project B1.\u201dnow reads:\u201cThe authors thank Kezhong Zhang of Wayne State University for providing the anti-CREB3L3 antibody. The authors also acknowledge the Research Open Access Publishing (ROAAP) Fund of the University of Illinois at Chicago for financial support towards the open access publishing fee for this article. The work was supported by R00 DK090210, R01 DK109015, University of Chicago DRTC (DK020595) Pilot & Feasibility award, Central for Society for Clinical and Translational Research Early Career Development Award and UIC Startup fund (C.W.L.); M.A.M. was supported by an American Heart Association Predoctoral Fellowship. M.B. was funded by the Deutsche Forschungsgemeinschaft: Collaborative Research Center SFB1052, project B1.\u201dThe original Article has been corrected."}
+{"text": "We evaluated the BSI results in 2018-2020.The IDEA Program monitors the 8,643 organisms were consecutively collected (1/patient) from 74 medical centers located in the US , western EU , and eastern EU . Organisms were susceptibility tested by reference broth microdilution methods in a central laboratory. S. aureus , E. faecalis , S. epidermidis , \u03b2-hemolytic streptococci , and E. faecium , but rank order varied markedly by geographic region. The top 3 GP organisms were SA, EF, and BHS in the US; SA, EF, and EFM in W-EU; and SA, S. pneumoniae, and BHS in E-EU. Dalbavancin was highly active against methicillin-susceptible (MSSA) and -resistant (MRSA) SA, with an MIC90 of 0.03 mg/L in all 3 regions (Table). Among SA, MRSA rates were higher in the US (41.3%) than W-EU (21.5%) or E-EU (27.3%), and ceftaroline susceptibility ranged from 95.4% (W-EU) to 96.6% (US). Vancomycin (VAN) susceptibility varied from 97.3% (E-EU) to 98.3% (W-EU) among EF (97.5% in US), and dalbavancin was active against all VAN-S EF . Among SEP, all isolates were inhibited at \u22640.25 mg/L of dalbavancin  and oxacillin resistance ranged from 66.9% in W-EU to 86.5% in E-EU (73.2% in US). BHS exhibited low dalbavancin MIC values  and high S rates for its comparators. Among EFM, VAN-S rates varied from 36.6% in the US to 61.6% in E-EU and 76.1% in W-EU, and dalbavancin inhibited all VAN-S EFM at \u22640.25 mg/L .Overall, the most common GP organisms were Dalbavancin exhibited potent activity and broad spectrum against a large collection of contemporary GP bacteria recovered from patients with BSI in US and EU. Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Michael D. Huband, BS, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support) Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support) Cecilia G. Carvalhaes, MD, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support) Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)"}
+{"text": "Scientific Reports 10.1038/s41598-021-86985-7, published online 05 April 2020Correction to: The original version of this Article contained an error in the Funding section.\u201cOpen access funding provided by Uppsala University. This research was funded by the Knut and Alice Wallenberg Foundation (WAF 2016.0112) and the European Research Council (ERC-2017-STG-757444).\u201dnow reads:\u201cOpen access funding has been provided by Uppsala University. This research has received funding from the Knut and Alice Wallenberg Foundation (WAF 2016.0112), the Swedish Research Council (2019-03797) and from the European Research Council (ERC) under the European Union\u2019s Horizon 2020 research and innovation programme (grant agreement No 757444).\u201dThe original Article has been corrected."}
+{"text": "The STAR-VA program was an initiative out of what is now called the VA Office of Mental Health and Suicide Prevention, partnering with the national Offices of Geriatrics and Extended Care and Nursing Services. Ongoing collaboration with these national, as well as regional and medical-center-level leaders, has been critical for informing program implementation and dissemination strategies. We will discuss several key partnered strategies, including (1) linking STAR-VA to national CLC systematic quality improvement efforts; (2) engaging national inter-office program leaders in decisions about outreach to and inclusion of facilities in STAR-VA training and implementation; (3) training local STAR-VA champions on strategies for engaging local leadership support; (4) briefing leaders across the system with program updates; and (5) using national VA data to inform STAR-VA sustained implementation. Discussion will address challenges and opportunities for engaging leadership stakeholders in facilitating sustained implementation of evidence-based programs."}
+{"text": "Scientific Reports 10.1038/s41598-017-04641-5, published online 08 September 2017Correction to: The original version of this Article contained an error in Figure\u00a01, where the unit for the y-axis of panel (c) was incorrect. The original Figure\u00a0In addition, in the Acknowledgements section, the grant numbers for Zhejiang Provincial Natural Science Foundation for Distinguished\u00a0Young\u00a0Scholar were incorrect.\u201cThis work was supported by the National Natural Science Foundation of China , Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholar (No. R17F040007), Ningbo Municipal Natural Science Foundation (No. 2014A610011), the Ningbo Natural Science Foundation of China , the State Key Basic Research Program of China (2013CB922300), Youth Innovation Promotion Association, Chinese Academy of Sciences and Royal Academy of Engineering, UK. The author appreciates the K.C. Wong Magna Fund in Ningbo University.\u201dnow reads:\u201cThis work was supported by the Zhejiang Provincial Natural Science Foundation for Distinguished\u00a0Young\u00a0Scholar\u00a0(No. LR17F040002), National Natural Science Foundation of China ,\u00a0Ningbo Municipal Natural Science Foundation (No. 2014A610011), the Ningbo Natural Science Foundation of China , the State Key Basic Research Program of China (2013CB922300), Youth Innovation Promotion Association, Chinese Academy of Sciences and Royal Academy of Engineering, UK. The author appreciates the K.C. Wong Magna Fund in Ningbo University.\u201dThe original Article has been corrected."}
+{"text": "Escherichia coli makes this an increasingly unsuitable option. Tebipenem (TBP) is an orally bioavailable carbapenem administered as a pro-drug (tebipenem pivoxil hydrobromide) with broad-spectrum activity that is currently in development for the treatment of patients with complicated UTI. Herein we describe a series of 7-day hollow-fiber in vitro infection model (HFIM) assays designed to evaluate the potential of PO TBP as step-down therapy from IV ertapenem (ETP).Intravenous (IV) to oral (PO) antibiotic step-down therapy has many benefits including reducing the length of hospital stay and lowering the risk of nosocomial infections and overall cost. While fluoroquinolones have been utilized as a step-down therapy for urinary tract infections (UTI) for some time, increases in fluoroquinolone-resistant E. coli isolates, selected based upon ETP and TBP MIC values and known resistance profiles, were evaluated at an initial burden of 107 CFU/mL. HFIM, ETP and TBP free-drug concentration-time profiles were simulated in the HFIM to represent those following IV and PO dosing, respectively. Each isolate was challenged in duplicate by ETP administered every 24 hours (q24h) for 1, 3 or 7 days of therapy. TBP 600 mg every 8 hours was simulated as a step-down therapy following either 1 or 3 days of ETP treatment as well as a 7-day monotherapy regimen. All active regimens were compared to a no-treatment control as well as ETP 1g q24h for 1 or 3 days followed by a halting of therapy. Samples were collected for enumeration of bacterial populations and observation of simulated PK profiles throughout.A panel of ESBL+ clinical 10 CFU/mL. ETP 1g q24h monotherapy successfully reduced bacterial burdens to below levels of detection over the 7-day period but was followed by regrowth matching that in the no-treatment control when treatment was halted on Days 1 and 3. Similar to ETP, TBP successfully reduced bacterial burdens as a 7-day monotherapy and following 1 and 3 days of IV ETP by preventing growth throughout the remainder of the study.Bacteria grew well in the no-treatment control group, reaching densities > 10These data demonstrate the potential utility of TBP as oral step-down from IV ETP therapy and the need for evaluation as a step-down from other IV therapeutics. Brian D. VanScoy, B.S., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Sean Jones, B.S., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Haley Conde, B.S., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Lawrence Friedrich, Pharm.D., Spero Therapeutics  Nicole Cotroneo, Spero Therapeutics  Paul G. Ambrose, Pharm.D., FIDSA, 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Research Grant or Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support)"}
+{"text": "Experimental & Molecular MedicineCorrection to: 10.1038/s12276-019-0351-y published online 06 December 2019After online publication of this article, the authors noticed an error in the Acknowledgments section.The correct statement in this article should have read as follows.\u201cThe biospecimens for this study were provided by the Samsung Medical Center BioBank. This research was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (HI14C3418); the National Research Foundation funded by the Ministry of Science, ICT and Future Planning (MSIP) of Korea (NRF-2015M3C9A1044522 and NRF-2018R1C1B3001648); and the intramural research fund of Ajou University Medical Center (2018).\u201dThe authors apologize for any inconvenience caused."}
+{"text": "The following information is missing from the Funding statement: DD acknowledges financial support from the Spanish Ministry of Economy, Industry and Competitiveness through the R&D&i State Program; Ref. CSO2017-89721-R)."}
+{"text": "OBJECTIVES/GOALS: The modified Atkins diet (MAD) is used in the management of drug-resistant epilepsy in adults. Some patients on MAD show an increase in serum levels of total cholesterol and low-density lipoprotein (LDL) cholesterol. We explored whether dietary fat composition predicts short-term elevations in serum lipid levels in diet-na\u00efve adults who begin MAD. METHODS/STUDY POPULATION: Participants self-reported their diet intake with 3-day food records at baseline, 1 month and 2 months. Food records were analyzed using Nutrition Data System for Research software. Fasting serum levels of total cholesterol (TC), high-density lipoprotein (HDL) cholesterol, and triglycerides were also collected and LDL level calculated at baseline, 1 month, and 2 months. RESULTS/ANTICIPATED RESULTS: 38 patients submitted complete food records at each study visit . Compared to baseline diet intake, there was a significant reduction in daily carbohydrate intake at 1 and 2 months months (p<0.001). There was also a significant increase in daily saturated fatty acid (SFA) intake at 1 and 2 months (p<0.001), daily mono-unsaturated fatty acid (MUFA) intake at 1 and 2 months (p<0.001), and daily cholesterol intake at 1 month (p<0.05) and 2 months (p<0.001), but no change in daily poly-unsaturated fatty acid (PUFA) intake over time. Compared to baseline, there was a significant increase in serum LDL at 1 month (p<0.001) and 2 months (p<0.01) and an increase in serum TC at 1 month (p<0.01) but not 2 months. DISCUSSION/SIGNIFICANCE OF IMPACT : Despite a significant increase in total fat, saturated fat and mono-unsaturated fat intake as well as an increase in total cholesterol and LDL levels following MAD initiation, dietary fat composition appears to minimally predict serum lipid values in the short term. CONFLICT OF INTEREST DESCRIPTION: Tanya McDonald has received speaking honoraria from Nutricia North America. Bobbie Henry-Barron receives grants from Johns Hopkins Institute for Clinical and Translational Research (ICTR) which is funded in part by Grant Number UL1 TR 001079 from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research, Nutricia and Vitaflo. Diane Vizthum receives grants from the Johns Hopkins Institute for Clinical and Translational Research (ICTR) which is funded in part by Grant Number UL1 TR 001079 from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Mackenzie C. Cervenka has received grant support from Nutricia North America, Vitaflo, Army Research Laboratory, The William and Ella Owens Medical Research Foundation and BrightFocus Foundation. She receives speaking honoraria from LivaNova, Epigenix, Nutricia North America and the Glut1 Deficiency Foundation and performs consulting with Nutricia North America and Sage Therapeutics and receives Royalties from Demos Health."}
+{"text": "E. coli (EC) causing UTI in U.S. patients and the activity of TBP and comparators against various subsets.Tebipenem (TBP) is an oral carbapenem in clinical development for treating complicated urinary tract infections (UTIs), including pyelonephritis. This study investigates the epidemiology of A total of 2,395 EC recovered from urine samples during the 2018-2020 STEWARD Surveillance Program were included. Isolates were collected from medical centers in all 9 US Census Regions and centrally tested by reference broth microdilution method. MIC interpretation was based on CLSI criteria. Isolates that met MIC criteria were subjected to genome sequencing, followed by screening of extended-spectrum \u03b2-lactamase (ESBL) genes and epidemiology typing (MLST).blaCTX-M and 2/360 (0.6%) had blaSHV-12. blaCMY  was the most common cephalosporinase, followed by blaDHA . A CRE phenotype was noted in 1 isolate from New York, which carried blaKPC-2. Acquired genes were not detected in 56 strains. 50 ST types were noted in isolates that met the ESBL criteria screening, with the majority of isolates being ST131 (56.2%). 21 (6.7%) and 19 (6.0%) isolates belonged to ST38 and ST1193, respectively, followed by STs represented by 8 or less isolates. Among ST131, 56.5% carried blaCTX-M from group 1 and 35.6% had genes associated with group 9. Overall, TBP showed consistent MIC50 values throughout the subsets. ERT had activity (\u226597.0% susceptible) against the various subsets; however, lower susceptibility rates (85.7-90.6%) were noted against isolates carrying plasmid AmpC. Other agents (ceftriaxone and cefazolin) had activity only against non-ESBL producers.A total of 16.1%, 15.4% and 14.6% of EC met the ESBL screening criteria in 2018, 2019 and 2020, respectively. 269/360 (74.7%) carried blaCTX-M comprised the majority of acquired genes detected among ESBL strains, which belonged mostly to ST131, emphasizing the expansion of this clone. TBP showed consistent activity against all subsets, regardless of resistance genotype or lineage. These data support the clinical development of TBP as a convenient oral treatment option for UTI caused by EC.Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Timothy B. Doyle, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Ian A. Critchley, Ph.D., Spero Therapeutics  Nicole Cotroneo, Spero Therapeutics  Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support"}
+{"text": "Enterobacterales isolates have increased and remain elevated in many US hospitals. Aminoglycoside (AMG) resistance often co-exist with resistance to other classes of antibiotics. A newer aminoglycoside, plazomicin, was evaluated against a large collection of MDR Enterobacterales clinical isolates from US hospitals.Multidrug-resistant (MDR) A total of 456 MDR isolates (1/patient) were collected from 32 US medical centers located in 23 states in 2018-2020 and susceptibility tested by broth microdilution method at a central laboratory. MDR was defined as nonsusceptible (NS) to \u22653 antimicrobial classes and extensively drug-resistant (XDR) as susceptible (S) to \u22642 classes. Isolates resistant to aminoglycosides and/or broad-spectrum cephalosporins were screened for aminoglycoside-modifying enzymes (AME), 16S rRNA methyltransferases, and \u03b2-lactamases by whole genome sequencing. 50/90, 0.5/1 mg/L) and showed MIC values 8- to 16-fold lower than amikacin . AMK S rates were 84.6% and 69.3% when EUCAST (\u22648 mg/L) and USCAST (\u22644 mg/L) breakpoints were applied, respectively. Among agents from other classes, S rates were 85.5% for meropenem, 88.4% for tigecycline, 49.3% for piperacillin-tazobactam, and 17.8% for cefepime; only the carbapenems and tigecycline were active against >50% of MDR isolates. PLZ retained activity against isolates NS to AMK (83.9%S), gentamicin , and/or tobramycin . PLZ showed markedly higher S rates than AMK against XDR (93.3% vs. 71.7%), AME producers (97.6% vs. 90.2%), and carbapenemase (CPE) producers (98.1% vs. 67.9%). PLZ was active against 99.0% of ESBL producers, while AMK S rates were 96.2%/87.0% as per the US FDA/EUCAST against these organisms. PLZ and AMK showed similar S rates when tested against GEN-NS isolates. GEN and TOB exhibited limited activity against MDR and all resistant subsets. PLZ inhibited 93.0% of the MDR isolates  (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support) Jaideep Gogtay, n/a, Cipla Therapeutics (Employee)Cipla USA Inc. (Employee) Cheung Yee, MSc, PhD, Cipla Therapeutics (Employee) Sandhya Das, n/a, Cipla Therapeutics (Employee) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)"}
+{"text": "Bone and joint infections (BJI) comprise a series of disorders, including septic arthritis, osteomyelitis, and prosthetic joint infections. Dalbavancin (DALBA) is a lipoglycopeptide with a very long half-life that allows the treatment of serious infections with once weekly or biweekly administration. We evaluated the activity of DALBA against pathogens isolated from BJI.S. aureus, 140 \u03b2-haemolytic streptococci (BHS), 71 coagulase-negative staphylococci (CoNS), 57 Enterococcus spp. (ESP), 22 viridans group streptococci (VGS), and 5 S. pneumoniae. Bacteria were identified by standard algorithms and MALDI-TOF-MS. Susceptibility testing was performed by the reference broth microdilution method in a central laboratory. A total of 798 organisms were collected from 62 US and 28 European (EU) hospitals in 2016-2020, including 503 S. aureus (63.0%) was the most common pathogen associated with BJI, followed by BHS (17.5%), CoNS (8.9%), and ESP (7.1%). All S. aureus isolates were susceptible (S) to DALBA , linezolid , teicoplanin , vancomycin , and daptomycin  rates among S. aureus (MRSA rates) were 35.5% and 15.4% in the US and EU, respectively. Ceftaroline (CPT) was active against 98.6% of S. aureus  and 94.7% of MRSA  isolates. Doxycycline and levofloxacin were active against 97.0% and 76.5% of S. aureus, respectively. Among CoNS, (54.9% OXA-R), DALBA  was the most potent agent, followed by DAPTO , CPT  and LNZ . The highest DALBA MIC value among BHS and VGS was 0.12 mg/L . VAN was active against 82.4% of ESP and DALBA inhibited all VAN-S ESP at \u22640.06 mg/L. in vitro activity against common gram-positive organisms (GP) causing BJI and appears to be a valuable option to treat BJI/osteomyelitis caused by GP.DALBA demonstrated potent Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Leonard R. Duncan, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Shionogi (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)"}
+{"text": "Cefiderocol (CFDC) is a novel siderophore-conjugated cephalosporin with broad activity against Gram-negative (GN) bacteria, including carbapenem-resistant isolates, and non-fermentative organisms. CFDC is approved by the FDA for complicated urinary tract infection (cUTI), hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia. In this study, we analyzed the susceptibility of CFDC and comparators against aerobic nonfastidious GN isolates collected from US patients hospitalized with pneumonia (PHP) in 2020 as a part of the SENTRY Antimicrobial Surveillance Program. Enterobacterales  and extensively drug resistant  phenotype isolates were analyzed.A total of 1,877 Gram-negative isolates were consecutively collected from PHP in 27 US hospitals during 2020. Susceptibility (S) testing was performed using the CLSI broth microdilution method. CFDC was tested in iron-depleted Mueller-Hinton broth. CLSI or FDA (2021) breakpoints were used. Both CLSI and FDA (2021) interpretations are shown in the table. Carbapenem-resistant Pseudomonas aeruginosa , followed by Klebsiella pneumoniae (n=239). The %S and MIC50/90 values of CFDC for both CLSI and FDA breakpoints and comparators are shown in the table for all organisms and resistant subsets. For Enterobacterales, all tested drugs had >99%S. The 18 CRE isolates had 94.4%S to CFDC and ceftazidime-avibactam. CFDC was the most active antimicrobial tested against PSA  and XDR PSA (94.6/93.2%). CFDC had the highest %S against Acinetobacter baumannii-calcoaceticus species complex , XDR ABC (94.6/93.2%), and against Stenotrophomonas maltophilia . The most common GN organism isolated from PHP was in vitro results suggest that CFDC may be an important option for the treatment of PHP caused by GN organisms, particularly for pathogens which have few treatment options. CFDC was highly active against US GN isolates from PHP, including CRE, XDR PSA and ABC, as well as SM. These Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Leonard R. Duncan, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Shionogi (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support"}
+{"text": "Enterobacterales (ENT) and CRE isolates, but have limited activity against metallo-\u03b2-lactamase (MBL)-producing ENT. We evaluated the activity of QPX7728 (QPX), a novel BLI with intravenous (IV) and oral availability, in combination with BL agents. We tested ENT isolates carrying the most common BL genes such as blaCTX-M, transferable AmpCs, oxacillinases, MBLs, and serine carbapenemases.The \u03b2-lactam (BL)/ \u03b2-lactamase inhibitor (BLI) combinations approved in the last 10 years are active against most ESBL-producing A total of 1,027 ENT isolates were susceptibility (S) tested by reference broth microdilution against aztreonam (ATM), cefepime (FEP), cefdinir (CDR), ceftibuten (CTB), ceftolozane (CT) and piperacillin (PT) with fixed 4 mg/L of tazobactam, biapenem (BPM), meropenem (MER), and tebipenem (TEB) combined with QPX at fixed 4 and 8 mg/L. All isolates were genetically characterized using whole genome sequencing and included 520 ESBL-producers and 507 CRE with 168 producing MBLs.90, \u226532 mg/L); however, MIC90 values decreased \u226532-fold with the addition of QPX at the highest concentration tested (Table). Oral agents, CTB,CDR and TEB were tested with QPX at a fixed 4 mg/L and showed a 32- to 128-fold increase in potency . ATM and FEP were tested with QPX at a fixed 4 and 8 mg/L and displayed MIC90 values ranging from 0.12-0.5 mg/L. ATM and FEP, tested with 8 mg/L of QPX, inhibited 99.8% of isolates at the breakpoint for the BL agent alone. BLI inhibitor combinations PT and CT displayed MIC90 values of 2 and 4 mg/L with the addition of 8 mg/L QPX. MER with QPX at a fixed 4 mg/L and 8 mg/L inhibited 99.8% and 100% of isolates, respectively. BL agents tested alone had limited activity against this challenge set of isolates ContraFect Corporation (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support) Yahse Edah, AS, Qpex (Research Grant or Support) Olga Lomovskaya, PhD, Qpex Biopharma (Employee) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support"}
+{"text": "Enterobacterales (ENT)\u2014especially Escherichia coli (EC), Klebsiella pneumoniae (KPN), and Proteus mirabilis (PM)\u2014are widely implicated in urinary tract infections (UTIs). Many oral agents are used to manage UTIs, but their usefulness has been compromised by the increased prevalence of extended-spectrum \u03b2-lactamases (ESBL) and presence of co-resistance to trimethoprim-sulfamethoxazole (TMP/SMX) and quinolones. Tebipenem (TBP) is an oral carbapenem in clinical development for treating complicated UTIs and acute pyelonephritis. This study assessed the in vitro activity of TBP and comparator agents against ENT responsible for UTIs in the US during 2019-2020. A total of 3,576 ENT recovered from urine samples during the 2019-2020 STEWARD Surveillance Program were included in the study. Isolates were collected from medical centers in all 9 US Census Regions and were centrally tested for susceptibility by reference broth microdilution method. MIC interpretation was performed based on CLSI criteria. 90, 0.015-0.06 mg/L) and ertapenem  showed similar MIC90 results against ENT, EC, and KPN (Table). Ceftazidime  had elevated MIC90 values and suboptimal susceptibility results (86.1-89.3%) against ENT, EC, and KPN. The oral agents, cefuroxime, amoxicillin-clavulanate, TMP-SMX, and levofloxacin showed susceptibility rates ranging from 63.1% to 87.1% against ENT, EC, and KPN. TBP  inhibited all PM at \u22640.25 mg/L. PM isolates were susceptible to ERT (100.0%), CAZ (98.7%), cefuroxime (94.4%), and amoxicillin/clavulanate (96.6%), whereas susceptibility rates of 71.8-76.8% were noted for TMP-SMX and levofloxacin.EC comprised 65.6% of all ENT pathogens, followed by KPN (14.3%), PM (6.6%), and other species (13.7%). TBP AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Ian A. Critchley, Ph.D., Spero Therapeutics  Nicole Cotroneo, Spero Therapeutics  Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support"}
+{"text": "TP53, encoding the tumor suppressor and transcription factor p53, is the most frequently mutated gene in human cancers  at the Shanghai Synchrotron Radiation Facility (SSRF). M.L. was funded by the National Key R&D Program of China (2017YFA0506200), the National Natural Science Foundation of China , the Gaofeng Clinical Medicine Grant (828318), the Shanghai Excellent Youth Academic Leader (20XD1422700), the Shanghai Medical and Health Excellent Discipline Leader Development Plan (2018BR36), the Shanghai Collaborative Innovation Center for Translational Medicine (TM201902), the Foundation of the National Facility for Translational Medicine (Shanghai) (TMSK-2020-003), and the Newton Advanced Fellowship (NAF\\R1\\180216). J.-L.W., S.C., and M.L. wrote the manuscript.]"}
+{"text": "Scientific Reports 10.1038/s41598-021-97109-6, published online 04 October 2021Correction to: The original version of this Article contained an error in the Acknowledgments section.Astragalus membranaceus\u00a0(2017-2020) and SRTP Project of Gansu Agricultural University .\u201d\u201cThis work was supported by National Administration of Traditional Chinese Medicine (ZYBZH-Y-GS-11); Science and Technology Department of Gansu Province Support Project (1204FKCA123); Gansu Provincial Department of Agriculture and Rural Areas Foundation to Prof. Yuan Chen for a Chief Expert of Traditional Chinese Medicinal Industry in Modern Agricultural Industry System (GARS-ZYC-1) and once again to Prof. Yuan Chen for Special Advantage Agricultural Products in Gansu Province -Evaluation of Longxi Huangqi (TYNPZ2020-18),\u00a0Gansu Zhongtian Pharmaceutical Co., Ltd on the GAP Base Construction of\u00a0now reads:Astragalus membranaceus (2017-2020) and SRTP Project of Gansu Agricultural University .\u201d\u201cThis work was supported by Gansu Provincial Department of Agriculture and Rural Areas Foundation to Prof. Yuan Chen for Evaluation of Gansu Provincial Special Advantage Agricultural Product- Longxi Huangqi (TYNPZ2020-18) and Foundation for a Chief Expert of Traditional Chinese Medicinal Industry in Modern Agricultural Industry System (GARS-ZYC-1); National Administration of Traditional Chinese Medicine (ZYBZH-Y-GS-11); Science and Technology Department of Gansu Province Support Project (1204FKCA123); Gansu Zhongtian Pharmaceutical Co., Ltd on the GAP Base Construction of The original Article has been corrected."}
+{"text": "Correction to: BMC Cancer 21, 1329 (2021)https://doi.org/10.1186/s12885-021-09049-zFollowing publication of the original article , the autThis research was supported by the Pre-research Grant for National Natural Science Foundation of China from North Sichuan Medical College (CBY19-YZ08 to Y. Liu), Clinical and Basic Research Overlapping Fusion Foundation of China from Affiliated Hospital of North Sichuan Medical College (2021LC010 to Y. Liu)."}
+{"text": "The correct title is: Fusion algorithm of visible and infrared image based on anisotropic diffusion and image enhancement. The correct citation is: Huang H, Dong L, Xue Z, Liu X, Hua C (2021) Fusion algorithm of visible and infrared image based on anisotropic diffusion and image enhancement. PLoS ONE 16(2): e0245563. The publisher apologizes for the error."}
+{"text": "Scientific Reports 10.1038/s41598-021-85917-9, published online 18 March 2021Correction to: The original version of this Article omitted the Acknowledgements and Funding section. The Acknowledgements section now reads:\u201cThe authors thank Dr. Samer Kharroubi from American University of Beirut for statistical guidance and Dr. Charbel Khalil from Reviva Regenerative Medicine Center, Lebanon, for the kind gift of AD-MSCs.\u201dThe Funding section now reads:\u201cThis study was funded by Beirut Arab University (BAU) and the Lebanese National Council for Scientific Research (CNRS-L).\u201dThe original Article has been corrected."}
+{"text": "Escherichia coli possess virulence genes, adaptability for human colonization and are often associated to resistance genes. We evaluated the prevalence, O-antigen and susceptibility profiles of ST131 among \u03b2-lactam resistant E. coli isolates collected in US hospitals.ST131 E. coli isolates collected during 2017 and 2018 were susceptibility tested using reference broth microdilution method. Among these, 1,154 displayed MIC values >1 mg/L against 2 of the following: ceftazidime, ceftriaxone, cefepime or aztreonam or resistance to imipenem or meropenem (CLSI breakpoints) and were submitted to whole genome sequencing (WGS) and data analysis (MLST and O antigen). The genes wzx, wzy, wzm, and wzt were used to identify the O-antigen. Reference guided assembly for gene cluster O-AGC was used to differentiate O25a and O25b.A total of 6,768 E. coli isolates, 627 (54.3%) belonged to ST131 or were single loci variants . A total of 586 (93.5% of ST131 and 50.8% of sequenced isolates) belonged to the O25b serotype. The remaining 41 isolates belonged to serotypes O16 (40 isolates) or O153var1 (1). ST131 isolates and O25b isolates were considerably more resistant to fluoroquinolones  when compared to the overall WGS isolate collection (75.6%-77.0%). ST131-O25b isolates were more resistant to 12 /16 antimicrobial agents analyzed, including all \u03b2-lactam agents (0.9%-12.7% more resistant), fluoroquinolones (34.5-41.0%), and aminoglycosides (1.2-37.3%). ST131 (49.0%) and ST131-O25b (51.5%) isolates had higher multi-drug resistant (MDR) rates compared to all E. coli isolates (7.3%), WGS isolates (41.4%), and isolates that did not carry these traits (32.4% for non-ST131 and 12.2% for non-O25b).Among the WGS E. coli isolates were common among \u03b2-lactam resistant E. coli from US hospitals. These isolates were significantly more resistant than their counterparts, despite the elevated resistance rates of the overall WGS collection. ST131-O25b E. coli isolates have the potential to present a challenge for antimicrobial treatment. Specific therapies that are effective against these isolates should be investigated.ST131 and ST131-O25b Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Timothy B. Doyle, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Andrew P. Davis, BS, Bravos Biosciences (Research Grant or Support) Valerie Kantro, BS, Bravos Biosciences (Research Grant or Support) Christopher M. Rubino, Pharm.D., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Research Grant or Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Sujata M. Bhavnani, Pharm.D., M.S., FIDSA, 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Paul G. Ambrose, Pharm.D., FIDSA, 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Research Grant or Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support)"}
+{"text": "Scientific Reports 10.1038/s41598-021-02707-z, published online 06 December 2021Correction to: The original version of this Article contained an error in the Funding section. Furthermore, the Acknowledgements section was a duplicate of the Funding section. The duplicate has been removed in the original Article.The Funding section\u201cFunding was funded by National Natural Science Foundation of China , Research Program Sponsored by State Key Laboratory of Aridland Crop Science , GSCS-2020-06, China Agriculture Research System of MOF and MARA, CARS-12, Research Program Sponsored by State Key Laboratory of Aridland Crop Science, Gansu Agricultural University, No. GSCS-2020-Z1.\u201dnow reads:\u201cFunding was financially supported Research Program Sponsored by State Key Laboratory of Aridland Crop Science, Gansu Agricultural University (No. GSCS-2020-Z1); by the China Agriculture Research System of MOF and MARA (CARS-12); by the National Natural Science Foundation of China (NO. 31960435); by the Research Program Sponsored by State Key Laboratory of Aridland Crop Science  (GSCS-2020-06) and the National Natural Science Foundation of China (NO. 31860388).\u201dThe original Article has been corrected."}
+{"text": "Microsystems & NanoengineeringCorrection to: 10.1038/s41378-021-00314-6 published online 19 October 20211, it is reported the Acknowledgement section need to be updated as below:Following publication of this articleThis work is partly supported by the EPSRC through an Engineering Fellowship (EP/R029644/1) and Programme Grant-Heteroprint (EP/R03480X/1) and North West Centre for Advanced Manufacturing project funded by the European Union\u2019s INTERREG programme (H2020-Intereg-IVA5055), managed by the Special EU Programmes Body. The views and opinions in this document do not necessarily reflect those of the European Commission or the SEUPB.The original article has been updated."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-021-98593-6, published online 27 September 2021Correction to: The original version of this Article contained an error in the Acknowledgments section.\u201cThis research was part of solar PV system project that received funding from the Middle Technical University for Research and Innovation Program 2020, Iraq.\u201dnow reads:\u201cThis work was supported in part by the Robotics and Internet of Things Laboratory, Prince Sultan University, Riyadh, Saudi Arabia.\"The original Article has been corrected."}
+{"text": "S. pneumoniae (SPN), including multidrug-resistant (MDR) strains. CPT fosamil is approved for clinical use in the United States (US) to treat community-acquired bacterial pneumonia (CABP). We evaluated the activity of CPT against clinical isolates of ceftriaxone-non-susceptible (CRO-NS) SPN from US medical centers. Ceftaroline (CPT) is a broad-spectrum cephalosporin with activity against 21,750 SPN isolates were consecutively collected (1 per patient) from 201 medical centers in 2008-2020 and tested for susceptibility (S) to CPT and comparator agents using CLSI broth microdilution methods. Among these isolates, 1,419 (6.5%) were CRO-NS (CRO MIC \u22652 mg/L). Other resistant subgroups analyzed included MDR  and extensively drug resistant  isolates.50/90, 0.25/0.25 mg/L); only 1 isolate had a CPT MIC \u22650.5 mg/L. The CPT-NS isolate exhibited CPT and CRO MIC values of 1 and 8 mg/L, respectively, and had multiple substitutions in the penicillin binding proteins (PBP), mainly PBP2x, when compared with reference sequences. Also, it showed 31 amino acid alterations in MurM. The most active comparator agents against CRO-NS SPN were linezolid , levofloxacin , tigecycline , and vancomycin . Overall, 20.5% of isolates were MDR and 7.9% were XDR. MDR and XDR rates decreased from 24.4% and 13.5% in 2008-2011 to 16.8% and 2.4% in 2018-2020, respectively. CPT retained potent activity against MDR  and XDR  isolates; whereas CRO exhibited limited activity against both MDR  and XDR  isolate subsets. Among CRO-NS isolates, 97.7% were MDR and 88.2% were XDR. CRO susceptibility varied from 86.9% in 2009 to 98.8% in 2019 and increased from 89.0% in the 2008-2011 period to 98.1% in the 2018-2020 period. CPT was active against 99.9% of CRO-NS SPN (MICCPT demonstrated potent and consistent activity over time (2008-2020) against a large collection of SPN from US medical centers, including CRO-NS, MDR, and XDR isolates. Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Cecilia G. Carvalhaes, MD, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support) S J Ryan Arends, PhD, AbbVie (formerly Allergan) (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)"}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-021-97735-0, published online 01 October 2021Correction to: The Funding section in the original version of this Article was incomplete.\u201cThis study was supported by the National Institute of Biomedical Imaging and Bioengineering grant R01 EB001659. This study was also partially supported by the National University of Singapore Start-up Grant R-608-000-172-133.\u201dnow reads:\u201cThis study was supported by the National Institute of Biomedical Imaging and Bioengineering grant R01 EB001659. This study was also partially supported by the National University of Singapore Start-up Grant R-608-000-172-133; and in part by the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413), Michael E. DeBakey VA Medical Center, Houston, TX; and the Gordon and Betty Moore Foundation.\u201dThe original Article has been corrected."}
+{"text": "FDA approval was extended in 2015 to treat patients with SSSI and CABP who developed bacteremia. Moreover, ceftaroline has also been used off-label to treat other infection types. We evaluated the S. aureus isolates were consecutively collected from 33 US medical centers in 2018-2020 and susceptibility tested by broth microdilution method against ceftaroline and comparators. Results were stratified by infection type and resistance profile. A total of 9,268 50/90, 0.25/1 mg/L) susceptibility (S) ranged from 98.5% (SSSI) to 95.4% . Ceftaroline retained potent activity and broad spectrum against methicillin-resistant S. aureus , with S rates varying from 96.3% (SSSI) to 89.2% . Overall S rate to erythromycin (ERY), levofloxacin (LEV), tetracycline (TET), and trimethoprim-sulfamethoxazole (TMP-SMX) were 44.0%, 67.9%, 94.1%, and 97.5%, respectively. Ceftaroline retained good activity against S. aureus resistant to ERY (94.8%S), LEV (91.4%S), TET (92.3%S), and/or TMP-SMX (98.7%S). Among the resistant subsets, ceftaroline S rates were generally highest among isolates from SSSI (93.1-100.0%), followed by other infections (81.8-100.0%), bloodstream infections , and pneumonia (86.6-98.1%); overall susceptibility was highest among TMP-SMX-R isolates (98.7%), followed by ERY-R (94.8%), MRSA (93.4%), TET-R (92.3%), and LEV-R (91.4%) isolates. Dalbavancin , teicoplanin , and vancomycin  exhibited complete activity (100.0%S), whereas daptomycin  and linezolid  were active against >99.9% of isolates.Ceftaroline  Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Leonard R. Duncan, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Shionogi (Research Grant or Support) Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)"}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-021-81759-7, published online 22 January 2021Correction to: In the original version of this Article, the Acknowledgements section was incomplete.\u201cThis work was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (NRF-2019R1A6A1A1105566012).\u201dnow reads:\u201cThis work was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (NRF-2019R1A6A1A1105566012). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2020R1C1C1003289). This work was supported by the Technology Innovation Program  funded By the Ministry of Trade, Industry & Energy .\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports 10.1038/s41598-021-94887-x, published online 28 July 2021Correction to: The Acknowledgements section in the original version of this Article was incomplete.\u201cYolanda Hartman, Sheila Bright, Catherine Langford, Sharon Samuel, Erika McMillian, Brian Wright, Lauren Radford, Charlotte Jeffers, Jennifer Bartels, Tolulope Aweda, Jonathan McConathy, Jinda Fan, Norio Yasui, Dattatray Devalankar, Himani Modi, Morgan Richardson, and staff of the University of Alabama Cyclotron Facility are gratefully acknowledged for their contributions and informative discussions. Funding was provided by the National Institutes of Health/National Institute of Neurological Disorders and Stroke T32 UAB Training Program in Brain Tumor Biology (T32 NS048039), the UAB Brain Tumor Core Facility (USPHS NCI P20CA151129), the National Center for Advancing Translational Research of the National Institutes of Health (UL1TR001417), the American Cancer Society (RSG-18-006-01-CCE), National Cancer Institute (R01CA24058) and the Comprehensive Cancer Center at UAB (NIH P30CA013148). JWL is supported by funding from the Department of Defense (W81XWH-18-1-0315) and National Institutes of Health (R01AI148711). JMW is supported by the Department of Defense (RCRP CA170769). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\u201dnow reads:\u201cYolanda Hartman, Sheila Bright, Catherine Langford, Sharon Samuel, Erika McMillian, Brian Wright, Lauren Radford, Charlotte Jeffers, Jennifer Bartels, Tolulope Aweda, Jonathan McConathy, Jinda Fan, Norio Yasui, Dattatray Devalankar, Himani Modi, Morgan Richardson, and staff of the University of Alabama Cyclotron Facility are gratefully acknowledged for their contributions and informative discussions. Funding was provided by the National Institutes of Health/National Institute of Neurological Disorders and Stroke T32 UAB Training Program in Brain Tumor Biology (T32 NS048039), the UAB Brain Tumor Core Facility (USPHS NCI P20CA151129), the National Center for Advancing Translational Research of the National Institutes of Health (UL1TR001417), the American Cancer Society (RSG-18-006-01-CCE), National Cancer Institute (R01CA24058). This was supported by the Preclinical Imaging Facility at the O\u2019Neal Comprehensive Cancer Center at UAB (NIH P30CA013148). JWL is supported by funding from the Department of Defense (W81XWH-18-1-0315) and National Institutes of Health (R01AI148711). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\u201dThe original Article has been corrected."}
+{"text": "E. cloacae species complex (ECL), S. marcescens (SM), C. freundii species complex (CF), and P. aeruginosa (PSA) are common pathogens in a variety of clinical infections. These organisms can overexpress the chromosomal AmpC that encodes resistance to several \u03b2-lactams. We evaluated the activity of ceftazidime-avibactam (CAZ-AVI) and comparators against these organisms.Enterobacterales [ENT] and \u226516 mg/L for PSA) and considered probable AmpC hyperproducers. Isolates were susceptibility tested by broth microdilution method. 17,650 isolates, including 4,400 ECL, 2,074 SM, 1,644 CF, and 9,532 PSA, were consecutively collected from 88 US medical centers in 2016-2020. Among these isolates, 3,127 were ceftazidime-nonsusceptible  and CAZ-AVI was more active than MEM  against these organisms. C-T  and PIP-TAZ  exhibited limited activity against CAZ-NS ENT. Among comparator agents, only amikacin (99.0%S), tigecycline (95.6%S), and imipenem (92.1%S) showed good activity against CAZ-NS ENT. Also, CAZ-AVI retained activity against 86.7% of ENT isolates that were NS to CAZ and MEM (n=113). CAZ-AVI  and C-T  were the most active compounds tested against PSA and both retained activity against CAZ-NS PSA. CAZ-AVI  and C-T  activity against CAZ-NS PSA was comparable to tobramycin . Susceptibility to CAZ ranged from 73.6% (ECL) to 97.5% . Overall, 99.8% of ENT (99.7-99.9%) and 97.1% of PSA were CAZ-AVI-S; whereas 84.3% (79.0-97.7%) of ENT and 97.4% of PSA were ceftolozane-tazobactam (C-T)-S, 83.0% (78.5-94.8%) of ENT and 80.0% of PSA were piperacillin-tazobactam (PIP-TAZ)-S, and 98.4% (98.3-98.7%) of ENT and 79.5% of PSA were meropenem (MEM)-S. CAZ-AVI retained potent activity and broad spectrum against CAZ-NS ENT  (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Cecilia G. Carvalhaes, MD, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support) Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support"}
+{"text": "S. aureus has been well established. We evaluated the in vitro activity of lefamulin against S. aureus from patients with cystic fibrosis (CF). Lefamulin is a first-in-class, oral and IV pleuromutilin antibiotic approved in the US, EU, and Canada for the treatment of community-acquired bacterial pneumonia (CABP) in adults. Lefamulin inhibits bacterial protein synthesis via a unique mechanism of action and its potency against n=224) were collected from the lower respiratory tract (LRT) of children (\u226417 years old) with CF and LRT infection. Organisms were from qualified respiratory specimens and determined to be the probable cause of infection by the participant center. The isolates were collected in 2018-2020 from 22 medical centers in 11 countries and tested by broth microdilution methods at JMI Laboratories. Most isolates were from the US (43.3%), Spain (24.1%), France (20.5%), and Costa Rica (7.1%). Unique isolates , with 99.6% of isolates inhibited at \u22640.25 mg/L, consistent with the susceptible [S] breakpoint published by the US FDA, CLSI, and EUCAST. Only 1 lefamulin-non-S  isolate was observed, a methicillin-susceptible (MSSA) collected in Costa Rica in 2018 and carrying a vga(A) gene. Lefamulin retained potent activity against methicillin-resistant (R) S. aureus , azithromycin-R , levofloxacin-R , clindamycin-R , and gentamicin-R  isolates as well as those isolates with multiple resistance phenotypes. Against MRSA, susceptibility to azithromycin was 23.5% and to levofloxacin 64.7%. All isolates were susceptible to vancomycin, linezolid and ceftaroline (Table). Among isolates from the US (n=97), the MRSA rate was 30.9% and all isolates were Lefamulin-S .Lefamulin was highly active against the CF in vitro antibacterial activity against S. aureus from children with CF, regardless of resistance phenotype. Lefamulin may represent a valuable treatment option for CF patients with S. aureus LRT infections. Lefamulin demonstrated potent Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Susanne Paukner, PhD, Nabriva Therapeutics GmbH (Employee) Steven P. Gelone, PharmD, Nabriva Therapeutics US, Inc. (Employee) S J Ryan Arends, PhD, AbbVie (formerly Allergan) (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)"}
+{"text": "E. coli causing UTI in U.S. patients and evaluated the in vitro activity of GEP and comparators against various drug resistance (R) subsets.Gepotidacin (GEP) is a novel bacterial type II topoisomerase inhibitor in Phase 3 clinical trials for the treatment of gonorrhea and uncomplicated urinary tract infections (UTI). This study characterized fluoroquinolone (FQ)-not susceptible (not S) E. coli collected from 38 U.S. sites were included as part of the GEP Global UTI Surveillance Program (2019). Isolates were tested for susceptibility by broth microdilution. E. coli with MICs \u22650.5 mg/L for ciprofloxacin (not S) and/or \u22651 mg/L for levofloxacin (not S) were selected for screening of FQ-R mechanisms, and subjected to genome sequencing, followed by screening of FQ-R genes and QRDR mutations in GyrA, GyrB, ParC and ParE.1,035 E. coli met the screening criteria for FQ-not S (Table). Overall, GEP had MIC90 values of 2 mg/L and 4 mg/L against FQ-S and FQ-not S isolates, respectively. Nitrofurantoin had activity against the FQ-S and FQ-not S subsets , whereas amoxicillin-clavulanate (86.5% and 59.6%S) and trimethoprim-sulfamethoxazole (75.8% and 37.0%S) had limited activity. Most FQ-not S isolates  had double mutations in GyrA and ParC, followed by those isolates  with double mutations in GyrA and single mutations in ParC and ParE. The third most common genotype was represented by isolates  with double mutations in GyrA and a single mutation in ParC. GEP had MIC50 values of 1 mg/L or 2 mg/L and MIC90 values of 2 mg/L or 4 mg/L when tested against isolates with various combinations of QRDR mutations. 4.3% (12/277) of FQ-not S E. coli carried qnrB (6) or qnrS (6), and GEP  had MICs of 0.5\u201332 mg/L against this subset.A total of 26.8%  E. coli causing UTI in the U.S. In addition, GEP MIC did not seem to be affected by any combinations of FQ-R genes and QRDR mutations tested, except against the rare presence of qnrB/S genes. These data support the clinical development of GEP as a treatment option for UTI caused by FQ-S and FQ-not S E. coli isolates.GEP demonstrated potent activity against FQ-S and FQ-not S TableRodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Timothy B. Doyle, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) S J Ryan Arends, PhD, AbbVie (formerly Allergan) (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Deborah Butler, n/a, GlaxoSmithKline, LLC (Employee) Nicole Scangarella-Oman, MS, GlaxoSmithKline, LLC (Employee) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support"}
+{"text": "Enterobacterales isolates. The use of these agents led to an increase of carbapenem resistance among Enterobacterales. Monitoring isolates that carry \u03b2-lactamases is important to understand their prevalence and susceptibility to clinically available antimicrobial agents. We evaluated the prevalence of \u03b2-lactamases and the activity of antimicrobial agents against 1,209 isolates collected in 69 US hospitals.Carbapenems are broadly used for the treatment of ESBL-producing Enterobacterales isolates collected during 2019 were susceptibility (S) tested by reference broth microdilution methods. Isolates submitted to whole genome sequencing were: (1) Escherichia coli (EC) and Klebsiella pneumoniae  displaying MIC values \u22652 mg/L for at least 2 of the following \u03b2-lactams: ceftazidime, ceftriaxone, aztreonam, or cefepime; (2) Enterobacter cloacae (ECL) and Citrobacter spp.  displaying MIC values \u226516 mg/L for ceftazidime and/or \u22652 mg/L for cefepime; and (3) Enterobacterales (n=118) displaying elevated carbapenem (meropenem and/or imipenem) MIC results at >1 mg/L.A total of 9,686 blaCTX-M-15 (n=516), followed by blaCTX-M-14 (n=153). Most of these isolates were EC (278/147 for blaCTX-M-15/blaCTX-M-14), but 220 KPN harbored blaCTX-M-15. A total of 302 EC and KPN isolates carried blaOXA-1. Among ECL and CIT, blaCTX-M-15 and SHV genes encoding ESBLs were noted among 18 and 18 isolates. Carbapenemase genes were noted among 77 isolates, including 65 blaKPC, 3 blaSME, 6 blaOXA-48-like, and 3 blaNDM. Ceftazidime-avibactam (CAZ-AVI) was the only agent active against all ESBL-producers that did not carry carbapenemases (Table). CAZ-AVI was active against 90.9% of the isolates producing carbapenemases. Isolates resistant to this combination included 3 NDM-producers and 1 isolate harboring blaKPC-31.A total of 723 isolates harbored ESBL genes but did not carry carbapenemases. The most common ESBL gene was Enterobacterales isolates carrying ESBLs, mainly blaCTX-M-15, were very prevalent in this collection of US isolates. CAZ-AVI was very active against isolates tested, including isolates producing carbapenemases that displayed resistance to many comparator agents.Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Lalitagauri M. Deshpande, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Pfizer, Inc. (Research Grant or Support) Timothy B. Doyle, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)"}
+{"text": "Scientific Reports 10.1038/s41598-021-93017-x, published on 2 July 2021Correction to: The original version of this Article contained an error in Affiliation 1, which was incorrectly given as \u2018Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology (GAIHST), Gachon University, Seongnam-si 13120, South Korea\u2019. The correct affiliation is listed below.Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon 21999, Korea.Additionally, this Article contained an error in the Acknowledgments section.\"This work was supported by Institute of Information & Communications Technology Planning & Evaluation (IITP) Grant funded by the Korea Government (MSIT) , and the GRRC program of Gyeonggi province. , and the Gachon Program (GCU-202008440010).\"now reads:\"This work was supported by Institute of Information & Communications Technology Planning & Evaluation (IITP) Grant funded by the Korea Government (MSIT) , and the GRRC program of Gyeonggi province. [GRRC-Gachon2020(B01)], AI-based Medical Image Analysis], and the Gachon Program (GCU-202106290001).\"The original Article has been corrected."}
+{"text": "Streptococcus pneumoniae (SPN), Haemophilus influenzae (HI), Haemophilus parainfluenzae (HP), methicillin-susceptible Staphylococcus aureus (MSSA), Escherichia coli (EC), Klebsiella pneumoniae (KPN), Pseudomonas aeruginosa (PSA), Chlamydia pneumoniae, Mycoplasma pneumoniae and L. pneumophila. In this study, the in vitro susceptibilities of DLX and comparator quinolones were determined for clinical isolates from CAP and CA-lower respiratory tract infections (LRTIs).Delafloxacin (DLX) is a broad-spectrum fluoroquinolone antibacterial approved in the US for the treatment of community-acquired bacterial pneumonia (CABP). DLX is indicated to treat CABP caused by CAP and CA-LRTI isolates were consecutively collected at 67 US medical centers participating in the SENTRY Surveillance Program during 2014-2020. Sites submitted 1 isolate per patient per infection episode. Isolate identification was determined at each site and confirmed using standard biochemical or molecular methods at JMI Laboratories. Susceptibility testing was performed according to CLSI broth microdilution methodology. CLSI (2021) interpretive criteria were applied, FDA criteria were used for DLX. The susceptibility results for DLX, levofloxacin (LEV), moxifloxacin (MOX), and ciprofloxacin (CIP) for the indicated species are shown in the table. As MOX does not have CLSI breakpoints for EC, KPN, or PSA, CIP was tested for those species instead. DLX had the highest percent susceptibility against MSSA (91.8%). SPN and HI were >97% susceptible, and HP was >91% for all 3 drugs. KPN susceptibility ranged from 86.4% for LEV to 76.9% for DLX. Susceptibilities for EC and PSA were similar for the 3 drugs, EC varied from 59.8% for LEV to 57.0% for DLX, and PSA varied from 71.6% for CIP to 64.0% to LEV. in vitro results suggest that DLX may be a useful therapeutic option for CABP caused by Gram-positive, Gram-negative and fastidious pathogens.DLX had good activity against recent CAP and CA-LRTI isolates from US hospitals. DLX had the highest susceptibility of the quinolones tested against MSSA. Quinolone-resistant SPN and HI were uncommon. These Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Michael D. Huband, BS, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support"}
+{"text": "Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral prodrug that is converted to tebipenem (TBP), the active moiety. TBP is a carbapenem with activity against multidrug-resistant Gram-negative pathogens, including extended-spectrum-\u03b2-lactamase-producing Enterobacterales and is being developed for treating complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). Data from three Phase 1 studies and one Phase 3 study in patients with cUTI/AP were used to develop a population pharmacokinetic (PPK) model for TBP and identify covariates that described the variability in TBP pharmacokinetics (PK).The PPK model was developed using TBP plasma and urine concentration-time data from the above-described Phase 1 and 3 studies. TBPPI-HBr doses, which ranged from 100 to 900 mg, were administered as single or multiple doses every 8 hours. After development of the structural model, stepwise forward and backward selection procedures were used to identify significant covariate relationships. The robustness of the final PPK model was assessed using a prediction-corrected visual predictive check (PC-VPC).The final dataset included 3448 plasma concentrations from 99 Phase 1 subjects and 647 Phase 3 patients and urine concentrations from 128 Phase 1 subjects. A two-compartment model with linear, first-order elimination and transit compartments to describe the rate of drug absorption after oral administration of TBP-PI-HBr best described TBP PK. The most clinically significant covariate effect, which would warrant dose adjustment, was the relationship between apparent oral clearance and creatinine clearance. In contrast, age, body size, sex, and fed status each had a minimal impact on TBP exposure. The PC-VPC showed good agreement between median simulated plasma concentrations based on the final PPK model and the median observed plasma concentrations for the pooled dataset .Figure 1. Prediction-corrected visual predictive check plot for the final population PK model using the pooled analysis datasetA robust description of TBP plasma PK in subjects and patients with cUTI/AP was achieved, such that derived measures of TBP plasma exposure are expected to be both accurate and precise. The population PK model was considered appropriate for model-based simulations and the assessment of PK-PD relationships for TBP.Harish Ganesan, M.S., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Vipul Kumar, PhD, Spero Therapeutics  Sujata M. Bhavnani, Pharm.D., M.S., FIDSA, 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) David Melnick, MD, Spero Therapeutics  Christopher M. Rubino, Pharm.D., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Research Grant or Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support)"}
+{"text": "The authors regret that there was an error in the calculation of the PF-10 score used in analysis. The affected the data presented in Tables 2 and 4, which have been updated below.The authors would like to apologise for any inconvenience caused.Table 2 Linear regression association of HRQOL measured using the PF-10 and HAQ-DI with gout and co-morbid characteristicsTable 4 Linear regression association of HRQOL measured using the PF-10 and HAQ-DI with sociodemographic characteristics.Abbreviations: CI: Confidence Interval; TIA: Transient Ischaemic Attack; MI: Myocardial Infarction; BMI: Body Mass Index; PF-10: Physical Function 10; HAQ-DI: Health Assessment Questionnaire Disability Index; CI: Confidence Interval.aAdjusted for comorbid and socio-demographic characteristics; b Adjusted for gout and socio-demographic characteristics; c Adjusted for gout and comorbid characteristics."}
+{"text": "FFC-AL-EIT was implemented by a Research Nurse Facilitator working with a community champion and stakeholder team for 12 months to increase function and physical activity among residents. FFC-AL-EIT included four steps: (Step I) Environment and Policy Assessments; (Step II) Education; (Step III) Establishing Resident Function Focused Care Service Plans; and (Step IV) Mentoring and Motivating. A total of 85 communities and 794 residents were included. The age of participants was 89.48 (SD=7.43), the majority was female  and white . Resident measures, obtained at baseline, four and 12 months, included function, physical activity, and performance of function focused care. Setting outcomes, obtained at baseline and 12 months, included environment and policy assessments and service plans. Effectiveness was based on less decline in function (p<.001), more function focused care (p=.012) and better environment (p=.032) and policy (p=.003) support for function focused care in treatment sites."}
+{"text": "Scientific Reportshttps://doi.org/10.1038/s41598-021-00144-6, published online 19 October 2021Correction to: The Funding section in the original version of this Article was omitted. The Funding section now reads:\u201cThe following authors are supported by grants from the British Heart Foundation (BHF): YL & KR (grant number: FS/PhD/21/29110) and KR & DC (grant number: PG/18/65/33872); KR is also in receipt of funding from the UKRI\u2019s Global Challenges Research Fund (GCRF), Grant Ref ES/P0110551/1, Oxford NIHR Biomedical Research Centre and the Oxford Martin School (OMS), University of Oxford. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the OMS, the BHF, the GCRF, the NIHR or the Department of Health and Social Care.\u201dThe original Article has been corrected."}
+{"text": "The correct citation is: Hao S, Snyder RA, Irish W, Parikh AA (2021) Association of race and health insurance in treatment disparities of colon cancer: A retrospective analysis utilizing a national hospital-based database in the United States. PLoS Med 18(10): e1003842."}
+{"text": "Following the publication of the original article , errors bold typeface.The changes have been highlighted in Reference26642: 2010(E).[20] Food Products-Determination of the glycaemic index (GI) and recommendation for food classification. ISO"}
+{"text": "In the original article, we neglected to include the grant number for the funder Fundamental Research Funds for the Central Universities. The grant number is SWU020014 to Hongyan Xu. The corrected funding statement appears below.FUNDING\u201cThis research work was supported by grants from the National Natural Science Foundation of China (31873035), the Fundamental Research Funds for the Central Universities (SWU020014 to HX) (2021), Science and Technology Program of Guangzhou (201904010172), Social Public Welfare Research (2019HY-XKQ02), Open Project of State Key Laboratory of Freshwater Ecology and Biotechnology (2019FB01), Central Public-interest Scientific Institution Basal Research Fund, CAFS , Guangdong Agricultural Research System, Grant/Award Number (2019KJ150), China-ASEAN Maritime Cooperation Fund (CAMC-2018F), International Agricultural Exchange and Cooperation (2130114), Science and Technology Program of Guangdong Provincial, Grant/Award Number (2019B030316029), and National Freshwater Genetic Resource Center (NFGR-2020).\u201d2, Yulin Li2, Xinping Zhu1,\u201d it should be \u201cXiaoli Liu1,2, Wei Li2, Yanping Yang2, Kaili Chen1, Yulin Li1, Xinping Zhu2, Hua Ye1 and Hongyan Xu1,2.\u201dIn the published article, there was an error in affiliations for authors Kaili Chen, Yulin Li, and Xinping Zhu. Instead of \u201cKaili ChenThe authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated."}
+{"text": "Enterobacter spp. are part of the ESKAPE pathogens that have been recognized as a threat to human health. Among this genus, E. cloacae species complex (ECL) is the most common species that causes human infections. ECL can develop resistance to \u00df-lactams and other antimicrobial classes due to alterations in gene regulatory pathways. We evaluated the activity of meropenem-vaborbactam, ceftazidime-avibactam, and comparator agents against 235 multidrug resistant (MDR) ECL isolates collected in Europe and the US during 2017-2019.A total of 2,459 ECL clinical isolates were collected in 40 European and 33 US hospitals. Isolates were susceptibility tested by reference broth microdilution methods and results were interpreted using CLSI, EUCAST, and US FDA breakpoints. MDR was defined as resistant to 3 or more drug classes when applying the CLSI breakpoints.MDR ECL were observed among 9.6% of the overall isolates. The MDR rate in Europe  was considerably higher than in the US . Meropenem-vaborbactam inhibited 94.5% and 97.4% of the MDR ECL isolates applying CLSI and EUCAST breakpoints, respectively (Table). Meropenem inhibited 77.9%/85.5% of the isolates (CLSI/EUCAST breakpoints). Cefepime inhibited only 26.0%/16.2% of the MDR ECL isolates while piperacillin-tazobactam inhibited only 13.2%/6.4%. Ceftazidime-avibactam inhibited 93.6% of the MDR ECL isolates. Amikacin and tigecycline were the most active non-beta-lactam comparators, inhibiting 91.9% and 80.0% of these isolates using CLSI/US FDA breakpoints. A total of 93.1% of the isolates were intermediate to colistin applying CLSI breakpoints or susceptible using the EUCAST criteria. Meropenem-vaborbactam inhibited 73.5% and 87.8% of the MDR ECL isolates nonsusceptible to meropenem and cefepime, the main therapeutic option against ECL isolates. Ceftazidime-avibactam inhibited 73.5% of these isolates.Enterobacterales species/species complex displaying MDR and carbapenem-resistance phenotypes, behind only Klebsiella pneumoniae. Meropenem-vaborbactam and ceftazidime-avibactam can be important options to treat infections caused by MDR ECL.In a global surveillance, ECL is the second most common Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)"}
+{"text": "Correction to: BMC Geriatr 21, 105 (2021)https://doi.org/10.1186/s12877-020-01976-zhttps://me-we.eu/the-project/), as follows:Funding: \u201cThe study was conducted in the framework of the ME-WE project, which has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 754702. This work was also partially supported by Ricerca Corrente funding from Italian Ministry of Health to IRCCS INRCA. This funding body did not play any role in designing the study nor in data collection, analysis and interpretation, nor in writing this paper\u201d.www.me-we.eu), namely: Linnaeus University (Sweden), coordinator; Eurocarers (Belgium); University of Sussex (United Kingdom); Carers Trust (United Kingdom); Kalaidos University of Applied Sciences (Switzerland); Netherlands Institute for Social Research (Netherlands); Vilans (Netherlands); National Institute of Health and Science on Ageing (IRCCS INRCA) ; Anziani e Non Solo ; University of Ljubljana (Slovenia).\u201dAcknowledgements: \u201cThe authors would like to thank researchers, professionals and organisations who contributed to the ME-WE project. In particular, the authors thank the partner organisations of the ME-WE project (After publication of this article , the autThe original article  has been"}
+{"text": "Scientific Reports 10.1038/s41598-021-85489-8, published online 15 March 2021Correction to: The Acknowledgements section in the original version of this Article was incomplete.\u201cThis study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (2018R1D1A1B07044100) and the Institute of Information & Communications, Technology Planning & Evaluation (IITP) grant funded by the Korean government (2017-0-00855).\u201dnow reads:\u201cThis study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (2018R1D1A1B07044100) and the Institute of Information & Communications, Technology Planning & Evaluation (IITP) grant funded by the Korean government (2017-0-00855). This work was supported by the Research Grant of Kwangwoon University in 2020.\"The original Article has been corrected."}
+{"text": "Nature Communications 10.1038/s41467-020-16741-4, published online 05 June 2020.Correction to: In the original version of the published article, several funding sources were omitted from the \u201cAcknowledgements\u201d section. The correct acknowledgement paragraph is:This work is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P30 GM124165). The Eiger 16M detector on 24-ID-E is funded by an NIH-ORIP HEI grant (S10OD021527). This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. We would also like to thank Dr. Laura Murray for help in cloning and crystallizing the G and U mutants, Gabriele Drews for technical assistance, and Dr. Olga Fedorova for the critical reading of the manuscript. We also thank all members of the Marcia, Pyle, and De Vivo labs for helpful discussion. Work in the Marcia lab is partly funded by the Agence Nationale de la Recherche (ANR-15-CE11-0003-01), by the Agence Nationale de Recherche sur le Sida et les h\u00e9patites virales (ANRS) (ECTZ18552), by ITMO Cancer (18CN047-00), and by the Fondation ARC pour la recherche sur le cancer (PJA20191209284). The Marcia lab uses the platforms of the Grenoble Instruct Center (ISBG: UMS 3518 CNRS-CEA-UJF-EMBL) with support from FRISBI (ANR-10-INSB-05-02) and GRAL (ANR-10-LABX-49-01) within the Grenoble Partnership for Structural Biology (PSB). M.D.V. thanks the Italian Association for Cancer Research (AIRC) for financial support (IG 23679). A.M.P. is a Howard Hughes Medical Institute investigator.This has now been corrected in both the PDF and HTML versions of the Article."}
+{"text": "Scientific Reports 10.1038/s41598-020-78814-0, published online 13 January 2021Correction to: The Acknowledgements section in this Article is incomplete.\"National Science Foundation of China (NSFC) (11604079); Science and Technology Program of Henan Province (192102210198); China Postdoctoral Science Foundation funded project (2018M632793); Foundation for University Young Key Teacher Program by Henan Province, China (2017GGJS155); Doctoral Fund Project of Henan Institute of Engineering (D2017023); the Key Scientific Research Projects of Institutions of Higher Learning in Henan Province (20A140006).\"should read:\"National Science Foundation of China (NSFC) (11604079); Science and Technology Program of Henan Province (192102210198 and 212102310903); China Postdoctoral Science Foundation funded project (2018M632793); Foundation for University Young Key Teacher Program by Henan Province, China (2017GGJS155); Doctoral Fund Project of Henan Institute of Engineering (D2017023); the Key Scientific Research Projects of Institutions of Higher Learning in Henan Province (20A140006).\""}
+{"text": "Scientific Reports 10.1038/s41598-021-02404-x, published online 30 November 2021Correction to: The Acknowledgements section in the original version of this Article was incomplete.\u201cThis work was supported by Open Research Fund of Key Laboratory of Healthy Freshwater Aquaculture, Ministry of Agriculture and Rural Affairs (ZJK202101), Central Public-interest Scientific Institution Basal Research Fund, .\u201dnow reads:\u201cThis work was supported by Open Research Fund of Key Laboratory of Healthy Freshwater Aquaculture, Ministry of Agriculture and Rural Affairs (ZJK202101), Central Public-interest Scientific Institution Basal Research Fund,  and National Key Research and Development Program of China (No. 2017YFC1600704).\"The original Article has been corrected."}
+{"text": "Enterobacterales (CNSE) produce carbapenemases, but some isolates do not carry these enzymes. Ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MBV), and imipenem-relebactam (IMR) have activity against CNSE isolates producing serine-carbapenemases, but these agents might have variable activity against isolates that do not produce these enzymes. We evaluated the activity of these agents against a collection of 170 carbapenemase-negative CNSE collected during 5 years in US hospitals.Most carbapenem-nonsusceptible Enterobacterales isolates  collected in US hospitals from 2016-2020 were susceptibility (S) tested by reference broth microdilution methods. Results were interpreted using CLSI 2020 breakpoints. CNSE displayed nonsusceptible (NS) MICs for imipenem or meropenem. CNSE isolates were screened for carbapenemase genes using whole genome sequencing.K. aerogenes (n=42), K. pneumoniae (32), and E. cloacae (32), but 13 other species also were carbapenemase negative. CAZ-AVI inhibited all carbapenemase-negative CNSE isolates . MBV and IMR inhibited 97.6% and 92.3% of the isolates. Amikacin (AMK) and tigecycline (TIG) inhibited 97.1% and 93.5%, while levofloxacin and meropenem (MEM) inhibited 63.5% and 64.7%. A total of 141 (82.9%) isolates were nonsusceptible (NS) to imipenem. When MEM NS isolates (n=60) were analysed separately, the S rates were lower for all agents except CAZ-AVI. CAZ-AVI inhibited all MEM NS carbapenemase-negative CNSE isolates. MBV and IMR inhibited 93.1% and 89.7% of these isolates, respectively. AMK and TIG inhibited 93.3% and 88.3%, respectively. Only 8.3% of the isolates were resistant to colistin.Among 685 (1.4% of the isolates) CNSE, 170 (24.8% of the CNSE) isolates did not produce carbapenemases. Most of these isolates were CAZ-AVI displayed good activity against carbapenemase-negative CNSE isolates, including all MEM NS that displayed greater resistance rates against all comparator agents. High-risk patients with infections caused by CNSE have an increased mortality rate compared to isolates susceptible to these agents. Implementation of appropriate therapy for these isolates is critical.Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors  Involved: Self): Research Grant or Support; Allergan  Involved: Self): Research Grant or Support; Amicrobe, Inc  Involved: Self): Research Grant or Support; Amplyx Pharma  Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc.  Involved: Self): Research Grant or Support; Astellas  Involved: Self): Research Grant or Support; Basilea  Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center  Involved: Self): Research Grant or Support; BIDMC  Involved: Self): Research Grant or Support; bioMerieux Inc.  Involved: Self): Research Grant or Support; BioVersys Ag  Involved: Self): Research Grant or Support; Bugworks  Involved: Self): Research Grant or Support; Cidara  Involved: Self): Research Grant or Support; Cipla  Involved: Self): Research Grant or Support; Contrafect  Involved: Self): Research Grant or Support; Cormedix  Involved: Self): Research Grant or Support; Crestone, Inc.  Involved: Self): Research Grant or Support; Curza  Involved: Self): Research Grant or Support; CXC7  Involved: Self): Research Grant or Support; Entasis  Involved: Self): Research Grant or Support; Fedora Pharmaceutical  Involved: Self): Research Grant or Support; Fimbrion Therapeutics  Involved: Self): Research Grant or Support; Fox Chase  Involved: Self): Research Grant or Support; GlaxoSmithKline  Involved: Self): Research Grant or Support; Guardian Therapeutics  Involved: Self): Research Grant or Support; Hardy Diagnostics  Involved: Self): Research Grant or Support; IHMA  Involved: Self): Research Grant or Support; Janssen Research & Development  Involved: Self): Research Grant or Support; Johnson & Johnson  Involved: Self): Research Grant or Support; Kaleido Biosceinces  Involved: Self): Research Grant or Support; KBP Biosciences  Involved: Self): Research Grant or Support; Luminex  Involved: Self): Research Grant or Support; Matrivax  Involved: Self): Research Grant or Support; Mayo Clinic  Involved: Self): Research Grant or Support; Medpace  Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd.  Involved: Self): Research Grant or Support; Melinta  Involved: Self): Research Grant or Support; Menarini  Involved: Self): Research Grant or Support; Merck  Involved: Self): Research Grant or Support; Meridian Bioscience Inc.  Involved: Self): Research Grant or Support; Micromyx  Involved: Self): Research Grant or Support; MicuRx  Involved: Self): Research Grant or Support; N8 Medical  Involved: Self): Research Grant or Support; Nabriva  Involved: Self): Research Grant or Support; National Institutes of Health  Involved: Self): Research Grant or Support; National University of Singapore  Involved: Self): Research Grant or Support; North Bristol NHS Trust  Involved: Self): Research Grant or Support; Novome Biotechnologies  Involved: Self): Research Grant or Support; Paratek  Involved: Self): Research Grant or Support; Pfizer  Involved: Self): Research Grant or Support; Prokaryotics Inc.  Involved: Self): Research Grant or Support; QPEX Biopharma  Involved: Self): Research Grant or Support; Rhode Island Hospital  Involved: Self): Research Grant or Support; RIHML  Involved: Self): Research Grant or Support; Roche  Involved: Self): Research Grant or Support; Roivant  Involved: Self): Research Grant or Support; Salvat  Involved: Self): Research Grant or Support; Scynexis  Involved: Self): Research Grant or Support; SeLux Diagnostics  Involved: Self): Research Grant or Support; Shionogi  Involved: Self): Research Grant or Support; Specific Diagnostics  Involved: Self): Research Grant or Support; Spero  Involved: Self): Research Grant or Support; SuperTrans Medical LT  Involved: Self): Research Grant or Support; T2 Biosystems  Involved: Self): Research Grant or Support; The University of Queensland  Involved: Self): Research Grant or Support; Thermo Fisher Scientific  Involved: Self): Research Grant or Support; Tufts Medical Center  Involved: Self): Research Grant or Support; Universite de Sherbrooke  Involved: Self): Research Grant or Support; University of Iowa  Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics  Involved: Self): Research Grant or Support; University of Wisconsin  Involved: Self): Research Grant or Support; UNT System College of Pharmacy  Involved: Self): Research Grant or Support; URMC  Involved: Self): Research Grant or Support; UT Southwestern  Involved: Self): Research Grant or Support; VenatoRx  Involved: Self): Research Grant or Support; Viosera Therapeutics  Involved: Self): Research Grant or Support; Wayne State University  Involved: Self): Research Grant or Support Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)"}
+{"text": "Volume 5 of Learning Health Systems. An open access publication, the journal has advanced research and scholarship on learning health systems in partnership with our reviewers. With indexing in multiple major sources, we believe the journal is now on a sustainable, positive trajectory.The publication of Issue 4 marks the completion of The journal has also published five Special Issues: \u201cPatient Empowerment and the Learning Health System\u201d (v.1); \u201cEthical, Legal, and Social Implications of Learning Health Systems\u201d (v.2); \u201cLearning Health Systems: Connecting Research To Practice Worldwide\u201d (v.3); \u201cHuman Phenomics and the Learning Health System\u201d (v.4); and \u201cCollaborative Learning Health Systems: Science and Practice\u201d (v.5). Our talented guest editors have been instrumental in helping these Special Issues come to fruition.We are keenly aware that these achievements would not have happened without the dedicated efforts and insightful comments of all those individuals who accepted invitations to review submitted articles. With busy schedules and full commitments in the midst of the Covid\u201019 pandemic, these individuals found the time and energy to contribute their expertise to our authors to help ensure that their papers met (and often exceeded) the journal's high standards for publication.Please accept our sincere gratitude for your outstanding efforts.Charles P. Friedman, Editor in Chief.The following list also includes reviewers of rejected manuscripts.Julia Adler\u2010Milstein (United States)John Ainsworth (United Kingdom of Great Britain and Northern Ireland)Jill Allison (Canada)Holt Anderson (United States)Anna Andreasson (Sweden)Patrick Archambault (Canada)Panagiotis Balatsoukas (United Kingdom of Great Britain and Northern Ireland)Maren Batalden (United States)Marc Berger (United States)Jeff Brown (United States)Julie Bynum (United States)Elizabeth Cohn (United States)Heather Colvin (United States)Derek Corrigan (Ireland)Benoit Cossette (Canada)Mary Costello (United States)Susan Cronin (United States)Jennie David (United States)Brendan Delaney (United Kingdom of Great Britain and Northern Ireland)Jordan Everson (United States)Rhonda Facile (United States)Marcy Fitz\u2010Randolph (United States)Thomas Foley (United Kingdom of Great Britain and Northern Ireland)Masanori Fukushima (Japan)Sarah Greene (United States)W. Ed Hammond (United States)Lamiece Hassan (United Kingdom of Great Britain and Northern Ireland)Frank Hulstaert (Belgium)Michael Ibara (United States)Amy Kilbourne (United States)Harold Lehmann (United States)Leslie Lenert (United States)David McCallie (United States)Loretta McCormick (Canada)Marianne McPherson (United States)Subha Madhavan (United States)Laura Merson (United Kingdom of Great Britain and Northern Ireland)Stephanie Morain (United States)Jessica Moreau (United States)Mark Musen (United States)Eileen Navarro (United States)Sally Okun (United States)Nancy Pandhi (United States)Richard Platt (United States)David Purcell (United States)Rohit Ramaswamy (United States)Barbara Rath (United States)Joshua Rubin (United States)Elin Salmiranta (Sweden)Edgar Schein (United States)Madeline Schmitt (United States)Michael Seid (United States)Archana Tapuria (United Kingdom of Great Britain and Northern Ireland)Jody Traver (United States)Robert Verheij (Netherlands)Jim Walker (United States)Chris Webb (United States)John Wilbanks (United States)David Williams (United States)Tracy Ziolek (United States)"}
+{"text": "N-tert-butyloxycarbonyl (N-Boc) group using oxalyl chloride\u2019 by Nathaniel George et al., RSC Adv., 2020, 10, 24017\u201324026, DOI: 10.1039/D0RA04110F.Correction for \u2018Mild deprotection of the  The authors regret the omission of a funding acknowledgement in the original article. This acknowledgement is given below.The authors acknowledge support of the Center for Pharmaceutical Research and Innovation (NIH P20 GM130456).The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers."}
+{"text": "Tebipenem pivoxil hydrobromide, an orally bioavailable prodrug of tebipenem, is currently in development for the treatment of complicated urinary tract infections. The spectrum of tebipenem activity against Enterobacterales is consistent with intravenous carbapenems such as ertapenem and meropenem including extended spectrum beta-lactamase (ESBL) and AmpC producing organisms. The goal of these studies was to determine the tebipenem exposure required to prevent on-therapy resistance and to evaluate the tebipenem regimen utilized in the recent Phase 3 clinical trial.Escherichia coli clinical isolates  (tebipenem MIC = 0.008 to 0.03 mg/L) were subjected to concentration-time profiles simulating free-drug plasma concentrations after oral administration of tebipenem regimens in a hollow-fiber in vitro infection model. Dose-ranging studies were completed using two isolates at an initial burden of 108 CFU/mL and with exposures for tebipenem regimens ranging from 4.69 to 1200 mg administered every eight hours (q8h). An additional isolate was subjected to only the tebipenem 600 mg q8h regimen evaluated in the Phase 3 trial. Samples were collected for the enumeration of bacterial burdens and evaluation of the simulated pharmacokinetic profile. Each sample for bacterial enumeration was suspended onto drug-free and tebipenem-supplemented agar plates in order to observe the density of the total- and drug-resistant subpopulations over the 10-day period.Three E. coli isolates. Tebipenem consistently lowered bacterial burdens below that of the initial inoculum at a dose of 600 mg q8h for all three E. coli isolates. Amplification of resistance was observed intermittently for all regimens, but was never equal to that of the total population at the 600 mg q8h clinical dose. Tebipenem MIC values for isolates collected from the drug-supplemented agar ranged from 0.06 to 0.25 mg/L, representing four two-fold dilutions from baseline.A full dose response, ranging from treatment failure to reductions in bacterial burden from baseline, were observed in the dose-ranging studies for the two These data support the selection of tebipenem dosing regimens that minimize the potential for on-therapy drug-resistance amplification.Brian D. VanScoy, B.S., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Haley Conde, B.S., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Sean Jones, B.S., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Ian A. Critchley, Ph.D., Spero Therapeutics  Thomas R. Parr, Ph.D., Spero Therapeutics  Nicole Cotroneo, Spero Therapeutics  Paul G. Ambrose, Pharm.D., FIDSA, 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Research Grant or Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support)"}
+{"text": "Scientific Reports 10.1038/s41598-021-96483-5, published online 23 August 2021Correction to: The original version of this Article contained an error in the Funding section.\u201cThis study was supported by a research grant from the Korean Healthcare Technology R&D project funded by the Ministry of Health and Welfare  and a CMB-Yuhan research grant of Yonsei University College of Medicine (6-2019-0124).\u201dnow reads:\u201cThis study was supported by a research grant from the Korean Healthcare Technology R&D project funded by the Ministry of Health and Welfare  and a CMB-Yuhan research grant of Yonsei University College of Medicine (6-2019-0124).\u201dThe original Article has been corrected."}
+{"text": "Scientific Reports6: Article number: 1880310.1038/srep18803; published online: 01252016; updated: 05222018The Acknowledgements section in this Article is incomplete.\u201cThe authors acknowledge funding from the Italian Ministry of Education, University and Research (MIUR) through the project \u201cThe global virtual-water network: social, economic, and environmental implications\u201d (FIRB - RBFR12BA3Y).\u201dshould read:\u201cThe authors acknowledge funding from the Italian Ministry of Education, University and Research (MIUR) through the project \u201cThe global virtual-water network: social, economic, and environmental implications\u201d (FIRB - RBFR12BA3Y). Funding from the European Research Council (ERC) is also acknowledged .\u201d"}
+{"text": "Scientific Reports6: Article number: 3183210.1038/srep31832; published online: 08262016; updated: 05042017In the original version of this Article, Affiliations 1 and 2 were not listed in the correct order. The correct affiliations are listed below:Affiliation 1School of Psychology & Neuroscience University of St. Andrews, South Street, St Andrews, Fife KY16 9JP, United Kingdom.Affiliation 2School of Experimental Psychology University of Bristol 12a, Priory Road, Bristol BS8 1TU, United Kingdom.This error has now been corrected in the PDF and HTML versions of the Article."}
+{"text": "Correction to:Oncogene (2017) 36, 1537\u20131545; doi:10.1038/onc.2016.320; published online 3 October 2016Following the publication of this article the authors note that they inadvertently omitted the correct acknowledgement for the support from the NIH and The Carl and Roberta Deutsch Foundation for the above referenced paper.The corrected acknowledgement should read:We acknowledge The Carl and Roberta Deutsch Foundation (PI: Farias-Eisner), Kelly Day, and NIH/NCI U54CA143930 Grant (PI: Farias-Eisner) for their financial support. We thank Professor Oliver Dorigo, Stanford University Medical Center, for the generous gift of cisplatin-resistant ovarian cancer cell lines. We thank Dr Xiangming Ding, UCLA Clinical Microarray Core, for the statistical assistance.The authors apologise for any inconvenience caused by this error."}
+{"text": "Scientific Reports7: Article number: 4262810.1038/srep42628; published online: 02162017; updated: 05032017The Acknowledgements section in this Article is incomplete.\u201cThis work was supported by National Natural Science Foundation Project (81522013), Chongqing Outstanding Youth Grant (cstc2014jcyjjq10005), Chongqing Key Laboratory of Ophthalmology , Chongqing Science & Technology Platform and Base Construction Program (cstc2014pt-sy10002), National Key Clinical Specialties Construction Program of China and Research and Cultivation Foundation Project of Chongqing Medical University (201407)\u201d.Should read:\u201cThis work was supported by National Natural Science Foundation Project , Chongqing Outstanding Youth Grant (cstc2014jcyjjq10005), Chongqing Key Laboratory of Ophthalmology , Chongqing Science & Technology Platform and Base Construction Program (cstc2014pt-sy10002), National Key Clinical Specialties Construction Program of China, Chongqing Graduate Student Research Innovation Project (CYB16096) and Research and Cultivation Foundation Project of Chongqing Medical University (201407)\u201d."}
+{"text": "Scientific Reports6: Article number: 2558210.1038/srep25582; published online: 05092016; updated: 09142016This Article contains errors in the Acknowledgements section.\u201cThis research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2013R1A1A2058053), and Institute for Information & communications Technology Promotion(IITP) grant funded by the Korea government(MSIP) . The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript\u201d.should read:\u201cThis research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2013R1A1A2058053), and the MSIP, Korea and Microsoft Research, under ICT/SW Creative research program supervised by the IITP(Institute for Information & Communications Technology Promotion) (IITP-2015- R-20150826-002098)\u201d."}
+{"text": "This article has been corrected: The correct Funding information is given below:FUNDINGNIH grant support in the Comprehensive Flow Cytometry Core (CFCC) (P30 AR48311), Dr. Londono is funded by a NIH Research Training Program in Basic and Translation Oncology T32 Grant (T32CA183926). Dr. Arend is supported by the Foundation for Women\u2019s Cancer (WeRoc/OChO Ovarian Cancer Research Grant), Norma Livingston Foundation, AAOGF/ABOG Career Development Award, and ACS-IRG (IRG-60-001-53-IRG). Dr. Hidalgo is supported by the NHLBI Diversity Supplement (HHSN268201300001) and a grant from the Robert Wood Johnson Foundation, New Connections Program.https://doi.org/10.18632/oncotarget.13466Original article: Oncotarget. 2016; 7:86803-86815."}
+{"text": "Scientific Reports 10.1038/s41598-017-01819-9, published online 12 May 2017Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cWe gratefully acknowledge the support of the National Institutes of Health (NIH)-National Institute on Drug Abuse (NIDA) grants R01 DA036154; R21 DA041287 to NEH and DA041749 to MN and National Institutes of Health (NIH)-National Institute on Mental Health (NIMH) R01 MH110262 to FK.\u201dshould read:\u201cWe gratefully acknowledge the support of the National Institutes of Health (NIH)-National Institute on Drug Abuse (NIDA) grants R01 DA036154; R21 DA041287 to NEH and DA034547 to MN and National Institutes of Health (NIH)-National Institute on Mental Health (NIMH) R01 MH110262 to FK.\u201d"}
+{"text": "Nature Communications 10.1038/s41467-017-01360-3, Article published online 3 November 2017Correction to: The original version of this Article omitted an affiliation of Cheng Hon Alfred Huan: \u2018Institute of Materials Research and Engineering (IMRE), A*STAR, 2 Fusionopolis Way, Innovis #08-03 138634, Singapore\u2019.This has now been corrected in both the PDF and HTML versions of the article."}
+{"text": "This article has been corrected: the funding information statement was updated and is as follows:FUNDINGThis work was supported by grant of the Municipal Medical Key Discipline of Chongqing (YuWeiKeJiao No. 2007-2), and by grant of Integrated Demonstration Project of Chongqing Science and Technology Commission (cstc2015jcsf10008-1).https://doi.org/10.18632/oncotarget.18602Original article: Oncotarget. 2017; 8:53531-53541."}
+{"text": "Scientific Reports7: Article number: 4374310.1038/srep43743; published online: 03082017; updated: 04102017This Article contains errors in the Acknowledgements section.\u201cThis work was supported by a Czech-Israel cooperative research grant issued by the Israel Ministry of science (grant number 3\u20139814) and the Czech Ministry of education (Grant LH13256 VES13-KontaktII). Additional support was given by the Czech Ministry of Health (Grant IGA MZ CR NT12282-5/2011) and the Charles University in Prague (Research Project PRVOUK-P26/LF1/4).\u201dShould read:\u201cThis work was supported by the Czech Science Foundation (grant GACR 16-13323S) and by the Czech-Israel cooperative research grant \u201d."}
+{"text": "Nature Communications7 Article number: 10833 ; DOI: 10.1038/ncomms10833 (2016). Published 03012016; Updated 08142017Technical support for this Article was not fully acknowledged. The Acknowledgements should have included the following: We thank Drs Ronald Petralia and Ya-Xian Wang, members of the Advanced Imaging Core, National Institute of Deafness and other Communication Disorders (NIDCD), for the images in Fig. 1k, l."}
+{"text": "Scientific Reports 10.1038/s41598-017-07871-9, published online 08 August 2017Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis study was supported by the National Key Research and Development Program of China (2016YFD0101007) to Dr. Ke-de Liu, the Natural Science Foundation of Hubei Province (36116006), and the Scientific & Technological Self-innovation Foundation of Huazhong Agricultural University (0900206305) to Dr. Cheng Dai. We are grateful to Dr. Qijun Chen for kindly providing pKSE401 and pCBC-DT1T2. We thank Dr. Chunying Kang, Dr. Robert M. Larkin and Dr. Liang Guo  for helpful discussion and critical reading of the manuscript.\u201dshould read:\u201cThis study was supported by the National Key Research and Development Program of China (2016YFD0101007) to Dr. Ke-de Liu, the Fundamental Research Funds for the Central Universities (No. 2662015BQ031) and the Natural Science Foundation of Hubei Province (No. 2016CFB141) to Dr. Cheng Dai. We are grateful to Dr. Qijun Chen for kindly providing pKSE401 and pCBC-DT1T2. We thank Dr. Chunying Kang, Dr. Robert M. Larkin and Dr. Liang Guo  for helpful discussion and critical reading of the manuscript.\u201d"}
+{"text": "The funding statement should have read as follows:In the article \u201cDesign and fabrication of complete dentures using CAD/CAM technology\u201d,This study was funded by the Clinical Support of PLA General Hospital (2014FC-SXYY-1003) and the Capital's Special Health Development Research (2014-4-5022)."}
+{"text": "Scientific Reports 10.1038/s41598-017-08223-3, published online 29 August 2017Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis research was supported by the European Research Council (ERC StG CACTUS 312292) and the Swedish Research Council (2014-1156).\u201dshould read:\u201cThis research was supported by the European Research Council (ERC StG CACTUS 312292 and MSCA ITN Brainview 642996) and the Swedish Research Council (2014-1156).\u201d"}
+{"text": "Nature Communications7: Article number: 13749; DOI: 10.1038/ncomms13749 (2016); Published: 12132016; Updated: 01202017The financial support for this Article was not fully acknowledged. The Acknowledgements should have included the following:This work was supported by the National Science Foundation Graduate Research Fellowship ; NSF IGERT 0734683 (S.D.S.); Christopher and Dana Reeve Paralysis Foundation (S.I.R. and K.V.S.); and the following to K.V.S.: Burroughs Welcome Fund Career Awards in the Biomedical Sciences, Defense Advanced Research Projects Agency Reorganization and Plasticity to Accelerate Injury Recovery N66001-10-C-2010, US National Institutes of Health Institute of Neurological Disorders and Stroke Transformative Research Award R01NS076460, US National Institutes of Health Director's Pioneer Award 8DP1HD075623-04, US National Institutes of Health Director's Transformative Research Award (TR01) from the NIMH #5R01MH09964703, and Defense Advanced Research Projects Agency NeuroFAST award from BTO #W911NF-14-2-0013."}
+{"text": "In the original publication of this article , the fun\u115fThe final funding statement can be found below:\u115fFundingThis work was supported by Natural Sciences and Engineering Research Council of Canada (NSERC) grants to IZ , NSERC Alexander Graham Bell Canada Graduate Scholarship-Doctoral (CGS-D) to RJ (#454402-2014), NSERC Alexander Graham Bell Canada Graduate Scholarship-Masters (CGS-M) to SC (#442618-2013), and an NSERC Undergraduate Student Research Award (USRA) to JB (#483630-2015). Work on the NGS platform of the Institut Curie was supported by the Agence Nationale de la Recherche (ANR Investissement d\u2019Avenir) (ANR-10-EQPX-03) and by the France G\u00e9nomique National infrastructure (ANR-10-INBS-09). The funding bodies had no role in study design, data collection, data analysis and interpretation, or preparation of the manuscript."}
+{"text": "Scientific Reports 10.1038/s41598-017-11037-y, published online 31 August 2017Correction to: This Article contains an error in the Acknowledgements section.\u201cFundamental Research Funds for the Central Universities, Huazhong University of Science and Technology (2016YXMS215), Wuhan, China.\u201dshould read:\u201cNational Natural Science Foundation of China .\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-017-01458-0, published online 02 May 2017Correction to: The original version of this Article omitted an affiliation for Jian Lu. The correct affiliations are listed below:Department of Mechanical and Biomedical Engineering, City University of Hong Kong, Tae Chee Avenue Kowloon, Hong Kong 999077, China.Center for Advanced Structural Materials, City University of Hong Kong Shenzhen Research Institute, 8 Yuexing 1st Road, Nanshan District, Shenzhen, China.In addition, the Acknowledgements section in this Article contained errors:\u201cThe authors gratefully acknowledge the financial support of the ITER-National Magnetic Confinement Fusion Program (2010GB109000 and 2014GB123000). J. LU acknowledges the financial support provided by the MOST 973 Program of China under the grant 2012CB932203 and the Croucher Foundation Grant (CityU9500006).\u201dnow reads:\u201cThe authors gratefully acknowledge the financial support of the ITER-National Magnetic Confinement Fusion Program (2010GB109000 and 2014GB123000). J. LU acknowledges the financial support from Guangdong Science and Technology Department (Ref: 2014B050504003) and SZSTI (Ref: ZDSYS201602291653165).\u201dThese errors have now been corrected in the HTML and PDF versions of this Article."}
+{"text": "Information is missing from the Funding section. Yashpal S. Kanwar was also a recipient of National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (US)(NIHNIDDK)RO1DK60635. The correcting Funding Disclosure Statement should read as follows: This work was supported by the following sources of funding: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases(US) (NIHNIDDK)RO1DK097240, Recipient: Janardan K. Reddy; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (US) (NIHNIDDK)RO1 DK083163, Recipient: Janardan K. Reddy; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (US)(NIHNIDDK)RO1DK60635, Recipient: Yashpal S Kanwar; and National Institutes of Health (US), National Institute of Allergy and Infectious Diseases(NIH) (AI)R21AI1094296, Recipient: Bayar Thimmapaya."}
+{"text": "Scientific Reports 10.1038/s41598-018-20626-4, published online 01 February 2018Correction to: The original version of this Article contained an error in Affiliation 2 which was incorrectly listed as \u2018MRAM Center, Department of Electronics and Computer Engineering, Hanyang University, Seoul, 04763, Republic of Korea\u2019.The correct affiliation is listed below:\u2018MRAM Center, Department of Nanoscale Semiconductor Engineering, Hanyang University, Seoul, 04763, Republic of Korea.\u2019In addition, the Acknowledgements section in this Article contained an error.\u201cThis work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2014R1A2A1A01006474) and Brain Korea 21 PLUS Program in 2014.\u201dnow reads:\u201cThis work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2017R1A2A1A05001285) and Brain Korea 21 PLUS Program in 2014.\u201dThese errors have now been corrected in the PDF and HTML versions of the Article."}
+{"text": "Scientific Reports 10.1038/s41598-017-09223-z, published online 18 August 2017Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cThis is contribution  of the University of Maryland Center for Environmental Science, Chesapeake Biological Laboratory.\u201dshould read:\u201cThis is contribution 5394 of the University of Maryland Center for Environmental Science, Chesapeake Biological Laboratory.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-018-22218-8, published online 28 February 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis work was supported by a National Research Foundation of Korea (NRF) grant by the Korean government .\u201dshould read:\u201cThis work was supported by a National Research Foundation of Korea (NRF) grant by the Korean government  and grant No 04-2016-0540 from the SNUH Research Fund.\u201d"}
+{"text": "The Funding statement is incorrect. The correct statement is: This work was supported by Ministry of Higher Education FRGS grant (FP012-2015A) and University of Malaya Prototype Research Grant Scheme (PR002-2015B)."}
+{"text": "Nature Communications8 Article number: 15855 ; DOI: 10.1038/ncomms15855 (2017); Published: 06272017; Updated: 08072017The financial support for this Article was not fully acknowledged. The Acknowledgements should have included the following:This research used resources of the Advanced Light Source and the Stanford Synchrotron Radiation Lightsource, which are DOE Office of Science User Facilities under contract no. DE-AC02-05CH11231 and DE-AC02-76SF00515, respectively. The SSRL Structural Molecular Biology Program is supported by the DOE BER, and by the NIH (including P41GM103393). The SIBYLS beamline 12.3.1 is supported by the IDAT program from the DOE BER and the NIH project MINOS (R01GM105404)."}
+{"text": "Scientific Reports 10.1038/s41598-018-22655-5, published online 15 March 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cThe work was partially supported by National Science Foundation of China (61603209), and Beijing Natural Science Foundation (4164086), and the Study of Brain-Inspired Computing System of Tsinghua University program (20151080467), and Ministry of Education, Singapore, under contracts RG28/14, MOE2014-T2-1-028 and MOE2016-T2-1-119. Part of this work is an outcome of the Future Resilient Systems project at the Singapore-ETH Centre (SEC), which is funded by the National Research Foundation of Singapore (NRF) under its Campus for Research Excellence and Technological Enterprise (CREATE) programme.\u201dshould read:\u201cThe work was partially supported by National Science Foundation of China , and Beijing Natural Science Foundation (4164086), and the Study of Brain-Inspired Computing System of Tsinghua University program (20151080467), and SuZhou-Tsinghua innovation leading program 2016SZ0102, and Ministry of Education, Singapore, under contracts RG28/14, MOE2014-T2-1-028 and MOE2016-T2-1-119. Part of this work is an outcome of the Future Resilient Systems project at the Singapore-ETH Centre (SEC), which is funded by the National Research Foundation of Singapore (NRF) under its Campus for Research Excellence and Technological Enterprise (CREATE) program.\u201d"}
+{"text": "Background: We investigated causal effect of completed growth, measured by adult height, on coronary heart disease (CHD), stroke and cardiovascular traits, using instrumental variable (IV) Mendelian randomization meta-analysis.Methods: We developed an allele score based on 69 single nucleotide polymorphisms (SNPs) associated with adult height, identified by the IBCCardioChip, and used it for IV analysis against cardiovascular risk factors and events in 21 studies and 60\u2009028 participants. IV analysis on CHD was supplemented by summary data from 180 height-SNPs from the GIANT consortium and their corresponding CHD estimates derived from CARDIoGRAMplusC4D.Results: IV estimates from IBCCardioChip and GIANT-CARDIoGRAMplusC4D showed that a 6.5-cm increase in height reduced the odds of CHD by 10% ,which agrees with the estimate from the Emerging Risk Factors Collaboration . IV analysis revealed no association with stroke . IV analysis showed that a 6.5-cm increase in height resulted in lower levels of body mass index (P\u2009<\u20090.001), triglycerides (P\u2009<\u20090.001), non high-density (non-HDL) cholesterol (P\u2009<\u20090.001), C-reactive protein (P\u2009=\u20090.042), and systolic blood pressure (P\u2009=\u20090.064) and higher levels of forced expiratory volume in 1\u2009s and forced vital capacity (P\u2009<\u20090.001 for both).Conclusions: Taller individuals have a lower risk of CHD with potential explanations being that taller people have a better lung function and lower levels of body mass index, cholesterol and blood pressure. All participating studies obtained informed consent for DNA analysis and received ethical approval.We included individual participant data from 60\u2009028 participants of European ancestry from 21 prospective studies  Broad Institute CARe consortium (IBC) CardioChip arrayIJE online).We selected 69 SNPs, representing 69 different loci, independently associated with adult height at array-wide significance (P\u2009<\u20092.4\u00d710\u22126) in gene-centric meta-analysis of height from 114\u2009223 individuals and 47 studies genotyped with the IBC Cardiochip array  to construct the allele score.2\u2009>\u20090.8) with those from IBC Cardiochip.Genotyping was conducted with the IBC Cardiochip array in 16 studies,IJE online.The primary outcome was prevalent or incident  CHD. The secondary outcome was prevalent or incident  stroke including haemorrhagic or ischaemic events. Validated events were preferred over non-validated, self-reported events. Details for outcome definitions in each study are provided in IJE online] and on lung function  given the established association with adult height.To gain insight into the mechanisms that may explain the association of height with CHD and stroke, we used available information from individual studies on established or promising risk factors for CHD and stroke .The IBC array data  Candidate Gene Association Resource (CARe) was downloaded with appropriate permissions from The database of Genotypes and Phenotypes (dbGaP) [http://www.mesa-nhlbi.org].CARe (Candidate gene Association Resource). The CARe Consortium wishes to acknowledge the support of the National Heart, Lung, and Blood Institute and the contributions of the research institutions, study investigators, field staff and study participants in creating this resource for biomedical research (NHLBI contract number HHSN268200960009C). The following nine parent studies have contributed parent study data, ancillary study data and DNA samples through the Massachusetts Institute of Technology-Broad Institute (N01-HC-65226) to create this genotype/phenotype database for wide dissemination to the biomedical research community: the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), the Cleveland Family Study (CFS), the Cooperative Study of Sickle Cell Disease (CSSCD), the Coronary Artery Risk Development in Young Adults (CARDIA) study, the Framingham Heart Study (FHS), the Jackson Heart Study (JHS), the Multi-Ethnic Study of Atherosclerosis (MESA) and the Sleep Heart Health Study (SHHS). The ARIC study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. The authors thank the staff and participants of the ARIC study for their important contributions. MESA was conducted and supported by contracts N01-HC-95159 through N01-HC-95169 and RR-024156 from the National Heart, Lung, and Blood Institute (NHLBI). The authors thank the participants of the MESA study, the Coordinating Center, MESA investigators and study staff for their valuable contributions. A full list of participating MESA investigators and institutions can be found at: [EAS (Edinburgh Artery Study). EAS is funded by the British Heart Foundation (Programme Grant RG/98002), with Metabochip genotyping funded by a project grant from the Chief Scientist Office of Scotland (Project Grant CZB/4/672).ELSA . ELSA is funded by the National Institute on Aging in the US  and by a consortium of UK Government departments involved in areas related to the ageing process . ELSA was developed by a team of researchers based at the National Centre for Social Research, University College London and the Institute of Fiscal Studies. The data were collected by the National Centre for Social Research.EPIC-NL (European Prospective Investigation into Cancer and Nutrition in The Netherlands). The EPIC-NL study was funded by \u2018Europe against Cancer' Programme of the European Commission (SANCO), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch Cancer Society, ZonMW, The Netherlands Organisation for Health Research and Development and World Cancer Research Fund (WCRF) (The Netherlands). Genotyping was funded by IOP Genomics grant IGE05012 from Agentschap NL.ET2DS is funded by the Medical Research Council (Project Grant G0500877), the Chief Scientist Office of Scottish (Programme Support Grant CZQ/1/38), Pfizer plc (Unrestricted Investigator Led Grant) and Diabetes UK . Research clinics were held at the Wellcome Trust Clinical Research Facility and Princess Alexandra Eye Pavilion in Edinburgh.LURIC was supported by the 7th Framework Program  of the European Union and by the INTERREG IV Oberrhein Program  with support from the European Regional Development Fund (ERDF) and the Wissenschaftsoffensive TMO. NORDIL (Nordic Diltiazem study). The NORDIL clinical study was supported by a grant from Pharmacia. Genetic studies were supported by the British Heart Foundation  and European Union Ingenious HyperCare Consortium: Integrated Genomics, Clinical Research, and Care in Hypertension (grant number LSHM-C7-2006-037093). Genotyping was supported by the British Heart Foundation (grant number PG/07/131/24254 to P.B.M.). We thank Prof. Thomas Hedner  and Prof. Sverre Kjeldsen , who are investigators of the NORDIL study.PROCARDIS (Precocious Coronary Artery Disease). The PROCARDIS consortium genotyping was funded by the British Heart Foundation (BHF) and EC Sixth Framework Programme (LSHM-CT-2007-037273) and the sample collection by AstraZeneca AB and the BHF. R.C., M.F. and H.W. are supported by the BHF Centre for Research Excellence; M.F. and H.W. acknowledge support from a Wellcome Trust core award (090532/Z/09/Z). R.C. acknowledges support from the MRC; Anders Hamsten obtained support for this project from the Swedish Heart-Lung Foundation, the Swedish Medical Research Council (8691), the Knut and Alice Wallenberg Foundation, the Karolinska Institute and the Stockholm County Council (560183).UCLEB . The UCLEB consortium is funded by a British Heart Foundation programme grant (ref RG/10/12/28456).WHI . The WHI programme is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.WHII . The WHII study is supported by grants from the Medical Research Council , British Heart Foundation (RG/07/008/23674), Stroke Association, National Heart Lung and Blood Institute (5RO1 HL036310), National Institute on Aging (5RO1AG13196) Agency for Health Care Policy Research (HS06516), and the John D. and Catherine T. MacArthur Foundation Research Networks on Successful Midlife Development and Socio-economic Status and Health. We gratefully thank the subjects and the investigators of this project.The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.Conflict of interest: Anke H Maitland-van der Zee has an unrestricted research grant for research on pharmacogenetics from GSK. All other primary authors declare no conflicts of interest.Key MessagesObservational studies show associations of adult height with risk of coronary heart disease (CHD) and stroke; however, these associations could arise from confounding or reverse causalityTo investigate the causal effect, we conducted a multi-locus Mendelian randomization study incorporating data from 180 height-related SNPs using both individual participant data from prospective cohorts and summary data from large genetics consortiaA 6.5-cm increase in adult height (instrumented by 180 SNPs) causally reduced the odds of CHD by 10%, with potential mechanisms including blood pressure, body mass index and non-HDL cholesterol; the effect of adult height on stroke was less clear.Supplementary DataClick here for additional data file."}
+{"text": "Nature Communications 10.1038/s41467-018-04291-9, published online: 10 May 2018Correction to: The original version of this Article omitted an affiliation of Xiewen Wen: \u2018College of Chemistry and Molecular Engineering, Beijing National Laboratory for Molecular Sciences, Peking University, Beijing 100871, China\u2019. This has been corrected in both the PDF and HTML versions of the Article."}
+{"text": "Scientific Reports 10.1038/s41598-017-08585-8, published online 18 August 2017Correction to: This article contains an error in the Acknowledgements section.\u201cThis work was supported in part by the Core-to-Core Program A. Advanced Research Networks and the Grants-in-Aid for Scientific Research (A) from the Japan Society for the Promotion of Science.\u201dshould read:\u201cThis work was supported in part by the Core-to-Core Program A. Advanced Research Networks and the Grants-in-Aid for Scientific Research (A) (JP17H01277) and (B) (JP16H03878) from the Japan Society for the Promotion of Science.\u201d"}
+{"text": "The following information is missing from the Funding section: This project was supported by the National Funds through FCT\u2014Portuguese Foundation for Science and Technology (UID/DTP/04045/2013)\u2014and the European Fund for regional development (FEDER) allocated by European Union through the COMPETE 2020 Programme (POCI-01-0145-FEDER-006969)."}
+{"text": "Scientific Reports 10.1038/s41598-018-20660-2, published online 09 February 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cThe Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201300025C & HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-agency agreement between NIA and NHLBI (AG0005). This manuscript has been reviewed by CARDIA for scientific content. This work was supported by National Heart, Lung, and Blood Institute training grant T32 predoctoral fellow T32HL007055.\u201dshould read:\u201cThe authors thank the staff and participants of HCHS/SOL (Investigators website - http://www.cscc.unc.edu.libproxy.lib.unc.edu/hchs/), NHANES, and the Coronary Artery Risk Development in Young Adults Study (CARDIA) for their important contributions. CARDIA is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201300025C & HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-agency agreement between NIA and NHLBI (AG0005). This manuscript has been reviewed by CARDIA for scientific content. This work was supported by National Heart, Lung, and Blood Institute training grant T32 predoctoral fellow T32HL007055.\u201d"}
+{"text": "Scientific Reports7: Article number: 45697; 10.1038/srep45697 published online: 04062017; updated: 07152017.The Acknowledgements section in this Article is incomplete.\u201cThis study was funded by the Central Public-interest Scientific Institution Basal Research Fund for Chinese Academy of Tropical Agricultural Sciences , the Special Fund for Agro-Scientific Research in the Public Interest, China (grant no. 201303143) and the China Agriculture Research System (grant no. CARS-12)\u201d.should read:\u201cThis study was funded by the Central Public-interest Scientific Institution Basal Research Fund for Chinese Academy of Tropical Agricultural Sciences , the Special Fund for Agro-Scientific Research in the Public Interest, China (grant no. 201303143) and the China Agriculture Research System (grant no. CARS-12)\u201d."}
+{"text": "Scientific Reports 10.1038/s41598-017-15454-x, published online 10 November 2017Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis work was supported by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea, HI14C1607 (S-HC), an NIH/NEI RO1-EY014878 and an unrestricted grant from RPB, Inc. (JMW).\u201dshould read:\u201cThis work was supported by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea, HI14C1607 and by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIP) (No. 2017R1A2B4012327) (S-HC), an NIH/NEI RO1-EY014878 and an unrestricted grant from RPB, Inc. (JMW).\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-018-19592-8, published online 19 January 2018Correction to: This Article contains an error in Figure 1 where panels C and D are reversed. The correct Figure 1 appears below as Figure\u00a0Additionally, this Article contains errors in the Methods section under subheading \u2018Lipid extraction and UHPLC-MS/MS analyses of sterols and oxysterols\u2019.TM or 6500TM; AB SCIEX, Ontario, Canada) equipped with atmospheric pressure chemical ionization (APCI).\u201d\u201cAnalysis of sterols and oxysterols were performed by UHPLC-MS/MS using a triple-quadrupole mass spectrometer ; AB SCIEX, Ontario, Canada) equipped with atmospheric pressure chemical ionization (APCI).\u201d\u201cMS conditions: spray voltage, 5000\u2009V; curtain gas, 10\u2009psi; ion source gas, 20\u2009psi; collision gas, high; entrance potential, 10\u2009V; collision energy, 25\u2009V; declustering potential, 80.00\u2009V; temperature, 300\u2009\u00b0C.\u201dshould read:\u201cMS conditions: declustering potential, 80\u2009V; entrance potential, 10\u2009V; collision energy, 25\u2009V; collision cell exit potential, 20.0\u2009V. APCI parameters: nebulizer current, 3\u2009mA; temperature, 300\u2009\u00b0C; curtain gas, 10\u2009psi for 4000\u2122 and 20\u2009psi for 6500\u2122; ion source gas, 20\u2009psi for 4000\u2122and 55\u2009psi for 6500\u2122.\u201dFinally, the Acknowledgements section in this Article is incomplete.\u201cThis work was supported, in part: by U.S.P.H.S. (NIH) grants R01 EY007361 (SJF), R00 HD073270 (LX), and R01 HD092659 (LX); by Clinical and Translational Science Award UL1 TR001412 to the University at Buffalo-The State University of New York from NCATS/NIH (SJF); by a Foundation Fighting Blindness Center Grant  (NSP); by a Research to Prevent Blindness Unrestricted Grant to the Department of Ophthalmology, University at Buffalo-The State University of New York from Research to Prevent Blindness (SJF); by startup funds from the Department of Medicinal Chemistry, School of Pharmacy, University of Washington (LX); and by facilities and resources provided by the VA Western New York Healthcare System (SJF) and the Louis Stokes Cleveland VA Medical Center (NSP).\u201dshould read:\u201cThis work was supported, in part: by U.S.P.H.S. (NIH) grants R01 EY007361 (SJF), R00 HD073270 (LX), and R01 HD092659 (LX); by Clinical and Translational Science Award UL1 TR001412 to the University at Buffalo-The State University of New York from NCATS/NIH (SJF); by a Foundation Fighting Blindness Center Grant (an unrestricted award) to the Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (NSP); by Research to Prevent Blindness Unrestricted Grants to the Departments of Ophthalmology, University at Buffalo-The State University of New York and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University from Research to Prevent Blindness ; by startup funds from the Department of Medicinal Chemistry, School of Pharmacy, University of Washington (LX); and by facilities and resources provided by the VA Western New York Healthcare System (SJF) and the Louis Stokes Cleveland VA Medical Center (NSP).\u201d"}
+{"text": "Gong and Lin was given incompletely. The full affiliation for these authors should read as follows: Department of Oral and Maxillofacial Oncology Surgery, Stomatological Medical Center, The First Affiliated Hospital of Xinjiang Medical University.In the article \u201cPrognostic value of GLUT-1 expression in oral squamous cell carcinoma: A prisma-compliant meta-analysis\u201d,"}
+{"text": "Present: The grant number information is incorrect in the Acknowledgments.Correct: The proper grant information appears below:ACKNOWLEDGMENTSThis research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2014R1A1A2055411).18541-18557. doi: 10.18632/oncotarget.8105Original article: Oncotarget. 2016; 7:"}
+{"text": "Scientific Reports7:1610; doi: 10.1038/s41598-017-01647-x; Article published online 03 May 2017The original version of this Article contained an error in the author list where the authors Tiffanie Stewart and Chooda Khanal were inadvertently combined.The affiliations of Tiffanie Stewart and Chooda Khanal are:\u201cDepartment of Electrical Engineering Florida International University, Miami, Florida, 33174, USA\u201dThis has now been corrected in the HTML and PDF versions of this Article."}
+{"text": "Scientific Reports 10.1038/s41598-017-10148-w, published online 29 August 2017Correction to: The Acknowledgements section in this Article was omitted. The Acknowledgements section should read:\u201cThis research was supported by IBS-R023-D1 and the Global Frontier Project (2014M3A6B3063710) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning. It was also supported by the Korea Health Technology R&D Project (HI14C0748) funded by the Ministry of Health and Welfare, Republic of Korea.\u201d"}
+{"text": "Nature Communications 10.1038/s41467-017-02354-x, published online: 02 Jan 2018.Correction to: In the original version of this Article, financial support was not fully acknowledged. The PDF and HTML versions of the Article have now been corrected to include the following:The National Basic Research Program (2015CB553602 to J.L.), the National Natural Science Foundation of China  and Tianjin Applied Basic and Frontier Tech Major Project (12JCZDJC34400 to J.L.) and Tianjin Higher Education Sci-Tech Development Project (20112D05 to J.L.)."}
+{"text": "The authors of this published article  would li\u201cThis study was funded by the US President\u2019s Malaria Initiative (PMI) through the United States Agency for International Development under Translating Research into Action, Cooperative Agreement No. GHS-A-00-09-00015-00, managed by University Research Co., LLC (URC).\u201d"}
+{"text": "Natural sea salt consumption confers protection against hypertension and kidney damage in Dahl salt-sensitive rats. Food & Nutrition Research. 61:1:1-10. When this article originally published online, the Acknowledgements section was incorrect. This has now been changed to read as follows:This research was supported by the Globalization of Korean Foods R&D Program , and by the Chung-Ang University Research Grants in 2015."}
+{"text": "Scientific Reports 10.1038/s41598-017-01411-1, published online 03 May 2017Correction to: This Article contains an error in the Acknowledgements section.\u201cThis study was supported by research funding from NCI R01 CA164225 (L.W.), Advancing A Healthier Wisconsin Research and Education Program (AHW REP) fund (L.W.), Ann\u2019s Hope Foundation from the Medical College of Wisconsin Cancer Center (L.W.), the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Cancer Research Program under Award No. W81XWH-14-1-0587 (L.W.), Worldwide Cancer Research Foundation (UK) research grant 16-1161 (L.W.).\u201dshould read:\u201cThis study was supported by research funding from NCI R01 CA164225 (L.W.), Advancing A Healthier Wisconsin Research and Education Program (AHW REP) fund (L.W.), Ann\u2019s Hope Foundation from the Medical College of Wisconsin Cancer Center (L.W.), the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Cancer Research Program under Award No. W81XWH-14-1-0587 (L.W.), Worldwide Cancer Research (UK)\u00a0research grant 16-1161 (L.W.).\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-017-17776-2, published online 13 December 2017Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cThis work was supported by grants from the Catalan Diabetes Association (NT), University of Barcelona (NT), Carlos III Health Institute (ISCIII) PI17/00108 co-funded by FEDER funds/European Regional Development Fund (ERDF)-\u201ca Way to Build Europe\u201d (EM) and by CIBERDEM which is a project of ISCIII. The authors thank the CRG Genomics and Bioinformatics facilities.\u201dshould read:\u201cThis work was supported by grants from the Catalan Diabetes Association (NT), University of Barcelona (NT), Carlos III Health Institute (ISCIII) PI16/00462 co-funded by FEDER funds/European Regional Development Fund (ERDF)-\u201ca Way to Build Europe\u201d (EM) and by CIBERDEM which is a project of ISCIII. The authors thank the CRG Genomics and Bioinformatics facilities.\u201d"}
+{"text": "Scientific Reports6: Article number: 3349110.1038/srep33491; published online: 09262016; updated: 12192016The Acknowledgements section in this Article is incomplete.\u201cThis work was supported by the Fonds der Chemischen Industrie and the Free State of Bavaria. The authors gratefully acknowledge financial support by the German Plastics Center SKZ and Julius-Maximilians Universit\u00e4t W\u00fcrzburg for start-up funding. Light-scattering experiments were possible through support of the Deutsche Forschungsgemeinschaft (INST 93/774-1 FUGG). RL, CF and JG thank the Deutsche Forschungsgemeinschaft (LU 1571/9-1 and GA 2051/1-1 respectively) for the financial support of their respective research stay at the University College London. GB and LM thank the support of the ERC-STG-MEVIC grant for funding the work and their salary.\u201dshould read:\u201cThis work was supported by the Fonds der Chemischen Industrie and the Free State of Bavaria. The authors gratefully acknowledge financial support by the German Plastics Center SKZ and Julius-Maximilians Universit\u00e4t W\u00fcrzburg for start-up funding. Light-scattering experiments were possible through support of the Deutsche Forschungsgemeinschaft (INST 93/774-1 FUGG). RL, CF and JG thank the Deutsche Forschungsgemeinschaft (LU 1571/9-1 and GA 2051/1-1 respectively) for the financial support of their respective research stay at the University College London. GB and LM thank the support of the ERC-STG-MEVIC grant for funding the work and their salary. This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing.\u201d"}
+{"text": "In the article titled \u201cTime-Shift Correlation Algorithm for P300 Event Related Potential Brain-Computer Interface Implementation\u201d , an acknThe authors would like to thank the Ministry of Science and Technology (under Grant MOST 104-2221-E-011-140) and the Taipei Medical University/National Taiwan University of Science and Technology cross-university collaboration project (under Grant TMU-NTUST-103-07) for partial support of this work."}
+{"text": "Complexes of the diuretic benzothiadiazine derivative chlorothiazide  with V(IV); Fe(II); Co(II); Ni(II); Cu(II), Ag(I) and U(VI) wereprepared and characterized by elemental analysis, spectroscopic, thermogravimetric, magnetic andconductimetric measurements. The complexes behave as effective inhibitors for two isozymes (I and II) ofcarbonic anhydrase (CA)."}
+{"text": "Metal complexes of the title ligand (L) containing Co(II), Ni(II) and Cu(II) were prepared andcharacterized by elemental analysis, IR, electronic spectroscopy and conductimetry. The new derivatives,possessing the following formulae, CuL"}
+{"text": "The title compound was prepared by an improved variant of the literature procedure, and metal complexes containing its anion and the following metal ions: Zn(II), Cd(II), Hg(II), Co(II), Ni(II), Cu(II), V(IV), Fe(III) and Ag(I) were synthesized and characterized by standard procedures . The parent sulfonamide and its metal complexes are potent inhibitors of two carbonic anhydrase (CA) isozymes, CA I and II, and they might possess applications as selective cerebrovasodilating agents."}
+{"text": "Correction to: Blood Cancer Journal (2018) 8: 6810.1038/s41408-018-0103-6;Published online 19 July 2018MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine and Department of Haematology, University of Oxford and Oxford University Hospitals NHS Trust, Oxford, UKNIHR Oxford Biomedical Research Centre, Oxford, UKSince the publication of the original article the authors noticed the the affiliation details for Paresh Vyas are incorrect. The correct affiliation details for this author are given below:"}
+{"text": "Nature Communications 10.1038/s41467-018-07467-5; published online 03 December 2018Correction to: The original version of this Article contained errors in the author affiliations.Affiliation 2 incorrectly read \u2018Department of Biochemistry and Molecular Genetics and Breast Surgery, Ehime University Graduate School of Medicine, 7910295, Japan\u2019 and affiliation 3 incorrectly read \u2018Department of Hepato-Biliary-Pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Matsuyama 7910295, Japan.\u2019These errors have now been corrected in both the PDF and HTML versions of the Article."}
+{"text": "This article has been corrected: The correct Acknowledgments and Funding information is given below:ACKNOWLEDGMENTS AND FUNDINGThis study was supported by grants from the Ministry of Science and Technology , the Kaohsiung Medical University \u201cAim for the Top 500 Universities Grant\u201d (Grant No. KMU-TP105C05), the Kaohsiung Medical University \u201cAim for the Top Journals Grant\u201d (Grant No. KMU-DT106005), and the Kaohsiung Medical University Hospital Research Foundation (KMUH106-6R13).https://doi.org/10.18632/oncotarget.21022Original article: Oncotarget. 2017; 8:104831-104854."}
+{"text": "Scientific Reports 10.1038/s41598-017-11606-1, published online 11 September 2017Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis work was supported by Malta Council of Science and Technology, grant R&I-2013-14 EPILEFREE to GDG. RC was supported by fellowship funded by EPILEFREE.\u201dshould read:\u201cThis work was supported by Malta Council of Science and Technology, grant R&I-2013-14 EPILEFREE to GDG. RC was supported by fellowship funded by EPILEFREE. MP was supported by a Research Officer Fellowship from the Faculty of Medicine and Surgery, University of Malta. The authors acknowledge the practical contribution of doctoral student Ms Maria Vella.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-018-30578-4, published online 13 August 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cLR is supported by Finep (1355/10) and CNPq (202077/2015-2). GP is supported by FAPESP (2014/06863-3) and CNPq (441878/2014-8). The Villum Center for Bioanalytical Sciences at University of Southern Denmark is acknowledged for access to advanced mass spectrometric instrumentation.\u201dshould read:\u201cLR is supported by Finep (1355/10) and CNPq (202077/2015-2). GP is supported by FAPESP (2014/06863-3) and CNPq (441878/2014-8). The Villum Center for Bioanalytical Sciences at University of Southern Denmark is acknowledged for access to advanced mass spectrometric instrumentation.Prof. Gilberto B. Domont and Prof. Fabio C.S. Nogueira from the Federal University of Rio de Janeiro, Brazil are acknowledged for critical discussion during the revision of the paper.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-017-09543-0, published online 29 August 2017Correction to: The Acknowledgements section in this Article is incorrect.\u201cThis research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MEST) (No. 2015M3A9E2028643).\u201dshould read:\u201cThis research was supported by the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning (Grant No. 2012\u2013049729)\u201d."}
+{"text": "Scientific Reports 10.1038/s41598-019-50000-x, published online 19 September 2019Correction to: The Acknowledgements section in this Article is incomplete.\u201cWork at Brookhaven National Laboratory was supported by US DOE, Office of Science, Office of Basic Energy Sciences under contract DE-SC0012704.\u201dshould read:\u201cThis work was funded by the Computation Material Science Program (Y.L. and C.P.). TEM studies at Brookhaven National Laboratory were supported by US DOE, Office of Science, Office of Basic Energy Sciences under contract DE-SC0012704.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-017-18851-4, published online 12 January 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cWe thank Mr. N. K. Skamangas for technical support and Dr. A. Kovoor for the D2 receptor expression plasmid, Dr. H. Itoh for G\u03b1oA and Dr. N. Lambert for sharing the G\u03b2\u03b3-Venus constructs. This work was supported by NIH grants DA036596 and DA026405 (KAM). MYN is supported by Israel Science Foundation grant 432/12 and Chief Scientist Ministry of Health (the ERA-NET network) and grant no. 3-9543 from the Chief Scientist Office of the Ministry of Health, Israel via the ERA-net network. MK is supported by Israel Science Foundation grant numbers 1454/13, 1959/13, 2155/15. YS is supported by the Israel Science Foundation grant numbers 1604/13 and 877/13, the ERC (StG-335377), by the Henry Chanoch Krenter Institute for Biomedical Imaging and Genomics, the estate of Alice Schwarz-Gardos, the estate of John Hunter, the Knell Family, the Peter and Patricia Gruber Award and the Hamburger Family. Lady Davis Fellowship to ADP is gratefully acknowledged. NKH and RAS are supported by fellowships from the National Health and Medical Research Council of Australia.\u201dshould read:\u201cWe thank Mr. N. K. Skamangas for technical support and Dr. A. Kovoor for the D2 receptor expression plasmid, Dr. H. Itoh for G\u03b1oA and Dr. N. Lambert for sharing the G\u03b2\u03b3-Venus constructs. This work was supported by NIH grants DA036596 and DA026405 (KAM). MYN is supported by Israel Science Foundation grant 432/12 and Chief Scientist Ministry of Health (the ERA-NET network) and grant no. 3-9543 from the Chief Scientist Office of the Ministry of Health, Israel via the ERA-net network. MK is supported by Israel Science Foundation grant numbers 1454/13, 1959/13, 2155/15. YS is supported by the Israel Science Foundation grant numbers 1604/13 and 877/13, the ERC (StG-335377), The Minerva Foundation Grant, by the Henry Chanoch Krenter Institute for Biomedical Imaging and Genomics, the estate of Alice Schwarz-Gardos, the estate of John Hunter, the Knell Family, the Peter and Patricia Gruber Award and the Hamburger Family. Lady Davis Fellowship to ADP is gratefully acknowledged. NKH and RAS are supported by fellowships from the National Health and Medical Research Council of Australia.\u201d"}
+{"text": "Correction to: BMC Med Inform Decis Makhttps://doi.org/10.1186/s12911-018-0696-5After publication of this supplement article , it was The correct affiliation of the first and correspondence authors is \u2018Guangdong Provincial Key Laboratory of Medical Image Processing, School of Biomedical Engineering, Southern Medical University, Guangzhou, China\u2019."}
+{"text": "Nancy Bennett, University of Rochester Medical Center, and Monica Farley, Veterans Affairs Medical Center and Emory University Department of Medicine.In the report \u201cUse of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged \u226565 Years: Updated Recommendations of the Advisory Committee on Immunization Practices,\u201d on page 1074, the ACIP Pneumococcal Vaccines Work Group should have included"}
+{"text": "Scientific Reports 10.1038/s41598-018-29524-1, published online 10 September 2018Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cThis work was supported by the National Natural Science Foundation of China (No. 21677071) and the Jiangsu Natural Science Foundation .\u201dshould read:\u201cThis work was supported by the National Natural Science Foundation of China (No. 21677071) and the Jiangsu Natural Science Foundation .\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-018-30851-6, published online 22 August 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis work was supported by Sao Paulo Research Foundation, (FAPESP) grant 2009/53904-9 and grant 2012/15165-2, Experimental Therapeutic Laboratory I (LIM 20), School of Medicine, University of Sao Paulo, School of Medicine Foundation (FFM/USP) and Financial Assistance to Educational Project or Research (AUXPE/PROAP) grant 2696/2013.\u201dshould read:\u201cThis work was supported by Sao Paulo Research Foundation, (FAPESP) grants 2009/53904-9, 2012/15165-2 and 2018/20380-6, Experimental Therapeutic Laboratory I (LIM 20), School of Medicine, University of Sao Paulo, School of Medicine Foundation (FFM/USP) and Financial Assistance to Educational Project or Research (AUXPE/PROAP) grant 2696/2013.\u201d"}
+{"text": "Correction to: Acta neuropathol commun (2019) 7: 4https://doi.org/10.1186/s40478-018-0654-6Alzheimer Society Research Program (ASRP) from the Alzheimer Society of Canada\u201d was missing. In this correction article the updated funding acknowledgement is shown. The missing funding acknowledgement has been indicated in bold.In the original publication of this article , the funThe Dementia Research Centre is supported by Alzheimer\u2019s Research UK, Brain Research Trust, and The Wolfson Foundation. This work was supported by the NIHR Queen Square Dementia Biomedical Research Unit and the NIHR UCL/H Biomedical Research Centre, the MRC UK GENFI grant and the Alzheimer\u2019s Society.IFH is funded by a research grant from Eli Lilly and Company, and the Engineering and Physical Sciences Research Council (EPSRC) UK (EP/N034864/1).JMO\u2019C is funded by UK Medical Research Council (MRC) Doctoral Training Grant Studentship (MR/J500422/1).LC is funded by an unrestricted grant from OPTOS Plc. Ltd.and a proportion of funding from the Alzheimer Society of Canada through the Alzheimer Society Research Program (ASRP).DM received a proportion of funding from EPSRC studentship from UCL\u2019s Centre for Doctoral Training in Medical Imaging, JDR is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH).MFL receives funding from BBSRC/AstraZeneca Industrial Partnership Studentship (BB/E528979/1), the UK Regenerative Medicine Platform Safety Hub (MR/K026739/1), Eli Lilly and Company, and the EPSRC (EP/N034864/1).IL receives funding from the Bill Brown Charitable Trust, Moorfields Eye Hospital Special Trustees and Mercer Fund from Fight for Sight."}
+{"text": "Nature Communications; 10.1038/s41467-019-08326-7; published online 29 January 2019.Correction to: The original version of this article incorrectly listed the present address of Bo Wu as \u2018Present address: Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou, Guangdong Province 510006, China\u2019. This is the author\u2019s primary affiliation. This has been corrected in both the PDF and HTML versions of the article."}
+{"text": "Scientific Reports 10.1038/s41598-018-32298-1, published online 17 September 2018Correction to: The Acknowledgements section in this Article in incomplete.\u201cS. Abate of CNR-SPIN Salerno is acknowledged for his valuable technical support. This work is partially supported by University of Salerno through grants FARB15PAGAN and FARB16CAVAL.\u201dshould read:\u201cS. Abate of CNR-SPIN Salerno is acknowledged for his valuable technical support. This work is partially supported by University of Salerno through grants FARB15PAGAN and FARB16CAVAL.A.V.U. acknowledges partial support from the Ministry of Education and Science of the Russian Federation in the framework of Increase Competitiveness Program of the National University of Science and Technology MISIS (Contract No. K2-2017-081).\u201d"}
+{"text": "Nature Communications 10.1038/s41467-019-09737-2, published online 15 April 2019.Correction to: The original version of this Article contained an error in the Acknowledgements, which incorrectly omitted from the end the following: \u2018J. Kang and L.W. Wang were supported by the Director, Office of Science, the Office of Basic Energy Sciences (BES), Materials Sciences and Engineering (MSE) Division of the U.S. Department of Energy (DOE) through the organic/inorganic nanocomposite program (KC3104) under contract DE-AC02-05CH11231. It used the computational resource of the Oak Ridge Leadership Computing Facility at the Oak Ridge National Laboratory through the INCITE project.\u2019 This has been corrected in both the PDF and HTML versions of the Article."}
+{"text": "Dr. Gelu Onose - 54 years ; graduated, in 1982, from the Faculty of General Medicine, within the (former) Institute of Medicine and Pharmacy, in BucharestProfessor at the (State) University of Medicine and Pharmacy (UMF) \u201cCarol Davila\u201d, in Bucharest, Romania - the M6 Chair- MD; - PhD; - MSc- Senior Physician of : - Physical & Rehabilitation Medicine (PRM) and- - Gerontology & Geriatrics (G-G)\u2022Chief of the M6 Chair of the \u201cC. Davila\u201d UMF and of the PRM Discipline and of the Physical and  Rehabilitation Clinic Division of the UMF, at the Teaching Emergency Hospital \u201cBagdasar-Arseni\u201d (TEHBA), in Bucharest\u2022President/ Co-Founder of the Romanian Society for Neurorehabilitation (RoSNeRa) - affiliated to the World Federation for NeuroRehabilitation (WFNR) - member of its Management Committee - and respectively, of the Romanian Society for Spinal Cord Pathology, Therapy and Rehabilitation in SCI (RoSCoS) - affiliated to the Internationa Spinal Cord Society (ISCoS) and to the European Spinal Cord Injury Federation (ESCIF)\u2022member of the Scientific Committee, afferent to the Prezidium of the World Academy for Multidisciplinary Neurotraumatology (AMN)A \u2022Selected and invited by Thomson Reuters, to participate in the invitation-only Academic Reputation Survey\u201d, within its related partnership with Times Higher Education's influential World University Rankings.(2010 and 2011)\u2022Invitated Peer-Reviewer (in 2010) by the \u201cJournal of Molecular Histology\u201d (ISI Thomson Reuters rated)\u2022A member of the Board of the Romanian Society of Physical and Rehabilitation Medicine\u20228 published medical books - one of them : \u201cThe Spondyloarthropathies\u201d, and received, in 2002, the \u201cIuliu Hatieganu\u201d Award of The Romanian Academy)\u20222 chapters within medical books\u2022About 200 scientific works and papers - communicated within national and international scientific meetings and/or published in peer-reviewed or non peer-reviewed medical journals - and professional interviews/ articles, in mass-media\u20223 Invention Certificates, appointed by the State Office for Inventions and Marks\u2022Gold Medal at the International Saloon of Inventions, Geneva/ Switzerland (2008)Main awards: the \u201cIuliu Hatieganu\u201d Award of The Romanian Academy (2002); the Award of the (Romanian) National Authority for Scientific Research; the \u2022member of the Editorial Board of medical journals:A \u2022\u201cJournal of Medicine and Life\u201d \u2022\u201cInfomedica\u201d\u2022(Romanian) \u201cRehabilitation, Physical Medicine and Balneology\u201d\u2022\u201cRomanian Neurosurgery\u201d\u2022Main co-organizer of the  National Conference of Neurosurgery and NeuroRehabilitation, with International participation"}
+{"text": "Nature Communications; 10.1038/s41467-019-08365-0; published online 25 January 2019Correction to: The original version of this Article contained an error in the author affiliations.Affiliation 5 incorrectly read \u2018Laboratory for Prediction of Cell Systems Dynamics, RIKEN Center for Biosystems Dynamics Research (BDR), Suite, Hyogo 565-0874, Japan.\u2019 This has now been corrected in both the PDF and HTML versions of the Article."}
+{"text": "In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways\u201d [In the article titled \u201cathways\u201d , a grantWe thank Morouge Alramadhan for technical support. We also thank the Universidad El Bosque for financial support for whole genome sequencing (Grant no. PCI-2017-9447). This work was supported by the National Institutes of Health (Grant nos. K08-AI113317 (TTT) and K24-AI121296 (CAA)), the Millennium Science Initiative of the Ministry of Economy, Development and Tourism, Government of Chile (JMM), and the Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT), FONDECYT 1171805, Ministry of Education, Government of Chile (JMM)."}
+{"text": "Correction to: Stem Cell Res Therhttps://doi.org/10.1186/s13287-015-0078-1The original article  containsAcknowledgementsThis work was supported by the Ministry of Science and Technology of China ; the National Natural Science Foundation of China ; National program for support of Top-notch young professionals (J.X.); Shanghai City, the medical cooperation projects (11DZ192130C); Projects of International Cooperation and Exchanges NSFC (81261130318); the Fundamental Research Funds for the Central Universities; Tongji University Talents Training Program (2011KJ051); New Century Excellent Talents in University (NCET-10-0606); 51th China Postdoctoral surface Project (2012 M510890); Shanghai Postdoctoral Research Funding Scheme of 2012 (12R21416200)."}
+{"text": "Scientific Reports 10.1038/s41598-018-36580-0, published online 28 January 2019Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis research was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (NRF-2017R1A2B2005081); and by the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, & Future Planning (2016M3C7A1913844).\u201dshould read:\u201cThis research was supported by Research of Korea Centers for Disease Control and Prevention (2018-ER6203-01); the Brain Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Science, ICT & Future Planning (2016M3C7A1913844); the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIP) (NRF-2017R1A2B2005081); and a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea(HI18C1629).\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-018-22300-1, published online 02 March 2018Correction to: The Acknowledgements section in this Article is incomplete.P. aeruginosa PA14 and pEX18Gm . We thank Shanghai Synchrotron Radiation Facility (SSRF) beamline BL17U for beamtime allowance. We thank the staffs of the National Center for Protein Sciences Shanghai (NCPSS) beamlines BL-18U and BL-19U and SSRF, Shanghai, People\u2019s Republic of China, for assistance during data collection.\u201d\u201cWe thank Matthew R Parsek for the gifts of should read:P. aeruginosa PA14 and pEX18Gm . We thank Shanghai Synchrotron Radiation Facility (SSRF) beamline BL17U for beamtime allowance. We thank the staffs of the National Center for Protein Sciences Shanghai (NCPSS) beamlines BL-18U and BL-19U and SSRF, Shanghai, People\u2019s Republic of China, for assistance during data collection.\u201d\u201cThe work was supported by National Natural Science Foundation of China (Grant Nos. 81670008 and 81501787) and National Key Research and Development Plan (Grant No. SQ2016YFJC040104). We thank Matthew R Parsek for the gifts of"}
+{"text": "Scientific Reports 10.1038/s41598-019-42237-3, published online 16 April 2019Correction to: The Acknowledgements section of this Article is incomplete.\u201cFunded by NIH R21 CA184612-01 and Melanoma Research Foundation CDA Grant Award (A.V.). NIH R01 CA204806 (N.L.). We would like to acknowledge the important technical contributions and advice of Kimberlyn Acklin, MS, SCYM(ASCP), at The George Washington University Flow Cytometry Core Facility and Bethany Rentz, RVT, at The George Washington University Office of Animal Research.\u201dshould read:\u201cFunded by NIH R21 CA184612-01 and Melanoma Research Foundation CDA Grant Award (A.V.), NIH R01 CA204806 (N.L.), Czech Science Foundation (No 15-19640S), the CAS (RVO: 86652036) and the project \u201eBIOCEV\u201d (CZ.1.05/1.1.00/02.0109) from the ERDF (C.B.). We would like to acknowledge the important technical contributions and the advice of Kimberlyn Acklin, MS, SCYM(ASCP), at The George Washington University Flow Cytometry Core Facility and Bethany Rentz, RVT, at The George Washington University Office of Animal Research.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-017-05102-9, published online 07 July 2017Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cThis study was supported by a BrightFocus Foundation grant M2015221 (MK), NIH grants EY023468 (WMD), EY0123456 (CBR), EY023287 (WDS), EY022359 (WDS), EY019696 (WDS), a Glaucoma Research Foundation Shaffer Grant , and a grant from the Foundation Fighting Blindness (CBR). A Core Grant for Vision Research  from NEI (to Duke University), supported much of the work, including the mass spectrometric analyses carried out by NPS.\u201dshould read:\u201cThis study was supported by a BrightFocus Foundation grant M2015221 (MK), NIH grants EY023468 (WMD), EY026161 (CBR), EY023287 (WDS), EY022359 (WDS), EY019696 (WDS), a Glaucoma Research Foundation Shaffer Grant , and a grant from the Foundation Fighting Blindness (CBR). A Core Grant for Vision Research  from NEI (to Duke University), supported much of the work, including the mass spectrometric analyses carried out by NPS.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-019-46182-z, published online 08 July 2019Correction to: The original version of this Article omitted an affiliation for Ilona Wehl and Stefan Br\u00e4se. The correct affiliations for Ilona Wehl and Stefan Br\u00e4se are listed below:Institute of Organic Chemistry, Karlsruhe Institute of Technology (KIT), Fritz-Haber-Weg 6, D-76131 Karlsruhe, Germany.Institute of Toxicology and Genetics (ITG), Karlsruhe Institute of Technology (KIT), Hermann von Helmholtz Platz 1 D-76344 Eggenstein-Leopoldshafen, Germany.Additionally, in the Supplementary Information file originally published with this Article the treatment in Supplementary Figure S1 was incorrectly listed as CoQ Peptoid.These errors have now been corrected in the HTML and PDF versions of this Article, and in the accompanying Supplemental Material."}
+{"text": "Scientific Reports 10.1038/s41598-018-30048-x, published online 17 August 2018Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cthe 4th Three-year Action Plan for Public Health of Shanghai (15GWZK0101) from Shanghai Municipal Commission of Health and Family Planning\u201dshould read:\u201cthe 4th Three-year Action Plan for Public Health of Shanghai (GWTD2015S01) from Shanghai Municipal Commission of Health and Family Planning\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-018-23875-5, published online 03 April 2018Correction to: The Acknowledgements section in this article is incomplete:\u201cWe would like to thank Kyunghwa Han for her statistical advice. This study was supported by the National Research Foundation of Korea Grant funded by the Korean Government (NRF-2014R1A1A2055116) and faculty research grants from Yonsei University College of Medicine (4-2013-0111).\u201dshould read:\u201cWe would like to thank Kyunghwa Han for her statistical advice. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2014R1A1A2055116) and faculty research grants from Yonsei University College of Medicine (6-2013-0058).\u201d"}
+{"text": "Two code files and one dataset related to Olympic Twitter activity are the foundation for this article. Through Twitter's Spritzer streaming API (Application Programming Interface), we collected over 430 million tweets from May 12th, 2016 to September 12th, 2016 windowing the Rio de Janeiro Olympics and Paralympics. We cleaned and filtered these tweets to contain Olympic-related content. We then analyzed the raw data of 21,218,652 tweets including location data, language, and tweet content to distill the sentiment and emotions of Twitter users pertaining to the Olympic Games Kassens-Noor E. et\u00a0al., 2019. We generalized the original data set to comply with the Twitter's Terms of Service and Developer agreement, 2018. We present the modified dataset and accompanying code files in this article to suggest using both for further analysis on sentiment and emotions related to the Rio de Janeiro Olympics and for comparative research on imagery and perceptions of other Olympic Games. For example, The Olympic Games increase visibility of host cities and broadcast the host's imagery across the world 1.1Tweets were downloaded from Twitter's Application Program Interface (Spritzer Stream) from May 12th, 2016 to September 12th, 2016 based on Olympic Game keywords and associated hashtags. We searched for hashtags related to all modern Summer and Winter Olympic Games, but only the following captured tweets: Olympic (Olympics/#olympic/#olympics/Olympic Games/Olympic), Rio (Rio2016/#Rio2016), Tokyo (Tokyo2020/#Tokyo2020), London (London2012/#London2012), International Olympic Committee (IOC/#IOC), Los Angeles (LA2024/#LA2024), Beijing (Beijing2008/#Beijing2008/Beijing2022/#Beijing2022), Paris (Paris2024/#Paris2024), Sydney (Sydney2000/#Sydney2000), Budapest (Budapest2024/#Budapest2024), Atlanta (Atlanta1996/#Atlanta1996), Athens (Athens2004/#Athens2004), Rome (Rome2024/#Rome2024), Sochi (Sochi2014/#Sochi2014), Barcelona (Barcelona1992/#Barcelona1992), Seoul (Seoul1988/#Seoul1988), Vancouver (Vancouver2010/#Vancouver2010), Hamburg (Hamburg2024/#Hamburg2024), Turin (Turin2006/#Turin2006), Calgary , Salt Lake City , and Pyeongchang (Pyeongchang2018/#Pyeongchang2018).Code file Execute and associated Code file Argument filtered the captured tweets to (a) remove retweets and duplicate tweets (b) search for and record Olympic Game keywords for all remaining tweets (c) search for and record all Sentiment and emotion keywords for every tweet based on Mohammand and Turney's"}
+{"text": "Panel A) chest X-ray and (Panel B) transthoracic echocardiography, with echocardiographic features of early cardiac tamponade, including diastolic collapse of the right ventricular free wall  abnormal tracer uptake in the heart, particularly the right atrium (asterisk) and (Panel D) lytic bone lesions in the spine (asterisk). Cardiac magnetic resonance imaging demonstrated an epicardial mass encasing the heart, the right coronary artery (dashed arrow), and superior vena cava; (Panel E) four-chamber and (Panel F) short-axis steady-state free precession cine images. The mass had high-native T1 values, was vascular on first pass perfusion imaging (Panel G) gadolinium contrast, suggestive of a solid tumour. Pericardial biopsy demonstrated a diffuse polymorphic cellular infiltrate, consisting of lymphocytes, plasma cells, and numerous large multi-nucleated cells with ill-defined pale cytoplasm. These abnormal cells displayed (Panel H) emperipolesis (arrow) and stained positive for CD163 and (Panel I) S100 (arrow), but not CD1a or Langerin. The underlying diagnosis was Rosai\u2013Dorfman disease; a rare idiopathic non-clonal proliferative histiocytic disorder that involves the heart in <1% of cases. Cardiac involvement in Rosai-Dorfman disease can present as epicardial disease, with pulmonary arterial involvement, or as an intracardiac mass.A 40-year-old man presented to hospital with exertional dyspnoea. A large pericardial effusion was identified by (J.M.T. was supported by the Wellcome Trust [211100/Z/18/Z] and the National Institute for Health Research. C.M. was supported directly and indirectly by the National Institute for Health Research University College London Hospitals Biomedical Research Centre, and the National Institute for Health Research Barts Biomedical Research Centre. jey232_SuppClick here for additional data file."}
+{"text": "The correct Material and Methods of the abstract is: Material and Methods: A total of 120 human premolars were randomly divided into two groups (n=60) according to the orthodontic adhesive used: APC Flash-Free Adhesive Coated Appliance System (APC FF) or Transbond PLUS Color Change Adhesive (TP), as control. A SBS test was performed and ARI value for each specimen was also assessed. Results were analyzed by two-way ANOVA and Tukey's Chi-square test ("}
+{"text": "Nature Communications; 10.1038/s41467-019-08506-5; published online 13 February 2019Correction to: The original version of this Article incorrectly omitted an affiliation of Kaikai Li: \u2018Shenzhen Environmental Science and New Energy Technology Engineering Laboratory, Tsinghua-Berkeley Shenzhen Institute (TBSI), Tsinghua University, Shenzhen 518055, China\u2019. This has been corrected in both the PDF and HTML versions of the Article."}
+{"text": "Nature Communications 10.1038/s41467-018-06088-2; published online 11 September 2018Correction to: The original version of this article incorrectly omitted an affiliation of Hongming Weng: \u201cBeijing National Laboratory for Condensed Matter Physics and Institute of Physics, Chinese Academy of Sciences, 100190, Beijing, China\u201dThis has been corrected in both the PDF and HTML versions of the article."}
+{"text": "Correction to: BMC Health Serv Res (2019) 19:743https://doi.org/10.1186/s12913-019-4578-zIn the original publication of this article , the autThe authors thank the Infection Prevention and Control (IPC) Program at Alberta Health Services for providing access to the IPC surveillance platform data."}
+{"text": "Following publication of the original article , South Coast Perioperative Audit and Research Collaboration (SPARC).Clare M. Morkane"}
+{"text": "The following information is missing from the Funding section: This study was also funded by the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (BIRAC/BT/AIR0275/PACE-12/17)."}
+{"text": "Correction to: BMC Medical Genomics 2019, 12(Suppl 1):18.https://doi.org/10.1186/s12920-018-0460-9Following publication of the original article , the autThis research and this article\u2019s publication costs were supported partially by the NCI Cancer Center Shared Resources (NIH-NCI P30CA54174 to YC), NIH , CPRIT (RP160732 to YC), and San Antonio Life Science Institute . AG is supported by the NIH/NCATS TL1 Translational Science Training award (TL1TR002647) and the AACR-AstraZeneca Stimulating Therapeutic Advances through Research Training grant. The funding sources had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript."}
+{"text": "Nature Communications 10.1038/s41467-018-06769-y; published online 23 October 2018Correction to: In the original PDF version of this article, affiliation 1, \u2018Institute for Diabetes and Obesity, Helmholtz Diabetes Center (HDC), Helmholtz Zentrum Muenchen & German Center for Diabetes Research (DZD), Neuherberg, Germany\u2019, was incorrectly given as \u2018Institute of Diabetes and Regeneration Research, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), Neuherberg, Germany \u2018. This has now been corrected in the PDF version of the article; the HTML version was correct at the time of publication."}
+{"text": "Correction to: Inflamm Regen (2017) 37:2010.1186/s41232-017-0051-8After publication of the original article , it cameIn addition, the following funding information should have been included as part of Declarations:\u201cSandesh Panthi was supported by Basic Science Research Program through the Korean National Research Foundation (NRF) funded by the Ministry of Science, ICT and Future Planning .\u201d"}
+{"text": "This article has been corrected: The correct Grant number information is given below:ACKNOWLEDGMENTS AND FUNDINGThis work was supported by the Public Welfare Technology Application Research project of Zhejiang Provincial Science, Technology Department of China (Grant No. 2014C33198), Zhejiang Provincial Natural Science Foundation of China (Grant No. LY16H160015), National Natural Science Foundation of China , scientific research foundation of the ministry of public health (WKJ2012-2-009), Zhejiang province key project of science and technology (2014C04008-2).51773-51783. https://doi.org/10.18632/oncotarget.10575Original article: Oncotarget. 2016; 7:"}
+{"text": "This article has been corrected: The proper Grant Support information is shown below:This research was supported by a Department of Defense Prostate Cancer Research Program Early Investigator Research Award \u2013 Predoctoral (MS), Prostate Cancer Foundation Young Investigator Award (AML), Randy Shaver Foundation Research Award (AML), Paul Calabresi NCI K12 Award through Mayo Clinic (AML) and an American Cancer Society Institutional Research Grant (AML).36693-36704. https://doi.org/10.18632/oncotarget.26401Original article: Oncotarget. 2018; 9:36693\u201336704."}
+{"text": "In the Acknowledgement section of the paper, \u201cThis study was supported in part by United States National Institutes of Health (NIH) Academic Research Enhancement Award 1R15GM114739 and National Institute of General Medical Sciences (NIH/NIGMS) 5P20GM103429, United States Food and Drug Administration (FDA) HHSF223201510172C through Arkansas Research Alliance (ARA) BAA-15-00121 and Arkansas Science and Technology Authority (ASTA) Basic Science Research 15-B-23 and 15-B-38\u201d should read asNational Institutes of Health (NIH) Academic Research Enhancement Award 1R15GM114739 and National Institute of General Medical Sciences (NIH/NIGMS) 5P20GM103429, Arkansas Science and Technology Authority (ASTA) Basic Science Research 15-B-23 and 15-B-38 and the Food and Drug Administration (FDA), contract No. HHSF223201510172C and HHSF223201610111C. However, the information contained herein represents the position of the author(s) and not necessarily that of the NIH and FDA.\u201d\u201cThis study was partially supported by United States The authors would like to apologise for any inconvenience caused."}
+{"text": "Scientific Reports 10.1038/s41598-018-23497-x, published online 23 March 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cThis research was supported by Special Fund for Forest Scientific Research in the Public Welfare (Grant No. 201504501), Zhejiang Xinmiao Talents Program (Grant No. 2018R46), Key Laboratory of Bio-based Material Science & Technology (Northeast Forestry University), Ministry of Education (Grant No. SWZCL2016-3) and Zhejiang Xinmiao Talents Program (Grant No. 2017R412011).\u201dshould read:\u201cThis research was supported by Special Fund for Forest Scientific Research in the Public Welfare (Grant No. 201504501), Zhejiang Xinmiao Talents Program (Grant No. 2018R412047), Key Laboratory of Bio-based Material Science & Technology (Northeast Forestry University), Ministry of Education (Grant No. SWZCL2016-3) and Zhejiang Xinmiao Talents Program (Grant No. 2017R412011).\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-018-23407-1, published online 23 March 2018Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cWe would like to thank all the research team members from Clinical Research Unit and clinical doctors from diabetes centre at Khoo Teck Puat Hospital, Singapore for assistance with participant recruitment and data input for the DN and SMART2D and follow-up study. This study was supported by Alexandra Health Enabling Grant (AHEG1504) and Small Innovation Grants (AHPL SIG I/13031 & STAR17109).\u201dshould read:\u201cWe would like to thank all the research team members from Clinical Research Unit and clinical doctors from diabetes centre at Khoo Teck Puat Hospital, Singapore for assistance with participant recruitment and data input for the DN and SMART2D and follow-up study. This study was supported by Alexandra Health Enabling Grant (AHEG1504), Small Innovation Grants (AHPL SIG I/13031 & STAR17109) and Singapore National Medical Research Council Grants (NMRC/PPG/AH (KTPH)/2011 and NMRC/CIRG/1398/2014).\u201d"}
+{"text": "In the funding statement the following sentence was omitted:\u201cThis work was supported in part by NCI Cancer Systems Biology Center U54 CA209988.\u201dThe correct funding statement is as follows:www.nsfgrfp.org) and was supported by the Berkeley Fellowship for Graduate Study (grad.berkeley.edu) and the Tau Beta Pi Engineering Honors Society, Williams No. 35 (www.tbp.org). CJT and MPC were supported by the National Institutes of Health (NIH) Center \u201cSystems Biology of Collective Cells Decisions\u201d through Stanford University NIH #P50GM107615, and by the National Cancer Institute (NCI) CSBC consortia \u201cModel-Based Predictions of Responses to RTK Pathway Therapies\u201d through OHSU NCI #U54CA112970 and \u201cMeasuring, Modeling and Controlling Heterogeneity\u201d through OHSU NCI #1U54CA209988-01A1. TR was supported by the Ruth L. Kirschstein T32 Program in Molecular and Cellular Biosciences Training Grant 5T32GM071338-09, Vertex Pharmaceuticals Scholarship (www.vrtx.com), and Tartar Trust Fellowship (www.ohsu.edu). EML was supported by the American Cancer Society Postdoctoral Fellowship (www.cancer.org). RCS is supported by the National Institutes of Health, National Cancer Institute R01-CA196228, R01-CA186241, and U54-CA209988, the Department of Defense Breast Cancer Research Program BC160550P1, the Colson Family Foundation , and the Prospect Creek Foundation . This work was supported in part by NCI Cancer Systems Biology Center U54 CA209988. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.MPC is supported by a National Science Foundation Graduate Research Fellowship ("}
+{"text": "Correction to: J Hematol Oncolhttps://doi.org/10.1186/s13045-018-0658-5The original article  containsFundingThis work was supported by the grants from Kyung Hee University (KHU20170844 for JW Choi) and the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea ."}
+{"text": "Nature Communications 10.1038/s41467-019-10079-2, published online 9 May 2019.Correction to: The original version of this Comment contained errors in the legend of Figure 2, in which the locations of the fifteenth and sixteenth GBA members were incorrectly given as \u2018(15) Australian Genome Foundry, Macquarie University; (16) Australian Foundry for Advanced Biomanufacturing, University of Queensland\u2019. The correct version replaces this with \u2018(15) Australian Foundry for Advanced Biomanufacturing (AusFAB), University of Queensland and (16) Australian Genome Foundry, Macquarie University\u2019. This has been corrected in both the PDF and HTML versions of the Comment."}
+{"text": "In the article titled \u201cSerial Changes of Neointimal Tissue after Everolimus-Eluting Stent Implantation in Porcine Coronary Artery: An Optical Coherence Tomography Analysis\u201d , a resea\u201cThis study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (nos. A085012 and A102064), grants from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (no. A085136), and the Cardiovascular Research Center, Seoul, Republic of Korea, and a research grant from Yonsei University, College of Medicine (6-2011-00217).\u201d"}
+{"text": "This article has been corrected: The correct Grant Support information is given below:GRANT SUPPORTThis study was financially supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2016R1D1A3B03930581 to YS Jeong), Medical Research Center Program (2017R1A5A2015369), Yonsei University Future-leading Research Initiative of 2015 (RMS2-2015-22-0094), JJ-2017-1 to YS Jeong, and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI17C0039).82491-82505. https://doi.org/10.18632/oncotarget.19700Original article: Oncotarget. 2017; 8:"}
+{"text": "The fourteenth author's name is spelled incorrectly. The correct name is: Patricia C. Salinas.The following information is also missing from the Funding statement: This study was supported by the MRC (MR/M024083/1) to PCS. The funding statement in full should read:This study was supported by grants from the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/M020991/1) and New Life Foundation (14-15/20) to SC-S and PLB; ERC (AdG 695709 DENDRITECIRCUITS to MH and StG 678790 NEWRON to CS-H) and the Wellcome Trust (PRF 536070) to MH; MRC (MR/M024083/1) to PCS. Additional support was funded by National Institute for Health Research (GOS ICH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."}
+{"text": "Scientific Reports 10.1038/s41598-019-49654-4, published online 13 September 2019Correction to: The Acknowledgements section in this Article is incomplete.\u201cWe thank J. Warren for help with the scanning electron microscopy (SEM) measurement. Work at Brookhaven National Laboratory was supported by US DOE, Office of Science, Office of Basic Energy Sciences under contract DE-SC0012704.\u201dshould read:\u201cWe thank J. Warren for help with the scanning electron microscopy (SEM) measurement. This work was funded by the Computation Material Science Program (Y.L. and C.P.). TEM studies at Brookhaven National Laboratory were supported by US DOE, Office of Science, Office of Basic Energy Sciences under contract DE-SC0012704.\u201d"}
+{"text": "In Silico Genome-Wide Analysis of the ATP-Binding Cassette Transporter Gene Family in Soybean (Glycine max L.) and Their Expression Profiling\u201d [In the article titled \u201cofiling\u201d , the AckThis work was financially supported by Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through Agri-Bio Industry Technology Development Program and financially supported by Ministry of Agriculture, Food and Rural Affairs (MAFRA) (117044-3)."}
+{"text": "Scientific Reports 10.1038/s41598-018-29065-7, published online 17 July 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cWe gratefully acknowledge the financial support from New York University Abu Dhabi (NYUAD) through the NYUAD Research Enhancement Fund as well as the ADEK Award for Research Excellence 2015 (Award number: AARE-073). The device fabrication was conducted in the microfabrication core facility of NYUAD.\u201dshould read:\u201cWe gratefully acknowledge the financial support from New York University Abu Dhabi (NYUAD) through the NYUAD Research Enhancement Fund as well as the ADEK Award for Research Excellence 2015 (Award number: AARE-073). The device fabrication was conducted in the microfabrication core facility of NYUAD.V.S. Pham and Q.V. Do are funded by Vietnam National Foundation for Science and Technology Development (NAFOSTED) under grant number 107.03-2016.11.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-018-29201-3, published online 27 August 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cThe authors would like to thank Lingjie Liao (China CDC), and Xingguang Li (China CDC) for technical support and analysis of the data. The authors would also like to thank the Group for the HIV Molecular Epidemiologic Survey. Contributing members of the Group [name of contributor (facility of the contributor)]: Yi Luan (Nanning CDC); Houjin Ma (Guilin CDC); Xing Liu (Liuzhou CDC); Mei Li (Qinzhou CDC); Ruiguo Ye (Yulin CDC); Daquan Luo (Baise CDC); Yanfei Meng (Guigang CDC); Shuyin zhao (Hezhou CDC); Bingjian Liang (Wuzhou CDC); Tianji Huang (Chongzuo CDC); Baohui Tang (Hechi CDC); Shuzhi Chen (Laibin CDC). Hao Zhu (Beihai CDC), Weifei Pang (Fangchenggang CDC). We would like to thank Editage [www.editage.cn] for English language editing.\u201dshould read:\u201cThe authors would like to thank Lingjie Liao (China CDC), and Xingguang Li (China CDC) for technical support and analysis of the data. The authors would also like to thank the Group for the HIV Molecular Epidemiologic Survey. Contributing members of the Group [name of contributor (facility of the contributor)]: Yi Luan (Nanning CDC); Houjin Ma (Guilin CDC); Xing Liu (Liuzhou CDC); Mei Li (Qinzhou CDC); Ruiguo Ye (Yulin CDC); Daquan Luo (Baise CDC); Yanfei Meng (Guigang CDC); Shuyin zhao (Hezhou CDC); Bingjian Liang (Wuzhou CDC); Tianji Huang (Chongzuo CDC); Baohui Tang (Hechi CDC); Shuzhi Chen (Laibin CDC). Hao Zhu (Beihai CDC), Weifei Pang (Fangchenggang CDC). We would like to thank Editage [www.editage.cn] for English language editing.This study was supported by the Guangxi Science and Technology Development plan (1298003-1-4), National Natural Science Foundation of China , Guangxi Science and Technology Bureau (AB16380213), Guangxi Bagui Honor Scholars, Ministry of Science and Technology of China (grant 2012ZX10001-002), Chinese State Key Laboratory of Infectious Disease Prevention and Control, and the International Development Research Center of Canada (grant 104519-010).\u201d"}
+{"text": "The following funding information and acknowledgment should have appeared in the article.Volume 9, issue 2, e00626-17, 2018, Artur Matysik was supported by the National Medical Research Council under its Clinical Basic Research Grant (NMRC/CBRG/0086/2015)."}
+{"text": "This article has been corrected: The 1st affiliation information has been updated. The proper affiliation is as follows:1State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China50642-50654. https://doi.org/10.18632/oncotarget.16892Original article: Oncotarget. 2017; 8:50642\u201350654."}
+{"text": "Correction to: Prog Orthod (2019) 20:25https://doi.org/10.1186/s40510-019-0282-0In the publication of this article , there aThe error:\u201cThis retrospective study was approved by the Institutional Review Board of XXXXX XXX University Medical Center (IRB No: K-2013-11018794). Skeletal Class III patients who had received bilateral sagittal split ramus osteotomy only by the same surgeon at the XXXXX XXX University Dental Hospital had been screened.\u201dShould instead read:\u201cThis retrospective study was approved by the Institutional Review Board of Kyung Hee University Medical Center (IRB No: K-2013-11018794). Skeletal Class III patients who had received bilateral sagittal split ramus osteotomy only by the same surgeon at the Kyung Hee University Dental Hospital had been screened.\u201dThe error:\u201cThis retrospective study was approved by the Institutional Review Board of XXXXX XXX University Medical Center (IRB No: K-2013-11018794).\u201dShould instead read:\u201cThis retrospective study was approved by the Institutional Review Board of Kyung Hee University Medical Center (IRB No: K-2013-11018794).\u201dThis has now been updated in the original article ."}
+{"text": "Correction to: BMC Systems Biology 20149 13:1https://doi.org/10.1186/s12918-018-0674-7Following publication of the original article , it was Correct:https://diacomp.org/; DK076169; sub-award #25034\u201375 to J.H.), and University of North Dakota Post-Doc Pilot Grant (to K.G.), and the North Dakota EPSCoR through National Science Foundation grant #OIA-1355466 (to B.A.M.). Funding bodies had no role in the design, execution, or analysis of this work.The National Institute of Diabetes and Digestive and Kidney Diseases , the NIDDK Diabetic Complications Consortium Pilot Grant , and University of North Dakota Post-Doc Pilot Grant (to K.G.). Funding bodies had no role in the design, execution, or analysis of this work.The National Institute of Diabetes and Digestive and Kidney Diseases , the NIDDK Diabetic Complications Consortium Pilot Grant (DiaComp,"}
+{"text": "Nature Communications 10.1038/s41467-018-05368-1; published online 03 August 2018Correction to: The original version of this article incorrectly omitted an affiliation of Patricia A. J. Muller: \u2018Cancer Research UK Manchester Institute, The University of Manchester | Alderley Park, Manchester, SK10 4TG, UK\u2019. This has been corrected in both the PDF and HTML versions of the article."}
+{"text": "Nature Communications; 10.1038/s41467-019-08824-8; published online 26 February 2019Correction to: The original version of this Article contained errors in the author affiliations.Affiliation 1 incorrectly read \u2018School of Chemical Engineering, University of New South Wales (UNSW), Sydney, NSW 2031, Australia\u2019 and affiliation 4 incorrectly read \u2018School of Engineering, RMIT University, Melbourne, VIC 3001, Australia.\u2019This has now been corrected in both the PDF and HTML versions of the Article."}
+{"text": "The following information is missing from the Funding section: The NE-CAT beamlines are funded by the NIH (NIGMS grant P41 GM103403 and NIH-ORIP HEI grant S10 RR029205), and used resources of the Advanced Photon Source at Argonne National Laboratory under DOE Contract No. DE-AC02-06CH11357."}
+{"text": "Scientific Reports 10.1038/s41598-018-26347-y, published online 21 May 2018Correction to: The Acknowledgements section in this Article is incomplete.\u201cWe thank to Dr. Leo Kurian and Dr. Peter Tsai for critical reading of the manuscript. We furthermore thank the Regional Computing Center of the University of Cologne (RRZK) for providing computing time on the DFG-funded HPC cluster CHEOPS as well as support. This work is supported by German Research Foundation , Cologne Fortune (MK), CureSMA (MK and MS), SMA Europe (MK), CECAD Exc-229 (NLK), AFM-Telethon (LTB), CMMC (BW) and EU FP7 NEUROMICS (BW).\u201dshould read:\u201cWe thank to Dr. Leo Kurian and Dr. Peter Tsai for critical reading of the manuscript. We furthermore thank the Regional Computing Center of the University of Cologne (RRZK) for providing computing time on the DFG-funded HPC cluster CHEOPS as well as support. This work is supported by German Research Foundation , Cologne Fortune (MK), CureSMA (MK and MS), SMA Europe (MK), Slaney Family Fund (MS), CECAD Exc-229 (NLK), AFM-Telethon (LTB), CMMC (BW) and EU FP7 NEUROMICS (BW).\u201d"}
+{"text": "Nature Communications 10.1038/s41467-019-08498-2, published online 08 February 2018Correction to: The original version of this Article contained an error in the first sentence of the Acknowledgements, which incorrectly read \u2018This publication was supported by Contract HR0011-15-C-0055 (DODOS) from the Defense Advanced Research Projects Agency (DARPA), Defense Sciences Office (DSO).\u2019 The correct version states \u2018Microsystems Technology Office (MTO)\u2019 in place of \u2018Defense Sciences Office (DSO)\u2019. This has been corrected in both the PDF and HTML versions of the Article."}
+{"text": "Volume 1 of Learning Health Systems. Reaching this milestone is thrilling for all of us who have been involved in getting the journal launched. We are keenly aware that this achievement would not have happened without the dedicated efforts and insightful comments of those individuals who accepted invitations to review submitted articles. In spite of busy schedules and full commitments, these individuals found the time and energy to contribute their expertise and suggestions to our authors to help ensure that their papers met (and often exceeded) this journal's high standards for publication. Please accept our sincere gratitude for a job well done!The publication of Issue 4 marks the completion of Editor in ChiefCharles P. Friedman, John Ainsworth (United Kingdom)Christel Anderson (United States)Holt Anderson (United States)Ruth Anderson (United States)Theodoros Arvanitis (United Kingdom)Bo Borgnakke (United States)Hendriek Boshuizen (Netherlands)Iain Buchan (United Kingdom)Michael Cantor (United States)Christopher Chute (United States)Laura Crawford (United States)Vasa Curcin (United Kingdom)Jennifer Dixon (United Kingdom)Stephen Duffield Patricia Dykes (United States)Lynn Etheredge (United States)Thomas Foley (United Kingdom)Oliver Gadabu (United States)Mari Greenberger (United States)Terry Hannan (United Kingdom)Wolfgang Kuchinke (Germany)Rebecca Kush (United States)Harold Lehmann (United States)Christopher Longhurst\u00a0(United States)David McCallie (United States)Mark McGilchrist (United Kingdom)Meryt McGindley (United States)Kenneth Mandl (United States)Erik Mayer (United Kingdom)Amalia Miller (United States)Megan Moncur (United States)Stephanie Morain (United States)Sally Okun (United States)Leon Osterweil (United States)Adam Porter\u00a0(United States)William Rouse (United States)Sonya Satveit\u00a0(Canada)Philip Scott (United Kingdom)Ben Shneiderman (United States)Jonathan Silverstein (United States)Sunnie Southern (United States)Kevin Sullivan (United States)Joshua Vest (United States)Jim Walker (United States)"}
+{"text": "Scientific Reports 10.1038/s41598-017-06943-0, published online 07 August 2017Correction to: This Article contains errors in the Acknowledgements section.\u201cThis work was supported by the Fundamental Research Funds for the Central Universities (Grant No. 310829165020) and the Shaanxi Province Science and Technology Development Program (Grant No. 2014K15\u201303\u201302).\u201dshould read:\u201cThis work was supported by the Fundamental Research Funds for the Central Universities (Grant No. 310829165020) and the National Natural Science Foundation of China (Grant No. 51778057)\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-019-43041-9, published online 01 May 2019Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cThis study was funded by the Brazilian Financing Agency for Studies and Projects (FINEP 01\u00b712\u00b70514\u00b700), Brazilian Ministry of Science, Technology, and Innovation (MCTI). We acknowledge the National Institute of Science and Technology (INCT) Brain Machine-Interface (INCEMAQ) CNPq 573966/2008-7 of Brazilian Ministry of Science, Technology, and Innovation (MCTI/CNPq/FNDCT/CAPES/FAPERN). We want to thank Neiva Paraschiva, Adriana Ragoni, Andrea Arashiro, Maria Cristina Boscarato, Fabio Asnis, Nathan Rios, Dr. Tiago Kunrath, and Susan Halkiotis (Duke University) for their work, help, and support for this study. We finally want to thank the patients for their long-term commitment, and their trust in this research and our team.\u201dshould read:\u201cThis study was funded by the Brazilian Financing Agency for Studies and Projects (FINEP 01\u00b712\u00b70514\u00b700), Brazilian Ministry of Science, Technology, Innovation, and Communication (MCTIC). We acknowledge the National Institute of Science and Technology (INCT) Brain Machine-Interface  of the National Council for Scientific and Technological Development (CNPq), Brazilian Ministry of Science, Technology, Innovation and Communication (MCTIC). Maria Cristina Boscarato, Fabio Asnis, Nathan Rios, Dr. Tiago Kunrath, and Susan Halkiotis (Duke University) for their work, help, and support for this study. We finally want to thank the patients for their long-term commitment, and their trust in this research and our team.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-018-38357-x, published online 12 February 2019Correction to: The Acknowledgements section of this Article is incomplete.\u201cThis work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2017R1A2B2005081) and the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2016M3C7A1913844).\u201dshould read:\u201cThis work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2017R1A2B2005081), the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2016M3C7A1913844), and a fund (2018-ER6203-00) by Research of Korea Centers for Disease Control and Prevention.\u201d"}
+{"text": "Scientific Reports 10.1038/s41598-017-11703-1, published online 11 September 2017Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cThis work was supported by Xinjiang Uygur Autonomous Region Science and Technology Program (No. 201430123) and National Natural Science Foundation of China .\u201dshould read:\u201cThis work was supported by Xinjiang Uygur Autonomous Region Science and Technology Program (No. 201430123) and National Natural Science Foundation of China .\u201d"}
+{"text": "Development (2018) 145, dev166728 (doi: 10.1242/dev.166728) are now available in the Image Data Repository with an explanatory Data Note hosted by Wellcome Open Research.Light-sheet imaging data associated with The corrected Data availability section is shown below and both the online full-text and PDF versions have been updated."}
+{"text": "Correction to: Confl Healthhttps://doi.org/10.1186/s13031-019-0224-yThe original publication of this article  containeFundingthrough the UK Research and Innovation GCRF RESEARCH FOR HEALTH IN CONFLICT (R4HC-MENA); developing capability, partnerships and research in the Middle and Near East (MENA) ES/P010962/1.This study was funded by the Collaborative Research Stimulus at the American University of Beirut, Lebanon, and by an accountable grant from the International Institute for Environment and Development (IIED) in the UK [grant no. 719.10/42, and"}
+{"text": "Scientific Reports 10.1038/s41598-019-44852-6, published online 10 June 2019Correction to: This Article contains typographical errors in the Acknowledgements section.\u201cThis research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. NRF-2018M3A9E8066253).\u201dshould read:\u201cThis research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. NRF-2018M3A9E8066254).\u201d"}
+{"text": "Anca Roxana Lupu, MD PhDCURRENT POSITION:Manager of Coltea Clinical Hospital BucharestProfessor - \u201cCarol Davila\u201d University of Medicine and Pharmacy-Bucharest from 2005Supervisor PhD from 2007Head of Hematology Department -Coltea Clinical Hospital BucharestPresident of the Romanian Society of HematologyVice-president of the Romanian Society Haemostasis and ThrombosisMember of the Council of Professors \u201cCarol Davila\u201d University of Medicine and Pharmacy -BucharestMember of the College of Physicians in BucharestMember of the General Assembly of the College of Physicians of RomaniaMember of advisory expert committees of the Ministry of Health and National Health Insurance HouseEDUCATION:Graduated from \u201cCarol Davila\u201d University of Medicine and Pharmacy as EnsignPOSTGRADUATE TRAINING1993 to present-MD Internal Medicine1998 to present-MD Hematology Clinic\u2003TEACHING TRAINING;2005 to present Professor -\u201cCarol Davila\u201d University of Medicine and Pharmacy Bucharest.POSTDOCTORAL COURSEProject MEDAS - \u201cTraining physicians and nurses in management and use of new technologies\u201d - POSDRU/63/3.2/S/20264LONG-TERM EXPERT SCIENTIFIC COUNCIL \u201cTo support postdoctoral research in the field of reconstructive surgery transplantation (transplantation Postdoc)\u201d POSDRU/89/1.5/S/ 64153Doctor of \u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest-1996Membership in scientific societies national and internationalMember of scientific teams in specialized medical publicationsPeer reviewer of some medical publicationsManual, book chapters and other -15 in totalSUPERVISOR PhD:1. PhD scholarship, the thesis defended-12. PhD scholarship 13. PhD extramural toll 104. PhD extramural toll - foreign 1Joined as referenced in numerous thesis committees support \u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Timisoara, Iasi, Sibiu, Craiova, Constanta."}